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Zusammenfassung 
Das Epstein-Barr Virus (EBV) ist das vierthäufigste infektiöse Karzinogen für Menschen. Das Virus 
etabliert eine lebenslange Latenz in den B-Zellen des Wirts, welche mit verschiedenen B-Zell 
Tumoren einhergeht. Eine EBV-Infektion von B-Lymphozyten in vitro führt zur Transformation in 
eine lymphoblastoide Zelllinie (LCL) und deren uneingeschränkten Proliferation. Diese 
Transformation wird unter anderem von den EBV nuklearen Antigenen (EBNAs) gesteuert. Dazu 
gehören EBNA2 (E2) und EBNA3A (E3A), zwei ko-exprimierte Transkriptionsfaktoren (TFs), die um 
die Bindung des DNA-Ankers C-Promotor Binding Factor 1 (CBF1) konkurrieren. Unter deren 
Zielgenen befinden sich auch mehrere lange, nicht-kodierende RNAs (lncRNAs), wichtige 
Transkriptionsregulatoren, die mit einer Vielfalt von Krankheiten assoziiert wurden. In dieser Arbeit 
wurde die E2- und E3A-abhängige Genregulation in einer umfassenden Transkriptomanalyse durch 
RNA-Seq untersucht, wobei wir uns auf E2 Ziel-Gene, mit besonderem Schwerpunkt auf lncRNAs, 
fokussiert haben. Unsere Ergebnisse zeigen, dass sich E2- und E3A-regulierte Ziel-Gene genomweit 
in ko-regulierten Genblöcken (CRGBs) gruppieren. Diese CGRBs bestehen sowohl aus 
proteinkodierenden als auch aus lncRNA Genen. Ausgewählte Ziel-Gene wurden durch RT-qPCR 
bestätigt und es konnte zudem gezeigt werden, dass sie während der Etablierung der Latenz nach 
EBV-Infektion reguliert werden. Mehrere dieser lncRNAs sind bereits aus verschiedenen 
Krebsarten bekannt. Weiterhin konnten wir hervorheben, dass die Regulation von lncRNAs und 
dem nächstgelegenen proteinkodierenden Gen positiv korreliert, was für die Regulation von 
entfernt gelegenen proteinkodierenden Gene durch E2 induzierte lncRNAs spricht. Wir entdeckten, 
dass E2 sowohl im Zellkern als auch im Zytoplasma in öffentlich zugänglichen Genbanken 
annotierte lncRNAs reguliert. Zusätzlich haben wir intergenisch (zu ENSEMBL annotierten Genen) 
transkribierte Gene detektiert, die im Zellkern angereichert waren. Diese sind zum Teil auch noch 
nicht von der umfassenden lncRNA Datenbank LNCat erfasst und können somit als neu definiert 
werden. Um direkte E2 Ziel-Gene von denen anderer Transkriptionsfaktoren, die durch E2 induziert 
werden, zu unterscheiden, haben wir auch E2-regulierte Gene nach Blockade der de novo 
Proteinsynthese beschrieben. 3 % der E2-Zielgene wurden unter fehlender de novo 
Proteinsynthese reguliert, einschließlich einiger lncRNAs. Wir fanden, dass 70 % der gemeinsamen 
Ziel-Gene von E2 und E3A gegenreguliert waren. Schließlich haben wir erste Effekte von E2 und 
E3A auf das virale Transkriptom untersucht, wo wir eine Induktion lytischer Gene vermuten. In 
einer unabhängigen Studie konnten wir den Beitrag von Early B Cell Factor 1 (EBF1) zur Chromatin-
bindung von E2 an CBF1-unabhängigen Bindungsstellen im humanen Genom funktionell 
bestätigen. Zusammenfassend zeigen unsere Daten, dass EBV lncRNAs reguliert welche zur 
Tumorgenese beitragen könnten. 
Die Ergebnisse dieser Arbeit erweitern das Wissen über die transkriptionelle Regulation von 
Wirtszellgenen durch E2 und liefern einen Ausgangspunkt für die Untersuchung der Wirkung von 
E2 auf das virale Transkriptom. 
   
 
Abstract 
Epstein-Barr virus (EBV), the fourth most common infectious carcinogen for humans, can establish 
a life-long latency in the host B cells, with such latent infection associated with various B cell 
malignancies. The infection of B lymphocytes by EBV in vitro results in transformation and unlimited 
proliferation of a so called lymphoblastoide cell line (LCLs). This transformation is driven by EBV 
nuclear antigens (EBNAs), in addition to other factors. These include EBNA2 (E2) and EBNA3A 
(E3A), which are co-expressed transcription factors (TFs) competing for binding to a well-studied 
anchor C promoter binding factor (CBF1). E2 and E3A have been shown to share cellular target 
genes, including several long non-coding RNAs (lncRNAs). LncRNAs are key transcriptional 
regulators, associated with a huge variety of diseases including cancer. Herein, we 
comprehensively assessed the E2 and E3A dependent gene regulation in a transcriptomic analysis 
by RNA-Seq. We focused on E2 target gene regulation with particular emphasis on known and novel 
lncRNAs. Our results show that E2 and E3A regulated target genes cluster genome-wide in co-
regulated gene blocks (CRGBs). These CRGBs consist of both protein-coding and lncRNA genes. 
Candidate target genes were confirmed by RT-qPCR and demonstrated to be regulated during the 
establishment of latency following EBV infection. Several of these lncRNAs were reported to be 
dysregulated in various cancer types. Further, we demonstrated that the regulation of lncRNAs and 
the closest protein-coding gene correlates positively, supporting the possibility that E2 induced 
lncRNAs regulate remote protein-coding genes. We discovered that E2 regulated lncRNAs 
annotated by public available genome databases in both the nucleus and the cytoplasm. 
Additionally, we detected intergenic transcribed genes (unannotated by ENSEMBL) enriched in the 
nucleus. To some extent, these intergenic transcribed genes were not covered by the 
comprehensive lncRNA database LNCat and can thus be defined as novel. To determine direct E2 
target genes and that of other transcription factors induced by E2, we profiled E2 differentially 
regulated genes with competent and inhibited protein synthesis.  3 % of the E2 target genes were 
regulated with absent de novo protein synthesis, including several lncRNAs largely emanating from 
enhancer marked chromatin, indicating that 97% of E2 targets are indirect targets. We found, that 
up to 70 % of the shared target genes of E2 and E3A were counter-regulated. Finally, we assessed 
first effects of E2 and E3A on the viral transcriptome finding an induction of lytic genes.  
In an independent study, we were able to functionally confirm the contribution of early B cell factor 
1 EBF1 to chromatin binding of E2 at CBF1 independent binding sites.  
In conclusion, our data indicate that EBV regulates lncRNAs which could contribute to 
tumorigenesis. The findings of this thesis extends the knowledge on the transcriptional regulation 
by E2 of host cell genes and provide an initial point for the investigation of the impact of E2 on the 
viral transcriptome. 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Success is not final, 
failure is not fatal: 
it is the courage to continue that counts. 
~Winston Churchill~ 
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1 Introduction 
 
1.1 The Epstein - Barr virus 
 
The Epstein-Barr virus or human herpes virus 4 (HHV 4) is a human pathogenic double stranded 
DNA virus, with a genome of 172 kb (Baer et al., 1984). It was first discovered by Michael Epstein 
and Yvonne M. Barr in 1964 (Epstein, Achong, & Barr, 1964). They isolated the virus from B 
lymphocytes of an African patient suffering from Burkitt’s lymphoma. Transmission befalls by body 
fluids, especially by saliva, in rare cases also by transplantations or blood transfusions (reviewed 
by Smatti et al., 2018). Ordinarily, the infection with EBV occurs in young childhood and is 
asymptomatic. However, when occurring during adolescence, the infection can result in infectious 
mononucleosis (IM; Henle, Henle, & Diehl, 1968). 90 % of the adult population is EBV positive 
(Chang, Yu, Mbulaiteye, Hildesheim, & Bhatia, 2009). The virus persists lifelong in the body, can 
be reactivated and usually remains undetected not causing a disease as it is controlled by the 
immune system. However, when reactivated, the virus is again contagious (reviewed in Smatti et 
al., 2018, Stanfield & Luftig, 2017, Young, Yap, & Murray, 2016, Thorley-Lawson, 2015, Amon & 
Farrell, 2005). Two EBV types, type 1 and 2 (or type A, B respectively) are existing, which are 
characterized by sequence variations in the Epstein-Barr nuclear antigen 2 (EBNA2/E2) and 
Epstein-Barr nuclear antigen 3 (EBNA3/E3) genes. The type 1 is more often represented worldwide 
and has a greater transforming potential, as type 1 virus transformed cells yield cell lines much 
more rapidly than type 2 virus transformants (reviewed in Young et al., 2016). 
 
1.1.1 EBV’s life cycle and its oncogenic potential 
 
An EBV infection starts in the oropharyngeal mucosa. There, in the epithelial cells, the virus 
replicates usually lytically. Primary infection of EBV causes humoral and cellular immune 
responses, where antibodies against an EBV capsid antigen or an early antigen are produced and 
EBV-specific cytotoxic T cells tackle the infected cells. Nevertheless, the virus is not completely 
eliminated, it may finally enter a circulating memory B cell and establish a latency (infection rate 1 
in 104 to 105 memory B cells; reviewed in Geng & Wang, 2015). It is still controversial how the virus 
enters the memory B cells. There are until now two infection models, one assumes a direct infection 
of memory B cells by EBV and the other one is the germinal center model, which is more consistent 
with different independent findings on EBV (reviewed in Thorley-Lawson, 2015; Young et al., 2016; 
Vockerodt et al., 2015). Contradictory are the findings in vitro versus in vivo, in vitro EBV can 
“immortalize” B cells by the coordinated expression of viral latent genes (“growth program”= 
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latency III). Here, EBV expresses all protein coding EBNA and latent membrane protein (LMP) genes 
as well as non-coding Epstein-Barr virus encoded small RNAs (EBER) and BamHI A rightward 
transcripts (BARTs) in order to persist latently in unlimited proliferating lymphoblastoide cells 
(LCLs) but it does not persist like this in vivo. In vivo, it persist by downregulating the viral gene 
expression in a quiescent resting memory B cell (reviewed in Thorley-Lawson, 2015). The germinal 
center model suggests that EBV first infects naïve B cells and drives B cell proliferation by the 
expression of the growth program. Following, EBV mimics a germinal center (GC) reaction by the 
expression of the transient “default program” (= latency II; EBNA1, LMPs, EBERs and BARTs 
expressed). From there the cell exits as memory B cell, where the viral gene expression is 
minimized (latency 0; only EBERs expressed), just during proliferation of the memory B cells, 
EBNA1 and the non-coding EBERs and BARTs are expressed (latency I) to ensure the replication of 
the viral DNA, which forms a circle and persists as an episome in the nuclei of infected cells and 
its distribution to daughter cells (reviewed in Young et al., 2016; Küppers, 2003). GCs are lymphoid 
structures where critical processes for antigen selection, maturation and selection of 
immunoglobulin class take place such as somatic hyper-mutation (SHM). No signs of SHM were 
found in EBV positive B cells isolated from GCs of patients with IM, which among other findings 
supports the direct infection model. However, in principle EBVs biological behavior is the initiation, 
establishment and maintenance of a persistent infection by mimicking normal B cell biology 
(Vockerodt et al., 2015; Figure 1). Its discovery in a tumor and its ability to drive unlimited B cell 
proliferation hints towards an oncogenic potential. According to recent epidemiologic studies on 
infection-attributable cancer, the fourth most common infectious cause of cancer of all counted 
cases at the different time points of the studies and different investigated populations was EBV, 
which corresponds to 1% of cancer burden (Oh & Weiderpass, 2014; de Martel et al., 2012; Khan 
& Hashim, 2014). EBV has been associated with a striking variety of cancer types. Thorley-Lawson 
categorized EBV-associated cancers into three groups i) tumors, for which the results need to be 
more profound (e.g. breast or hepatocellular cancer), ii) tumors, for which there is strong evidence 
(e.g. nasopharyngeal or gastric cancers), but a latently infected biological equivalent is missing and 
iii) tumors which are solidly linked to EBV (Thorley-Lawson, 2015). This last group includes post-
transplant lymphoproliferative disease (PTLD), Hodgkin’s lymphoma (HL) and Burkitt’s lymphoma 
(BL).  
 
Post-transplant lymphoproliferative disease (PTLD) 
EBV-induced transformation is suppressed by an EBV-specific immune response targeting mainly 
E3 proteins in healthy carriers. In T cell immunosuppressed patients after transplantations or in 
AIDS patients, the response is impaired and this can lead to the uncontrolled expansion of EBV-
transformed B cells. This can result in EBV-positive B cell tumors arising after solid organ or 
hematopoietic stem cell transplantation. PTLDs are a heterogeneous collection of B cell tumors 
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(Vockerodt et al., 2015). All the viral genes of the growth program of latency III are expressed. 
However, there is evidence for SHM in most of these tumors hinting towards a GC or post-GC B cell 
origin. (Thorley-Lawson, 2015; Küppers, 2003). LCLs are an important model to study EBV-
associated cancers and they express type III latency genes. Thus, the viral expression program in 
immunodeficient patients can be compared to the pattern observed in LCLs (Longnecker & Neipel, 
2007). 
 
Classical Hodgkin’s lymphoma (HL) 
HL accounts for 30 % of lymphoid malignancies. It is marked by the atypical large Hodgkin and 
Reed-Sternberg (HRS) tumor cells. However, these cells only constitute less than 1 % of the tumor 
tissue since most of it is comprised of diverse benign blood cells. B cells are almost always the 
origin of HRS cells. The SHM machinery is silenced in these cells and they acquire mutations. It’s 
assumed that HRS cells derive from pre-apoptotic GC B cells that escaped apoptosis. The latency 
II default expression program of EBV may play a role in the escape of the pre-apoptotic GC B cells. 
Up to 40 % of the tumors contain EBV, with higher incidences in children and also in elderly people 
presumably because of the underdeveloped or senescent immune system (Geng & Wang, 2015; 
Küppers, 2003; Vockerodt et al., 2015; Thorley-Lawson, 2015). 
 
Burkitt’s lymphoma (BL) 
This lymphoma was the first EBV associated disease. In the endemic form, which occurs for 
example in equatorial Africa, almost all cases are EBV positive. At lower incidence, in the sporadic 
form outside of endemic areas or in an HIV-associated form, EBV is only associated with up to 30 % 
of the cases. BL is marked by one of three different translocations of the proto-oncogene MYC to 
immunoglobulin genes, all leading to a constitutive activity of this transcription factor (TF). This 
overexpression is the cause for the high proliferation of BL cells. BL cells are derived from 
centroblasts, they show active SHM. In this tumor, minimal expression of viral genes (latency I 
program) exists. The overexpression of MYC which leads to uncontrolled proliferation would also 
induce apoptosis. Therefore, the BL cell has to overcome this by another incident, where EBV might 
contribute to by the expression of the long non-coding RNAs EBERs (Küppers, 2003; Vockerodt et 
al., 2015). 
 
Which exact role EBV plays in lymphomagenesis still remains to be unraveled. The high frequency 
of EBV positive cases of diverse lymphomas despite the low frequency of EBV positive B cells in 
virus carriers indicates an involvement of EBV in the B cell transformation. 
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Figure 1: Schematic representation of the EBV life cycle. Upper panel: Dynamic of viral gene expression. The 
different stages of the life cycle are accompanied by the different expression of certain viral genes. 
Characteristic for the pre-latent phase is the expression of latent genes (brown line) and a limited subset of 
lytic genes corresponding to the so-called immediate early and early lytic class (turquoise line). After the pre-
latent phase, latency is established. The synthesis of new virus is repressed during the initial latency phase 
due to the lack of expression of other crucial viral genes. An extrachromosomal plasmid represents the EBV 
genome during latency in the nucleus of infected cells supported by the expression of latent genes. 
Exogenous or viral stimuli can trigger the switch to the lytic phase, where again the expression of early and 
late lytic genes support amplification of viral genomes and the expression of structural proteins (grey line) is 
accountable for viral progeny (modified from Hammerschmidt, n.d.). Middle panel: Normal persistence. EBV 
resides in host memory B cells. Two models are proposed to explain the viral entry in memory B cells. The 
germinal center model suggests that EBV first infects naïve B cells and drives B cell proliferation by the 
expression of the growth program. Following, the infected B cell mimics a germinal center (GC) reaction by 
the expression of the transient default program (latency II; EBNA1 and LMPs expressed).  From there it exits 
as memory B cell, where the viral gene expression is minimized (latency 0), just during proliferation of the 
memory B cells, EBNA1 is expressed (latency I) to ensure the replication of the viral DNA, which forms a circle 
and persists as extrachromosomal plasmid in the nuclei of infected cells and its distribution to daughter 
cells. In the direct infection model, EBV directly infects memory B cells, potentially including an intermediate 
latency III stage. Lower panel: The EBV-associated malignancies. This figure displays at which latency state 
infectious mononucleosis (IM), post‑transplant lymphoproliferative disease (PTLD), Hodgkin’s lymphoma or 
Burkitt’s lymphoma occurs. When primary B cells get infected with EBV in vitro, they arrest in latency III as 
LCLs and proliferate unlimitedly (Figure modified from Young, Yap, & Murray, 2016). 
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1.1.2 EBV latent proteins E2 and E3A and chromatin tethering 
 
By the activation of resting B cells, EBV exploits the cellular transcription and translation 
machineries. The transformation process is driven by the coordinated expression of nine latent 
viral genes coding for nuclear and membrane antigens as well as non-coding genes. Among the 
nuclear antigens are EBNA2 (E2) and EBNA3A (E3A), two co-expressed key genes. Instant post 
infection, E2 together with Epstein-Barr nucleus antigen leader protein (EBNA-LP) is the first gene 
expressed (Alfieri, Birkenbach, & Kieff, 1991), followed by E3A and others. The EBNA proteins are 
TFs of EBV which modulate viral and host gene expression. 
 
1.1.2.1 E2 
 
E2 was discovered, when P3HR1, a laboratory-derived EBV strain with an E2 deletion was unable 
to transform B cells in vitro (Rabson, Gradoville, Heston, & Miller, 1982). Returning the E2 gene 
back into P3HR1 has confirmed the indispensability of E2 in the B cell transformation (Cohen, 
Wang, Mannick, & Kieff, 1989; Hammerschmidt, & Sugden, 1989). E2 is encoded by a single exon; 
the structure of the entire protein has not been solved so far. E2 is not able to bind to DNA itself. 
It requires cellular adaptor proteins to bind to chromatin. The contact of E2 with different 
transcription factors and co-activators occurs at an acidic activation domain of E2. E2 regulates 
transcriptional initiation and elongation to some extend by cyclin-dependent kinase 9 (CDK9) 
dependent phosphorylation of the C-terminal domain (CTD) of RNA polymerase II (PolII; Palermo, 
Webb, Gunnell, & West, 2008). 
The so far best investigated DNA adaptor for E2 is C-promoter binding protein (CBF1, also known 
as RBPJκ). In the absence of E2, CBF1 recruits a corepressor complex for the repression of target 
gene transcription. When bound by E2 and coactivators, the repression is relieved by competition 
with the corepressor (reviewed in Kempkes & Ling, 2015). CBF1 belongs to the Notch signaling 
pathway. By binding to CBF1, E2 mimics a constitutively activated NOTCH receptor (Sakai et al., 
1998). The Notch pathways play a role in cell fate determination, cell differentiation and 
developmental pattern formation in Drosophila. E2 might execute Notch-like functions. 
Alternative anchors of E2 are discussed. In the recent past, we and others could show that early B 
cell factor 1 (EBF1) is also an important DNA anchor for E2 (Glaser et al., 2017; Lu et al., 2016; 
see section 3.1, p. 38). EBF1 is important to activate B cell-specific genes and is claimed to act as 
pioneer factor, meaning its binding evokes chromatin accessibility, histone modifications and 
target gene expression (reviewed in Boller, Li, & Grosschedl, 2018).  
E2 is a transactivator of viral and cellular promoters. The knowledge about E2 functions is largely 
based on genetic analysis of E2-responsive elements within viral promoters. E2 activates the viral 
C promoter, as well as the LMP1 and LMP2A and LMP2B promoters. A variety of genome-wide 
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array-based screens or candidate investigations in EBV-infected B cells or E2 expressing B cell 
lines were accomplished to study the impact of E2 on target gene expression. A lot of target genes 
were detected to be upregulated by E2, like SLAMF1, DNase1L3 or ABHD6 (Sabine Maier et al., 
2006). E2 also induces genes in the absence of de novo protein synthesis, like MYC (Kaiser et al., 
1999). E2 can also be an active repressor of target genes, like CD79B (Maier et al., 2006) or BCL6 
(Boccellato et al., 2007). 
 
1.1.2.2 E3A 
 
E3A belongs to the E3 protein family, a group of latency-associated proteins, co-expressed together 
with E2. It is assumed that this protein family has arisen during the evolution of EBV by multiple 
gene duplication events because they are similar in sequence and gene structure. Nevertheless 
there are no hints towards redundant functions. E3s are critical in EBV persistence and for 
modulation of B cell lymphomagenesis. E3A is essential for in vitro B cell transformation 
(Tomkinson, Robertson, & Kieff, 1993), controversially, researcher were able to establish E3A 
negative LCLs (Hertle et al., 2009; Skalska et al., 2013; Skalska, White, Franz, Ruhmann, & Allday, 
2010). Furthermore, it is important for the efficient proliferation of the B cells since important 
tumor suppressor pathways are targeted by E3A. E3A is exclusively located in the nucleus (it 
contains six nuclear localization signals) and is tightly associated with chromatin, but also is not 
able to bind to DNA directly. E3A is regarded as transcriptional repressor. 
CBF1 is also an anchor for all E3 proteins and together, they can interfere with E2-mediated 
transactivation, since has been shown that E3A binds to the same site on CBF1 as E2 (Robertson, 
Lin, & Kieff, 1996). Thus, E2 and E3 interaction with CBF1 is presumably mutually exclusive.  
Microarrays have uncovered that E3A not only represses but also activate host genes. Target genes 
of E2 and E3A have been sown to overlap, E2 and E3A either act in concert or counteract. For 
example, E3A antagonizes the MYC activation by E2 (Hertle et al., 2009; McClellan et al., 2013). It 
has further been shown by our laboratory that E2 and E3A directly compete for CBF1 binding 
(Harth-Hertle et al., 2013) at enhancers resulting in either activation (E2) or repression (E3A) of 
the enhancer. It still remains to be unraveled how widely E2 and E3A have antagonistic roles in the 
host gene regulation (reviewed in Allday, Bazot, & White, 2015). 
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1.2 Epigenetic regulation 
 
Epigenetics is the “study of changes in gene function that are mitotically and/or meiotically 
heritable and that do not entail a change in DNA sequence” (Wu Ct & Morris, 2001). Epigenetic 
changes are not based on DNA sequence changes such as mutations or chromosomal 
recombinations, but modifications which result in phenotypic changes. Epigenetic mechanisms 
include DNA methylation, covalent and noncovalent chromatin variations and expression of non-
coding RNAs. DNA methylation is defined as methylation of cytosine residues of CpG sites. Covalent 
chromatin variations are histone modifications, while non-covalent mechanisms include chromatin 
remodeling or the incorporation of special histone variants (Goldberg, Allis, & Bernstein, 2007). 
Chromatin remodeling is defined as the ATP-dependent change in nucleosome positioning. 
 
1.1.3 Histone modifications 
 
Histones (H) are the components of the nucleosome, which is the basic unit of chromatin. 
Chromatin is the compact form of DNA, where the helix winds around a histone octamer comprising 
of two dimers of H2A an H2B and a tetramer of H3 and H4 histone variants. The histone tails stick 
out of the nucleosome and can be post-translationally modified. Acetylation, phosphorylation, 
methylation, and ubiquitylation are the most common modifications among many others. 
Posttranslational modifications (PTM) on histones can be indicatory for transcriptionally active or 
silent chromatin. These histone modifications can be assessed by chromatin immunoprecipitation 
(ChIP). High levels of acetylated lysine on the H3 and H4 tails (e.g. H3K27ac), trimethylation of 
lysine 4 on H3 (H3K4me3) or trimethylation of H3 lysine 79 (H3K79me3) are among others marks 
for active genes. However, marks for inactive genes include trimethylation of lysine 27 on the H3 
(H3K27me3) or trimethylation of H3 lysine 9 (H3K9me3). Sequence-specific TFs, which regulate 
transcription, can recruit chromatin-modifying enzymes to target sites. Histone acetylation for 
instance is dynamic and regulated by two contrary acting enzymes, the histone acetyltransferases 
(HATs; e.g. CBP/ p300) and histone deacetylases (HDACs). Histone methylation mainly occurs at 
lysines or arginines and is regulated by methyltransferases and demethylases. Among the histone 
lysine methyltransferases (HKMTs) are mixed lineage leukemia 3 and 4 (MLL3, MLL4 respectively), 
two H3K4 monomethyltransferases or polycomb repressive complex 1 and 2 (PRC1, PRC2 
respectively), two H3K27 trimethyltranferases. Histone modifications regulate chromatin structure 
by recruitment of remodeling enzymes. As a result, these modifications can influence transcription 
(Figure 2; reviewd by Zhang, Cooper, & Brockdorff, 2015; Bannister & Kouzarides, 2011).  
The so-called histone code hypothesis suggests specified functions for genomic elements 
according to distinct combinatorial patterns of histone modifications (reviewed by Rando, 2012). 
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Additionally to histone modifications, the different classes of elements are marked by distinct 
patterns of TF binding (Heintzman et al., 2007). Therefore, the chromatin can be categorized in 
different segments according to their histone modifications and other features. Ernst et al. 
published 2011 a chromatin state segmentation (CSS) according to the Hidden Markov Model 
(HMM) for the nine human cell lines included in the ENCyclopedia Of DNA Elements (ENCODE) 
project (i.a. GM12878, a EBV-immortalized B cell; Ernst et al., 2011). Focusing on enhancers, they 
can be divided into strong, weak and poised enhancers according to their chromatin state. They 
mainly act as cis- regulatory elements that are bound by specific TFs to enhance the transcription 
of corresponding genes, irrespective of their orientation and location relative to the promoters. A 
promoter is comprised of two elements. The core promoter corresponds to the region around the 
transcriptional start side (TSS) and is required for the initiation of transcription and the recruitment 
of RNA polymerase II (PolII). The proximal promoter resides upstream of the TSS and contains 
several TF-binding sites of the corresponding genes (Lee, Hsiung, Huang, Raj, & Blobel, 2015). 
Enhancers are believed to be essential for tissue specificity and developmental regulatory gene 
expression (Bulger & Groudine, 2011; Plank & Dean, 2014). They exhibit epigenetic 
characteristics: In general, an open chromatin architecture (DNase I hypersensitive sites), binding 
sites for PolII (RNA Polymerase II) and coactivators like the mediator complex or p300/CBP, and 
especially histone modifications such as H3K4me1 or H3K27ac (histone 3 Lysine 4 
monomethylation, histone 3 lysine 27 acetylation respectively; Ernst et al., 2011). 
Recently, regions which are basically comprised of multiple adjacent enhancers and bound by 
groups of specific TFs were defined as super-enhancers. These enhancers drive genes important 
for cell function and identity. They show exceptionally broad and high binding signals for H3K27ac, 
mediator 1 (Med1) and bromodomain-containing protein 4 (BRD4; Whyte et al., 2013; Hnisz et al., 
2013). 
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Figure 2: Schematic representation of ChIP-signals of post-translational histone modifications of active (A) 
and repressed (B) genes. A Exemplified PTMs found at the promoter regions and the gene bodies of actively 
transcribed genes. A representative histone modifier MLL mediates H3K4 monomethylation. Open 
chromatin is displayed by a slack nucleosome chain (NDR=nucleosome depleted region). B Exemplified 
PTMs found at the promoter regions and the gene bodies of silenced genes. A representative histone 
modifier PRC mediates H3K27 trimethylation. Closed chromatin is displayed by a dense nucleosome chain 
(Figure modified from Barth & Imhof, 2010). 
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1.1.4 Long-range chromatin interactions and three-dimensional (3D) genome 
organization 
 
Chromosome conformation capture (3C)-based techniques present opportunities to explore 
chromatin interactions and 3D-genome organization in an unprecedented scale and resolution. 
These methods provide resolution on the 3D organization of the human genome, which appears 
to be essential for gene regulation (Bickmore, 2013; Dekker, Marti-Renom, & Mirny, 2013; Sexton 
& Cavalli, 2015). The “family of 3C-techniques” aims to detect physical interactions of genomic 
regions and involve five steps: crosslinking the chromatin at sites of physical interactions by 
formaldehyde fixation, shearing the chromatin by sonication or restriction enzyme digest, ligation 
under dilute conditions in order to bias towards a ligation between DNA ends of close proximity, 
detection of ligation junctions and computational calculation of interaction frequencies (Hakim & 
Misteli, 2012). Distal regulatory elements such as enhancers need to be physically conjoined with 
their target genes on DNA level. At a higher level, topologically associating domains (TADs) have 
been suggested to be a superordinate unit of mammalian genome organization. A TAD is 
considered as self-interacting genomic region and up to 2 Mb in size. A TAD is defined by applying 
certain algorithms to Hi-C data (Dixon et al., 2012). DNA sequences within a TAD physically interact 
more frequently with each other than with sequences outside of the TAD. The protein CTCF and the 
protein complex cohesin are thought to be important for TAD formation (Pombo & Dillon, 2015). 
TADs have been reported on the basis of lower-resolution contact maps. With increasing resolution, 
much smaller (median length= 185 kb) contact domains could be observed, too small to be 
detected in previous maps. These domains were also conserved across cell types and exhibited 
patterns of long-range contacts (subcompartments). Detection of TADs involves the detection of 
domain boundaries, which were not as distinct with higher resolution. Additional boundaries were 
reported beyond those of previous maps, which were associated with subcompartment transition 
or looping (Rao et al., 2014). Recently, several different high-throughput technologies based on 
Chromatin Conformation Capture  (3C) have been developed such as Hi-C (simultaneously 
capturing all genomic interactions as a population-average snapshot; Lieberman-Aiden et al., 
2009), ChIA-PET (chromatin interaction analysis by paired-end tag sequencing; G. Li et al., 2010) 
or Capture Hi-C (hybridization selection to capture interactions of candidate fragments; Mifsud et 
al., 2015). ChIA-PET combines chromatin immunoprecipitation (ChIP) with a 3C method to enrich 
for interactions mediated by one TF. 
Looping data obtained for the EBV-immortalized B cell GM12878 cells through Capture Hi-C are 
provided by Mifsud et al. Furthermore, CTCF-mediated chromatin conformation was assessed in 
GM12878 cells by ChIA-PET (Szalaj et al., 2016; Tang et al., 2015b). Using Hi-C, the genomic 
architecture of the genomes of the nine ENCODE cell lines was investigated (Rao et al., 2014). 
GM12878 cells showed the densest organization with 4.9 billion contacts. 
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1.1.5 Non-coding RNAs (ncRNAs) 
 
The fraction of the genome coding for proteins constitutes approximately 1.2 %. Many regulatory 
elements are transcribed into non-coding RNAs (Human Genome Sequencing Consortium 
International 2004). This is indicatory for a substantial role of ncRNAs in complex organisms. RNAs 
are also involved in epigenetic events. Non-coding RNAs include a huge variety of small non-coding 
RNAs like microRNAs (miRNAs), small interfering RNAs (siRNAs) or small nucleolar RNAs (snoRNAs) 
and the long non-coding RNAs (lncRNAs). Small RNAs have been shown to induce 
posttranscriptional and transcriptional RNA interference (RNAi)-related pathways. They collaborate 
with the DNA methylation machinery or components of the chromatin (Goldberg et al., 2007). 
LncRNAs also possess the potential to influence epigenetic processes such as DNA methylation, 
histone modification activity or posttranscriptional regulation, since they exhibit complex structural 
features (reviewed in C. Wang et al., 2017). 
 
1.3 Long non-coding RNAs (lncRNAs) 
 
The quantity of ncRNAs steadily increases due to identifications through genome-wide human 
transcriptional studies. NONCODE for example is an integrated knowledge database designed for 
ncRNAs, despite transfer RNAs (tRNAs) and ribosomal RNA (rRNAs) and especially the number of 
lncRNAs has increased from the NONCODE version 3.0 to version 4.0 (two years) by almost 3 fold 
from 73,327 to 210,831 (Xie et al., 2014; for information on databases see below). The expansion 
of the regulatory potential of ncRNAs might be a reason for the evolution of developmental 
processes, which could be responsible for the complexity of organisms (Mattick, 2004).  
 
1.3.1 Definition of lncRNAs 
 
LncRNA are distinguished from small ncRNAs by the size. LncRNA transcripts are longer than 
200 nt and have no coding potential. Additionally, they are poorly conserved compared to small 
non-coding RNAs (only a small number is conserved across species like XIST, NEAT1 or MALAT1). 
The bulk of lncRNAs are transcribed by PolII (confirmed by PolII occupancy) like messenger RNAs 
(mRNAs). They can be post-transcriptionally modified by splicing, capping and polyadenylation. 
Generally lower expression, a fewer number of exons and a much higher tissue specificity 
distinguish them from mRNA (Derrien, 2012; Iyer, et al., 2015). For further characterization, they 
can be divided into subgroups according to their genomic location relative to protein-coding genes, 
the sequence, the structure and their functional features. Until now, there is no consensus on the 
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classification and the nomenclature. Types of classifications consider the genomic location, such 
as intergenic lncRNA (lincRNA) or intronic lncRNA, or the orientation of the product regarding the 
DNA strand, such as sense or  antisense lncRNAs, as well as the association with known chromatin 
states like enhancer or promoter associated lncRNAs (eRNAs, pRNAs respectively). Especially 
eRNAs can be product of either unidirectional or bidirectional transcription. The classifications 
might overlap (Figure 3A). It has to be mentioned here, that no clear definition regarding the kind 
of association of a lncRNA with a chromatin state exists. For instance, the association might be 
either an intersection of e.g. the transcription start side or the entire gene body of the lncRNA with 
a certain chromatin state (Bonasio & Shiekhattar, 2014; Fritah, Niclou, & Azuaje, 2014; Rashid, 
Shah, & Shan, 2016; Salviano-Silva, Lobo-Alves, Almeida, Malheiros, & Petzl-Erler, 2018; K. C. 
Wang & Chang, 2011). 
 
1.3.2 Cellular functions of lncRNAs 
 
The location of the lncRNA might occasionally determine the functional context of a lncRNA 
(reviewed in C. Wang et al., 2017). LncRNAs can exert diverse transcriptional or post-transcriptional 
functions in the nucleus as well as in the cytoplasm as described in the following section. In some 
cases it appears that the lncRNA transcription rather than the lncRNA itself is regulatory. The 
expression of lncRNAs is strictly regulated and cell type-/ tissue-specific, hinting towards a crucial 
role in physiological mechanisms. Variations of their expression or mutations in their primary 
sequence have been linked to disorders. Despite a missing conservation at primary sequence level 
between lncRNAs, parallels can be found in their mode of action, since lncRNAs can bind to other 
molecules such as proteins, DNA or RNA (Bonasio & Shiekhattar, 2014; Fritah et al., 2014; Rashid 
et al., 2016; Salviano-Silva et al., 2018; K. C. Wang & Chang, 2011). There is evidence that the 
majority of nascent RNA generated in the nucleus is rapidly turned over (Lam, Li, Rosenfeld, & 
Glass, 2014).  
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1.3.2.1 LncRNAs in the nucleus 
 
Initially, lncRNAs were thought to primarily reside in the nucleus. Wang & Chang reviewed the 
molecular mechanisms for functions of lncRNAs in 2011 and suggested four archetypes of 
mechanisms: signals, decoys, guides and scaffolds (Figure 3B). Individual lncRNAs may realize 
several archetypes. Since 2011, multiple other mechanisms for lncRNAs were discovered 
(reviewed in Salviano-Silva et al., 2018). 
Since the expression of lncRNAs is cell type specific, they could serve as molecular signals in 
response to certain stimuli, interpret a cellular context or integrate developmental clues. They 
function as indicators of transcriptional activity (e.g. HOTAIR; Rinn et al., 2007) 
LncRNAs can furthermore positively or negatively regulate transcription. The decoy lncRNA binds 
and titrates away a protein target, which could be a TF or a chromatin modifier for instance (e.g. 
MALAT1; Tripathi et al., 2010). The guide archetype binds to protein(s) and directs leads the 
ribonucleoprotein complex to specific targets. Changes in gene expression can be triggered in cis 
(e.g. XIST; Wutz, Rasmussen, & Jaenisch, 2002) or in trans (e.g. JPX; Tian, Sun, & Lee, 2010). 
Finally, lncRNAs can provide a platform for the assembling of several molecular components. This 
is a complex class of lncRNAs with different domains binding to distinct effector molecules. By 
binding multiple different effectors, these molecules are combined in time and space (e.g. ANRIL; 
Kotake et al., 2011; Yap et al., 2010). 
 
eRNAs 
Combining the outcomes of several deep sequencing approaches, eRNAs were defined as 
following. Putative enhancer regions, marked by high levels of H3K4me1 give rise to eRNAs, and 
their expression is additionally characterized by H3K27ac modification. It was demonstrated that 
the histone methyltransferases MLL3/4 promotes the synthesis of eRNA (Dorighi et al., 2017). 
These enhancer regions can be associated with binding of LDTFs (lineage determining TFs), 
transcriptional co-activators (e.g. Mediator, p300, CBP), PolII (serine 5 phosphorylated) and more. 
In general, eRNAs exhibit a 5’ cap and are predominantly monoexonic. eRNAs which display 
polyadenylation are linked to unidirectional transcription, whereas the transcripts without 
polyadenylation are linked to bidirectional transcription. The latter are more common (Lam et al., 
2014). eRNAs have a half-life of approximately 2 min compared to the approximately 80 min half-
life of mRNAs (lincRNAs similar to mRNA, other lncRNAs approx. 7 min (Schwalb et al., 2016). 
eRNAs are dynamically regulated upon stimuli. eRNAs are enriched at enhancers which are 
engaged in chromatin looping, which hints towards a potential functions of eRNAs in looping 
formation. Enhancer transcription could be simply transcriptional noise at open chromatin, the 
process of enhancer transcription could be important or the RNA transcript itself is important for 
enhancer activity. Numerous reports imply a contribution of eRNAs in enhancer mediated 
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activation of neighboring coding genes. This contribution could be in the facilitation of proper 
formation of chromosomal looping between enhancers and TSS (reviewed in Lam et al., 2014).  
 
1.3.2.2 LncRNAs in the cytoplasm 
 
Many lncRNAs reside in the cytoplasm and exert their function there. Rashid et al. summarized 
their functions in four groups: modulation of mRNA stability, modulation of translation, competing 
endogenous RNAs and mediation of protein modifications (Figure 3C).  
Several lncRNAs are known to target mRNA transcripts and modulate their stability, some of them 
increase mRNA stability by e.g. sequestering STAU1 (TINCR; Kretz, 2013) and others decrease the 
stability e.g. by recruiting STAU1 (½-sbsRNA; Gong & Maquat, 2011; Kim et al., 2007). Staufen 1 
(STAU1)-mediated mRNA decay (SMD) is induced when the 3’ untranslated region (UTR) of a mRNA 
binds to STAU1. Involvement of lncRNAs in translational regulation has also been reported in order 
to manage complex protein dynamics in a spatio-temporal manner. LncRNAs have been observed 
to promote translation by activating polysomes for cap-independent translation (AS Uchl 1; Carrieri 
et al., 2012) or inhibit translation by enhancing the translational repressor machinery (lincRNA-
p21; Yoon et al., 2012). There is a competition about miRNA binding between coding and non-
coding RNAs. Competing endogenous RNAs (ceRNAs) can protect coding genes from repression by 
sequestering miRNAs and therefore hinders the miRNA from binding to its targets (e.g. HULC; J. 
Wang et al., 2010). LncRNAs furthermore can modulate modifications of cytoplasmic proteins like 
phosphorylation/ dephosphorylation or ubiquitilation/ deubiquitilation. An example for modulation 
of phosphorylation is the lncRNA NKILA which binds directly to IκB and hinders IκB  kinase (IKK) 
from phosphorylating IκB (Liu et al., 2015). 
 
An example for a compartment independent function of lncRNAs is that they can serve as 
precursors for miRNAs (e.g. H19; Dey, Pfeifer, & Dutta, 2014). 
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Figure 3: Definition and function of lncRNAs. A Definition for lncRNAs based on their genomic location relative 
to protein-coding genes lincRNA/intronic lncRNA; the orientation of the product regarding the DNA strand 
sense or antisense lncRNAs, as well as the association with known chromatin states (eRNAs). B, C Regulatory 
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mechanisms of lncRNAs in the nucleus (B) and the cytoplasm (C). B.1 Molecular signals, activating or 
silencing gene expression e.g. acting as eRNAs, inducing transcription in cis or in trans B.2 Decoy for 
regulatory proteins, such as transcription factors and chromatin modifiers B.3 Guiding proteins (in general, 
chromatin modifiers) to specific target sites, e.g. as eRNAs recruiting proteins such as mediator to format 
chromatin loops B.4 As scaffolds, binding different proteins and forming RNP complexes C.1 Modulators of 
mRNA stability C.2 Modulators of translation C.3 CeRNAs as shields for mRNA C.4 Mediators for protein 
modification; Serving as precursors for miRNA (compartment independent; Figure modified from Salviano-
Silva, Lobo-Alves, Almeida, Malheiros, & Petzl-Erler, 2018). 
 
 
1.3.3 Databases dedicated to lncRNAs 
 
The first evidence for lncRNA transcription was revealed when after cloning no translated products 
could be detected. Since then, major progress in the detection of lncRNAs was made by tilling 
arrays and more recently with deep sequencing methods. For 50 out of 700 lncRNAs, a significant 
effect on cancer cell growth could be observed in a recent large-scale lncRNA knock out screening 
(Zhu et al., 2016). Although it is evident, that individual lncRNAs exert important functions in 
diverse biological processes, a large gap exists between the huge amount of detected lncRNAs and 
an associated proven molecular or cellular function. Still, lncRNAs become increasingly available 
in public datasets. There were several databases established which differ in quality and data 
coverage. First, the number of lncRNAs contained in these databases varies from < 10,000 to 
> 70,000 and second the determination varies from experimentally confirmation to bioinformatical 
prediction (Fritah et al., 2014). Xu et al. developed LNCat (lncRNA atlas, freely available at 
http://biocc.hrbmu.edu.cn/LNCat/), a comprehensive database for lncRNAs by reviewing 24 
lncRNA annotation resources referring to >205,000 lncRNAs in over 50 tissues and cell lines. 
Furthermore, the resources were characterized with respect to exon structure or expression for 
instance. This atlas contains three of the largest and best known resources for lncRNAs, GENCODE, 
LNCipedia and NONCODE (J. Xu et al., 2016). 
 
1.3.4 LncRNAs in human diseases 
 
The combination of an epigenetic function with tissue specificity, variability and plasticity suggest 
that lncRNAs are crucial factors in disease genesis (C. Wang et al., 2017). Since lncRNAs have 
fundamental functions in maintaining cellular and organismal homeostasis, dysregulation of 
lncRNAs was demonstrated in diverse studies to be associated with a huge variety of diseases 
including cancer (Hu et al., 2018). The lncRNA DSCAM-AS1 for example is upregulated in breast 
cancer and mediates tumor progression and tamoxifen resistance by targeting heterogeneous 
nuclear ribonucleoprotein L (hnRNPL; Niknafs et al., 2016). lncRNAs have already been reviewed 
to exert functions during malignant hematopoiesis (Alvarez-dominguez & Lodish, 2014; Alvarez-
Dominguez & Lodish, 2017). For instance, maternally expressed gene 3 (MEG3) was observed to 
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be down-regulated in acute myeloid leukemia (AML) by hyper-methylation of its promoter 
(Benetatos et al., 2010) and it might be involved in the regulation of the retinoblastoma (Rb) and 
p16INK4a pathway and thus in cell proliferation of many cancer types (Benetatos, Vartholomatos, 
& Hatzimichael, 2011). In this respect, Yan et al. analyzed the Cancer Genome Atlas (TCGA) data 
regarding alterations at transcriptional, genomic and epigenetic levels and identified potentially 
clinically relevant noncoding transcripts (Yan et al., 2015). Here, they included lncRNAs of 5,037 
human tumor specimens across 13 cancer types. They could show that the dysregulation of 
expression of lncRNAs is common in cancer, with the majority of lncRNAs being cancer type unique 
but some alterations are also shared between different cancer types. Furthermore, they suggest 
that somatic copy number alterations lead to the dysregulation of lncRNAs in cancer as well as 
epigenetic silencing of lncRNAs. Moreover, their data suggest a determination of tumors by 
lncRNAs as biomarkers. 
 
1.4 EBV and chromatin conformation regulation of the host 
genome 
 
By next generation sequencing techniques combining ChIP-Sequencing, RNA-Sequencing, 3C-
Sequencing and other sequencing methods, a mass of data regarding genome regulation is 
available. Comprehensive data sets provided by the ENCODE project on functional DNA elements 
can be obtained for an EBV-immortalized B cell, GM12878. E2 preferentially binds to active 
chromatin of enhancers (Glaser, PhD thesis, 2017; Zhao et al., 2011), the same holds true for E3A 
(Glaser, PhD thesis, 2017; Zhou et al., 2015), indicating that enhancers are frequently occupied 
target sites for the transcriptional regulation by EBV. The genome can be regulated over a long 
distance, mediated by chromatin contacts. Enhancers can loop to promoters, two or more genomic 
regions can be connected with each other (reviewed in Pombo & Dillon, 2015). EBV has been 
reported to rearrange enhancer-promoter loops. It has been shown, that MYC expression can be 
activated by E2 from distal enhancers 3’ of the transcription start side of MYC (Wood et al., 2016; 
Zhao et al., 2011). Furthermore, it was observed that E2 binding sites accumulate in super-
enhancers and that these E2 super enhancers were not close to known TSSs. It could be revealed 
that all EBNA proteins co-occur at the same enhancer sites in the genome (EBV enhancers) and 
that 10% of them show hallmarks of super-enhancers (EBV super-enhancers, ESE). Furthermore, 
it could be shown that most of the EBV super-enhancers reside in the same TAD as their 
corresponding genes (Zhou et al., 2015). Liang et al. could report that E2 regulates the eRNAs 
MYC-428 and MYC-525 which are derived from ESEs and that these eRNAs regulate MYC 
expression (Liang et al., 2016). 
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1.5 Objectives 
 
In the Kempkes laboratory, extensive investigations on E2 target genes have already been 
conducted. More recently, microarrays on E2 (Thumann, PhD thesis, 2016) and E3A targets (Hertle 
et al., 2009) gave additional insights into transcriptional regulation by both viral TFs. This, and 
investigations by other research groups revealed that E2 and E3A share target genes with subsets 
of counter- and co-regulated genes (Glaser, PhD thesis, 2017). Furthermore, it could be published 
by our group that E2 and E3A compete for CBF1 binding to an enhancer at a model locus (Harth-
Hertle et al., 2013). The major anchor for E2 is CBF1, however, our laboratory could observe CBF1 
independent binding of E2 to chromatin. This raised the question if alternative cellular TFs can be 
used by E2 as anchor to DNA as well. Genome-wide binding analyses comparing E2 with 89 other 
cellular TFs revealed also a high correlation of E2 with the B cell TF EBF1. To functionally investigate 
this correlation, ChIP experiments followed by quantitative polymerase chain reaction (qPCR) were 
performed. 
As could be reported for E2 and E3A, both TFs preferentially bind to enhancer regions (Glaser, PhD 
thesis, 2017; Zhao et al., 2011; Zhou et al., 2015). Additionally to the competition of E2 and E3A 
for enhancer binding, it was observed by our group that E3A represses transcription deriving from 
an intergenic enhancer at a well-studied model locus, CXCL9/10, as assessed by RT-qPCR 
(quantitative reverse transcription polymerase chain reaction; Figure 4). Using ChIP-primer for E2 
and E3A binding sites on cDNA at an enhancer locus which is marked with features of active 
chromatin (high GRO-Seq, H3K27ac and H3K4me1 signals, PolII- and CTCF-binding), we noticed 
E3A-dependent regulation of transcription of the enhancer and the neighboring genes. These 
enhancer transcripts could be enriched in the nucleus. We hypothesize that E2 and E3A control 
the transcription of lncRNAs which are presumably involved in the regulation of neighboring or 
remote coding genes (Figure 5). The regulation by E2 and E3A could occur on a higher level of 
chromatin organization. E2 and E3A might counter-regulate shared target genes genome-wide. Our 
previous work has shown in a microarray analysis that E2 can induce multiple lncRNAs (Glaser et 
al., 2017; Thumann, PhD thesis, 2016). Many lncRNAs have been reported to have certain 
relevance in human diseases such as cancer (Hu et al., 2018). Since EBV is associated with several 
lymphomas and other cancers (Ko, 2015; Pattle & Farrell, 2006), one conceivable mechanism for 
the challenge of cancer could be the induction or repression of lncRNAs, which again could have 
an impact on the regulation of protein coding genes. 
For the genome-wide detection of E2 and E3A target genes RNA-Sequencing was conducted, 
comparing the cytoplasmic with the nucleic compartment of established lymphoblastoid cells. The 
main obstacle was the approach for the analysis and the accompanied parameters, since the 
bioinformatic thresholds and definitions have a major impact on the outcome of the data. The 
resulting data were analyzed in context of information collected by our lab and publicly available 
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information on LCLs (GM12878). ChIP-Seq Data on E2 and E3A were acquired in our lab, as well 
as a comprehensive cluster analysis for EBNA peaks (pan EBNA, merged E2, E3A and E3C peaks), 
which was used in the following to describe E2 binding sites relevant for the analysis.  
Despite numerous efforts to comprehensively catalog lncRNAs, there are several reasons why the 
identification of lncRNAs is incomplete, for instance the high tissue- and pathway-specificity of 
lncRNA expression (Iyer, et al., 2015). The main aim of this thesis was the identification and 
characterization of already annotated and potentially novel E2-regulated lncRNAs. 
 
 
 
 
Figure 4: E3A-dependent repression of transcription of intergenic enhancer at model locus. Upper panel: IGV 
image displaying a GRO-Seq track showing the coverage in GM12878 (Core LJ, et al. 2014; data range set 
to auto scale), tracks obtained from ChIP-Seq (H3K27ac, H3K4me1, RNA PolII and CTCF sourced from 
ENCODE for GM12878; E2 and E3A generated in our lab; data range set to auto scale) and a RefSeq 
annotation track; Lower panel: Bar graphs showing the absolute quantification of RT-qPCR of the intergenic 
region (left) and the protein coding gene CXCL10 in different RNA preparations. RNA was isolated from 107 
wt and ΔE3A LCLs (total) or cell fractions (1.2 x 107 cells for cytoplasm and 2 x 108 cells for nucleus) and 
2 µg RNA was reverse transcribed to cDNA. Concentration of cDNA copies per 50 ng RNA as indicated (ntech. 
=3). Statistical significance is indicated (paired t-test). 
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Figure 5: Working hypothesis - Control the transcription of lncRNAs by E2 and E3A which might be involved 
in the regulation of neighboring/remote coding genes. Extension of the proposed model for E3A by the E2 
counter-action. The transactivator E2 binds through CBF1 to intergenic regions (preferably enhancers), 
positively influencing the transcription of neighboring genes by the induction of a lncRNA (eRNA). E3A 
displays E2 from CBF1, negatively influencing the transcription of neighboring genes by repression of a 
lncRNA. The repression of the chromatin domain is sealed by the polycomb repressive mark H3K27me3 
(blue flags) mediated by PRC proteins (Figure modified from Harth-Hertle et al., 2013). The regulation by E2 
and E3A could occur on a higher level of chromatin organization. 
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2 Material & methods 
 
2.1 Cell culture related information 
2.1.1 Donor samples 
 
Surgically removed adenoids were obtained from anonymous donors from Munich, Germany. The 
local ethics committee (Ethikkommission bei der LMU Muenchen) approved the use of this human 
material. 
 
2.1.2 Isolation of human primary cells 
 
Human primary B cells were isolated from adenoids by Ficoll gradient centrifugation with Ficoll-
Paque Premium (density 1.077+/-0.001 g/ml; GE Healthcare). T cell numbers were minimized by 
erythrocyte rosetting. Successful depletion of T cells was verified by staining for the B cell marker 
CD19 (α-CD19 antibody: APC Mouse Anti-Human CD19, Cat#555415, BD Pharmingen; isotype 
CNTRL: Mouse IgG1 neg. CNTRL APC, #MCA928APC, Serotec) and for the T cell marker CD3 (α-
CD3 antibody: PE Mouse Anti-human CD3, Cat# 555333, BD Parmingen; isotype CNTRL: Mouse 
IgG1 neg. CNTRL RPe, #MCA928PE, Serotec) and subsequent analyzation by flow cytometry using 
the FACSCalibur (BD Biosciences) and FlowJo software (BD Biosciences). Primary B cells were 
seeded in RPMI 1640 medium (Gibco Life Technologies) supplemented with 20 % FCS (fetal calf 
serum, Bio&Sell), 4 mM L-Glutamine and 0.5 x penicillin/streptomycin (Gibco Life Technologies), 
1 mM Pyruvat (Gibco Life Technologies), 100 µM α-TG (SIGMA), 1 % MEM NEAA (Gibco Life 
Technologies). 
 
2.1.3 Cell Lines and cell culture conditions 
 
DG75 cells are an EBV negative Burkitt’s lymphoma cell line. They were maintained as suspension 
cultures in RPMI 1640 medium (Gibco Life Technologies) supplemented with 10 % FCS (fetal calf 
serum, Bio&Sell), 4 mM L-Glutamine and 1 x penicillin/streptomycin (Gibco Life Technologies). 
They were split twice a week according to their density 1:3 to 1:4. The DG75doxHA-E2/CBF1 wt 
(CKR128-34) and the DG75doxHA-E2/CBF1 ko (CKR178-10) cell lines carry the Dox inducible HA-E2 
expression plasmid (described in Glaser et al., 2017), where eGFP and NGFR are simultaneously 
expressed together with HA-E2. E2 expression can be induced by doxycycline treatment (1 μg/ml). 
Jurkat cells are immortalized human T lymphocyte cells. They were maintained as suspension 
cultures in RPMI 1640 medium (Gibco Life Technologies) supplemented with 10 % FCS (Bio&Sell), 
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4 mM L-Glutamine and 1 x penicillin/streptomycin (Gibco Life Technologies). They were split twice 
a week 1:5.  
The LCL ER/EB2-5 has been described before (B Kempkes et al., 1995). It is an EBV immortalized 
B cell line that has been infected with the mini-EBV plasmid 554-4 (E2 expression plasmid flanked 
by genomic sequences of the B95-8 virus strain) and EBV strain P3HR1 that is deleted for the open 
reading frame of E2. ER/EB2-5 cells express an E2 open reading frame fused to the estrogen 
receptor hormone binding domain (ER/E2). For analysis of E2 dependent gene regulation, medium 
of ER/EB 2-5 cells was depleted for estrogen (3x washing with estrogen free medium) and cells 
were cultured in estrogen free medium for 4 days. For cycloheximide (ChX) treatment 50 µg/ml of 
the protein synthesis inhibitor (Sigma) was added after depletion for 1 h. For the reactivation of 
E2, 1 µM β-estradiol (E2758 Sigma) was added to the estrogen-free cell culture medium and after 
6 h cells were harvested for further analysis (Figure S1). They were split twice a week 1:3. 
The LCL EB2-3 has been described before as well (B Kempkes et al., 1995). It was used as a 
control (CNTRL) cell line for ER/EB2-5. It originates from the same donor as ER/EB2-5 and got 
infected with P3HR1 and the mini-EBV plasmid 554 (normal E2 protein expression). They were split 
twice a week 1:3. 
The wt (CP364-1) and ΔE3A mutant (CP364-42; “E3AmtB”) LCLs were described before (Hertle et 
al., 2009). Both LCLs originate from primary B cells of the same donor infected with recombinant 
EBV, either the wt BAC (2089) or a ∆E3A BAC (Be715). They were split twice a week 1:4 to 1:5.  
The cell line ΔE3A-LCLdoxHA-E3A (MH1680-9) was established by transfection of the ΔE3A mutant cell 
line with respective pRTS-1 derivatives (MH1680-9; Harth-Hertle et al., 2013). Addition of 
doxycycline (1 µg/µl) leads to the simultaneous expression of N-terminal HA-tagged E3A and nerve 
growth factor receptor (NGFR). They were cultivated in 1 μg/ml puromycin containing media. They 
were split twice a week 1:4. 
All LCL cells were maintained as suspension cultures in RPMI 1640 medium (Gibco Life 
Technologies) supplemented with 20 % FCS (Bio&Sell), 4 mM L-Glutamine and 1 x penicillin/ 
streptomycin (Gibco Life Technologies).  
Supernatant from the marmoset B cell line B95.8 was used as the source of wild-type virus to 
generate LCL from primary B cells. 0.5 μg/ml cyclosporin A (Sigma) was initially added to the 
cultures to inhibit T cell growth. 
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2.1.4 Flow cytometry 
 
Inducibility of E2 expression in DG75doxHA-E2/CBF1 wt and ko cell lines was evaluated by 
monitoring the expression of the eGFP surrogate marker of pCKR74.2 (Figure S2). Cells were 
induced for 24 h with doxycycline (dox), washed with phosphate buffered saline (PBS) and fixed 
with 0.5 % paraformaldehyde (PFA) in PBS. Inducibility of E3A expression in LCLdoxHA-E3A 
(MH1680-9) was evaluated by staining for NGFR expression (Figure S3). Cells were induced for 
24 h with dox, washed with PBS and stained with 50 µl α-NGFR (= hybridoma supernatant, 
HB8737-1, E. Kremmer) for 20 min on ice. Subsequently, cells were washed with PCS and stained 
with 50 µl 1:400 goat α-mouse Cy5 (Dianova; ~0.7µg/µl; 1:1 in glycerol). Afterwards, cells were 
washed again with PBS and fixed with 0.5 % PFA in PBS. For quantification of induced cells, 
FACSCalibur (BD Biosciences) and for analysis FlowJo software (BD Biosciences) were applied 
(Figure S3). 
 
2.2 RNAi related techniques 
2.2.1 Transfection 
 
5x 106 DG75 cells were transfected by electroporation at 250 V and 950 μF in 250 μl reduced 
serum media (Opti-MEM, Gibco Life Technologies; without supplements) using 0.4 cm electrode 
gap cuvettes (Bio-Rad) and the Bio-Rad Gene Pulser. 
 
2.2.2 siRNA knock down in DG75 cells 
 
5x 106 cells were transfected with 100 pmol control siRNA-A (siCNTRL) or EBF1 siRNA (siEBF1; 
both Santa Cruz Biotechnology, sc-37007 and sc-10695) by electroporation. 24 h after 
transfection, 1x 107 induced, siRNA treated cells were harvested for chromatin isolation and 
5x 106 cells for protein isolation (Figure S4). 
 
2.3 Immunoblotting 
 
5x 106 cells were lysed in 200 μl NP-40 lysis buffer (1% NP-40, 150 mM NaCl, 10 mM Tris- HCL 
pH 7.4, 1 mM EDTA pH 8.0, 3 % Glycerol) for 2 h on ice. 30 μg of total cell lysate were submitted 
to SDS-PAGE under reducing conditions. Immunoblotting was performed on polyvinylidene 
difluoride (PVDF) membranes. Western blots were probed with the following primary antibodies: 
rat α-E2 (R3; IgG2A; E. Kremmer), rat α-CBF1 (RBP-J 7A11, E.Kremmer), rat α-GST (GST 6G9, 
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IgG2A, E. Kremmer), mouse α-EBF (Santa Cruz Biotechnology, sc-137065) and α -GAPDH (EMD 
Millipore MAB374). Horseradish peroxidase (HRP)-coupled secondary antibodies (Santa Cruz 
Biotechnology) and an enhanced chemiluminescence (ECL) kit (GE Healthcare) were used for 
visualization. For subsequent quantification of protein levels, exposed films were scanned in 
transmission mode and protein band intensities were determined by densitometry using ImageJ 
software (http://rsbweb.nih.gov/ij/; Schneider, Rasband, & Eliceiri, 2012). 
 
2.4 DNA related techniques 
2.4.1 Chromatin immunoprecipitation (ChIP) 
 
This ChIP protocol is based on reference (Ciccone, Morshead, & Oettinger, 2003) with minor 
modifications as indicated below. In brief, 107 DG75doxHA-E2 cells were harvested and washed twice 
in ice cold PBS, resuspended in 20 ml RPMI 1640 (Gibco Life Technologies) and formaldehyde 
(1 % final) was added for crosslinking. The reaction was stopped by addition of glycine (125 mM 
final) after 7 min and gentle shaking for 5 min at room temperature (RT). Cells were pelleted and 
washed twice in ice cold PBS. Nuclei were isolated by washing the cells 3x with 10 ml of ice cold 
Lysis Buffer (10 mM Tris-HCl, pH 7.5, 10 mM NaCl, 3 mM MgCl2, 0.5 % NP-40, 1x proteinase 
inhibitor cocktail (PIC, Roche)) and subsequent centrifugation (300x g for 10 min at 4 °C). Nuclei 
were resuspended in 1 ml Sonication Buffer (50 mM Tris-HCl, pH 8.0, 10 mM EDTA, pH 8.0, 0.5 % 
SDS, 1x PIC) and incubated on ice for 10 min. Chromatin was sheared to an average size of 200–
300 bp by four rounds of sonication for 10 min (30 sec pulse, 30 sec pause) using a Bioruptor 
device (Biogenode). Cell debris was separated by centrifugation at maximum speed for 10 min at 
4 ˚C and chromatin containing supernatants were stored at -80 ˚C or directly used for IP. To 
prepare input DNA, 12.5 μl aliquots (1/10 of the amount used per IP) were saved at -80 ˚C. For 
IPs 250 μl chromatin (equals 5x 106 cells) were diluted 1:4 with IP Dilution Buffer (12.5 mM Tri-
HCl, pH 8.0, 212.5 mM NaCl, 1.25 % Triton X-100, 1x PIC) and incubated with 100 μl of hybridoma 
supernatant on a rotating platform at 4 ˚C overnight. A combination of E2 and HA-tag specific 
antibodies (α-E2 R3 (rat IgG2a), α-E2 1E6 (rat IgG2a), and α-HA R1-3F10 (rat IgG1)) was used to 
precipitate E2 and an isotype-matched unspecific antibody mixture ( α-GST 6G9 (rat IgG2a) and α-
CD23 Dog-CD3 (rat IgG1) both by E. Kremmer) was used as isotype control. The EBF antibody (C-
8; sc-137065, Santa Cruz Biotechnology) was used to precipitate EBF1 and an antibody specific 
for ovalbumin (M-Ova 3D2, E. Kremmer) was used as an isotype control. Protein G sepharose (GE 
Healthcare) was equilibrated with IP Dilution Buffer, added to the lysate and incubated at 4 ˚C for 
4 h with constant rotation. Beads were extensively washed with: 2x Wash Buffer I (20 mM Tris-HCl, 
pH 8.0, 2 mM EDTA, pH 8.0, 1 % Triton X-100, 150 mM NaCl, 0.1 % SDS, 1x PIC), 1x Wash Buffer 
II (20 mM Tris-HCl, pH 8.0, 2 mM EDTA, pH 8.0, 1 % Triton X-100, 500 mM NaCl, 0.1 % SDS, 1x 
PIC), 1x Wash Buffer III (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, pH 8.0, 250 mM LiCl, 1 % NP-40, 
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1 % sodium deoxycholate, 1x PIC) for 5 min under rotation, and 2x with TE (10 mM Tris-HCl, pH 8.0, 
1 mM EDTA, pH 8.0) for 1 min. Protein-DNA complexes were eluted with 2x 150 μl Elution Buffer 
(25 mM Tris-HCl, pH 7.5, 10 mM EDTA, pH 8.0, 1 % SDS) at 65 ˚C for 15 min. Input samples were 
adjusted to 300 μl with Elution Buffer. Eluates and input samples were incubated with Proteinase 
K (1.5 μg/μl final, Roche) for 1 h at 42 ˚C. Cross-linking was reversed by incubation at 65 ˚C 
overnight. DNA was recovered using QIAquick PCR purification kit (Qiagen). 
 
2.4.2 Chromatin immunoprecipitation quantitative polymerase chain 
reaction (ChIP-qPCR) 
 
qPCR was performed using LightCycler 480 SYBR Green I Master (Roche) on a LightCycler 480 II 
instrument (Roche) as described previously (Harth-Hertle et al., 2013). Two technical replicates 
were analyzed for each biological replicate. All primer were established to fit an annealing 
temperature of 63 ˚C. To account for differences in amplification efficiencies, a standard curve 
was generated for each primer pair using serial dilutions of sheared DNA (input) as template. DNA 
quantities detected in input samples were adjusted to the amount of chromatin used per IP by 
multiplication with 20. Values obtained from IP samples with unspecific IgG CNTRL were subtracted 
from the DNA amounts recovered by IP with specific antibody. The percent of input was calculated 
as (DNA from specific IP corrected for IgG CNTRL background/ DNA input) x 100. To validate the 
ChIP, qPCR known (ChIP-Seq) positive and negative loci were performed. To adjust to divergent E2 
inducibility in wildtype and knock out cells, the percent input was calculated relative to a known 
negative locus (ChIP-Seq; percent input at tested locus/percent input of known negative locus). To 
display the change in binding, the mean relative input of the wildtype cells treated with control 
siRNA was set to one. A paired t-test was performed to assess significance of differences of means. 
Graphs were created using Graph Pad Prism. 
 
2.4.3 Isolation of genomic DNA and quantification by quantitative polymerase 
chain reaction (qPCR) 
 
For the isolation of complete genomic DNA QIAamp DNA Mini Kit was applied according to the 
manufacturers’ instructions using 5 x 106 cells as input material. DNA was eluted in 100 µl H2O 
and concentration was monitored using the Qubit 2.0 Fluorometer. Isolated gDNA was quantified 
using the Roche LightCycler 480 II instrument and LightCycler 480 SYBR Green I Master (Roche) 
reagent according to the manufacturers’ instructions (see section 3.2.1 p. 44; primers see Table 
4 p. 37). 
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2.4.4 EBV copy number assessment 
 
gDNA was isolated from 5x 106 Namalwa, wt LCL and ∆E3A LCL cells and qPCR of a cellular (ß2m) 
and a viral (BALF5) housekeeping genes was performed (Figure 11B). Absolute quantification was 
conducted (see 2.5.3) and mean amount of DNA copies/14 ng of DNA for ß2m and BALF5 were 
obtained (ntech=3). The mean amount of DNA copies over three biological replicates for BALF5 was 
divided by the amount of DNA copies of ß2m for every cell line and normalized to Namalwa cells, 
since they are known to carry two EBV copies (Whitaker, 1985). 
 
2.5 RNA related techniques 
2.5.1 RNA extraction 
 
For total RNA extraction with the RNeasy Mini Kit (Qiagen), 4 x 105 to 1 x 107 cells were lysed in 
RLT buffer (Qiagen) supplemented with β-Mercaptoethanol (Sigma) according to the 
manufacturer’s protocol. The lysed cells were loaded onto a QIAShredder and spun down for 2 min 
with full speed at RT. The protocol was followed including the optional DNase digest for 30 min 
instead of 15 min. Nuclear and cytoplasmic fractions were obtained as published (Weil, Boutain, 
Audibert, & Dautry, 2000) with some modifications. Two-fold approach with each 108 cells were 
harvested and washed twice with ice-cold PBS followed by centrifugation for 5 min at 500x g. 108 
cells were resuspended in 2 ml Lysis Buffer (0.5 % NP40, 1.5 mM NaCl, 10 mM Tris HCl pH 7.8, 
1.5 mM MgCl2, 10 mM EDTA, pH 8, RNase inhibitor 100 U/ml from Promega) and incubated for 
10 min on ice. After centrifugation at 500x g for 5 min at 4 °C, the supernatant containing the 
cytoplasmic fraction was spun down for 1 min with full speed (= 25,000x g) at 4 °C. 200 µl (107 
cell equivalents) of the supernatant was submitted to RNA isolation (with 700 µl RLT-Buffer). The 
nuclear pellet was washed once with Lysis Buffer and subsequently submitted to RNA isolation 
using 2.4 ml RLT buffer. The nuclear fraction was soaked 20x through a 20-gauge needle to destroy 
precipitates. The lysed pellet of 108 cells was split and loaded on three QIA-Shredder. The protocol 
of the RNeasy Mini Kit was followed including the optional DNase digest with the double amount 
of DNase (55 KU) for 1 h. After elution, the nucleic RNA of 2 x 108 cells was pooled. RNA quantity 
and quality was monitored by Qubit 2.0 Fluorometer and BioAnalyzer (Agilent), RIN >7 (RNA 
integrity number; Figure S5 left). Successful fractionation was verified by RT-qPCR of crucial 
candidate genes for the cytoplasm (GAPDH) and the nucleus (NEAT1; based on De Santa et al., 
2010; Figure S6). 
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2.5.2 Reverse transcription (RT) of RNA into cDNA 
 
RNA was reverse transcribed to obtain cDNA as target for PCR analyses (RT-qPCR). SuperScript IV 
First-Strand Synthesis Reaction (Thermo Fischer Scientific) was applied according to the 
manufacturers’ instructions using 1 to 4 µg RNA as input. As a standard procedure for each 
analyzed sample, two reactions were set up, one containing reverse transcriptase and the second 
without enzyme, serving as negative control for genomic DNA contamination. For qPCR analysis, 
undiluted or up to 1:8 diluted cDNA (according to 50 ng input RNA per well) was used as template 
for quantification.  
 
2.5.3 Quantitative polymerase chain reaction (RT-qPCR) 
 
RT-qPCR was performed using LightCycler 480 SYBR Green I Master (Roche; 10 µl reaction volume: 
5 µl LightCycler 480 SYBR I Green, 1 µl 5 µM Forward Primer, 1 µl 5 µM Reverse Primer, 1 µl H2O 
and 2µl sample) on a LightCycler 480 II instrument (Roche) according to the manufacturer’s 
protocol. Cycling conditions were 10 min at 95 °C and 45 cycles of 3 sec at 95 °C, 10 sec at 63 °C 
and 20 sec at 72 °C. All Primers were established to fit an annealing temperature of 63 °C 
(primers see Table 2 p. 34/ Table 3 p. 37). PCR products were analyzed by melting curve analysis 
and tested for correct size by gel electrophoresis. If possible, primer were designed to generate an 
amplicon of similar size (200 to 400 bp) to not bias the SYBR green signal intensities of different 
products. Standard curve generation was performed as described before with minor changes 
(Harth-Hertle et al., 2013). Absolute quantification of transcripts was performed using cDNA 
equivalent to 50 ng RNA prepared from 1 to 4 µg RNA as a template and was based on the 
standard samples of known concentration and the respective PCR efficiency for each primer pair. 
Analysis was done by the LightCyler® 480 software (SW1.5). Relative quantification was calculated 
by the software, taking a calibration of each plate into account. As housekeeping genes for the E3A 
system served GAPDH. Since E2 is inducing cell growth, most of the housekeeping genes are 
regulated by E2, like GAPDH or gusB (data not shown). Eisenberg et al suggested a new set of 
housekeeping genes which show constant expression levels across 16 human tissue types 
(including white blood cells; Eisenberg et al 2013). The charged multivesicular body protein, 
CHMP2A, was one of the suggested housekeeping genes and showed no substantial regulation by 
E2 in our RNA-Seq data. Thus, CHMP2A was used as housekeeping gene for E2. U6snRNA served 
as a non-coding housekeeping gene. It has to be mentioned that U6snRNA is a transcript produced 
by PolIII, whereas the other E2 regulated targets are presumably PolII produced targets. 
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2.5.4 Endpoint PCR 
 
To apply a temperature gradient, a diagnostic PCR analysis was conducted using, apart from the 
temperature, the same cycling conditions as for the LightCycler on the PeqLab Cycler. To stick with 
the same reaction conditions, the LightCycler 480 SYBR I Green (Roche) was used here as well in 
a 20 µl reaction volume (10 µl SYBR I Green, 1 µl 5 µM Forward Primer, 1 µl 5 µM Reverse Primer, 
3 µl H2O and 5 µl sample; for primers, see Table 2 p. 34, ◊ only for endpoint PCR). Subsequently, 
the products were loaded on a 2 % agarose gel containing 0.01 % (v/v) EtBr. Subsequently, 
fragments were visualized under UV light. 
 
2.5.5 Transcriptome analysis by RNA-Seq 
 
For the complete E3A cell system libraries and the nuclear libraries of the E2 cell system, 30 µg of 
isolated RNA were applied to a DNase digestion in solution (1 U/µl, 1 U/µg RNA; Promega) for 1 h 
at 37 °C followed by 10 min at 65 °C for termination and RNA quality was examined using the 
Agilent BioAnalyzer (Figure S5, left; RNA Nano Kit), which identifies the major abundant RNA 
fractions contained in the samples (peaks of 18S/28S rRNA). The rRNA was depleted by subjecting 
5 µg fractionated, DNase-digested RNA to the RiboZero Magnetic Gold Kit (Epicentre). The RNA 
quality was examined again using the BioAnalyzer (Figure S5, right; RNA Pico Kit). After rRNA 
depletion, the major abundant RNA fractions, 18S/28S rRNA, are not detectable any more. With 
samples of the E3A cell system and the nuclear fractions of the E2 cell system were proceeded as 
follows: 50 ng of the rRNA depleted RNA were applied as input to the library preparation using the 
ScriptSec v2 RNA-Seq Library Preparation Kit from Epicentre. The obtained libraries were di-tagged, 
barcoded libraries. To purify these libraries, the AMPure Bead-System was applied, retaining 
fragments of 200 to 500 bps. The libraries were sent to external Sequencing Facility LAFUGA (Blum 
Lab-Genomics, Gene Center Munich), which verified the quality of the libraries for us. The libraries 
were sequenced in a 100 bp-paired-end, multiplexed fashion on the HiSeq1500 Sequencer from 
Illumina (6 libraries per lane were loaded on the flow cell). The libraries (of three biological 
replicates) from E3A experiments was sequenced three times (three technical replicates), the 
libraries (of three biological replicates) from E2 experiments was sequenced two times (two 
technical replicates). 
For the cytoplasmic libraries of the E2 cell system, an in house service of the Munich Sequencing 
Alliance (Institute of Human Genetics, Helmholtz Zentrum Muenchen) was used. 20 µl of the 
DNase digested RNA (~500 µg/ml) were sent to the in house sequencing facility, which verified the 
RNA quality, depleted for rRNA using the RiboZero Magnetic Gold Kit (Epicentre) and prepared the 
libraries for us, using the TrueSeq Stranded Total RNA Sample Prep Kit (Illumina). The libraries 
were sequenced in a 100 bp-paired-end, multiplexed fashion on the HiSeq2500. 
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2.5.6 Bioinformatic methods 
 
Multiplexed fastqsanger files of self-prepared libraries were provided on the GALAXY platform of 
LAFUGA (https://blum-galaxy.genzentrum.lmu.de). Files were demultiplexed using the Illumina 
demultiplex tool (Galaxy Version 1.0.0). Cytoplasmic E2 libraries were provided already 
demultiplexed. 
 
2.5.6.1 Analysis of the human transcriptome 
 
The analysis of the human transcriptome was performed in collaboration with Gergely Csaba from 
the group of Ralf Zimmer, Teaching and Research Unit Bioinformatics, LMU. The analysis of RNA-
Seq requires a concatenation of different tasks, basically mapping, counting and DE- testing (Figure 
6). 
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Figure 6: Flow Chart displaying the process of RNA-Seq analysis. Three major tasks have to be completed for 
identification of regulated genes: mapping, counting and differential expression testing.  If libraries are 
prepared in a multiplexed manner to load more than one sample on one lane, the read files obtained from 
the sequencer, have to be demulitplexed prior to mapping. For mapping, raw reads are aligned based on 
their sequence to the sample corresponding genome using the mapper HISAT, STAR, ContextMap2 or 
TopHat2. For Counting, number of reads aligning to a defined (genomic position by chromosome number, 
start- and end) feature like gene, transcript, exon or other region are counted based the chosen annotation 
file (were the features are annotated to a genomic position). After counting the aligned reads in different 
conditions, the numbers of reads can be compared for a condition pair by using the tools limma, edgeR, a2a 
and DE-Seq, which perform differential expression testing.  
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Mapping of RNA-Seq reads 
 
RNA-Seq reads mapping to the human genome (genome built hg19 = GrCh37) was conducted. 
Technical replicates of the self-prepared libraries were merged. As a consequence, in average 
8x 107 reads were obtained for every sample. For mapping, four different mappers, HISAT (D. Kim, 
Langmead, & Salzberg, 2015), ContextMap2 (Bonfert, Kirner, Csaba, Zimmer, & Friedel, 2015), 
STAR (Dobin et al., 2013) and TopHat2 (D. Kim et al., 2013) were used. 
Covered regions consistently found by all mapper (read pair had to reside completely within a gene) 
were extracted and assigned to a gene or transcript. For gene/transcript/exon annotation, the 
GRCh37 assembly of ENSEMBL (release 75) was used (= Gencode v19). Regions not identical to 
any ENSEMBL gene annotation (in a strand specific manner) were extracted and assigned with a 
new ID for intergenic genes. Regions not overlapping any exons within a gene were extracted and 
assigned with a new ID for intronic genes. 
A general remark has to be made here, library preparation kits can be responsible for reads 
mapping to the opposite strand of a transcribed locus. The two kits used in this thesis perform 
different regarding this, resulting in different absolute number of reads mapping to opposite strand 
regions for the cytoplasmic fraction. These opposite strand reads have to be considered in later 
analysis of antisense genes. 
 
Counting of aligned reads 
 
For counting, an in house count software (can be obtained from AG Zimmer) was applied to 
calculate number of aligned reads mapping to a gene. Either read pairs aligning completely to a 
gene were counted (read origin = gene) or read pairs aligning to a gene were only counted, if the 
fragment structure is fully consistent with a known transcript corresponding to that gene (read 
origin = gene with transcript support). In the latter case, the amount of reads was the sum of reads 
aligning to the gene and reads aligning to the transcripts. Objects for counting were read pairs 
(= fragment). If multiple read pairs were generated by the same RNA- fragment, two ways of down-
sampling were applied to circumvent PCR amplification biases (one fragment could be amplified 
better than others). Either, the counts were downsampled on fragment level: Under the assumption 
that multiple detected identical fragments are PCR artefacts, each fragment is just counted once. 
Or, counts were downscaled in a way that the impact of highly amplified fragments was decreased. 
Therefore, the ratio of counts per fragment for all samples divided by the maximal detected counts 
per fragment multiplied with the log2FC of the max. detected counts per fragment was taken into 
account for each fragment. Counts per gene were the sum of all downscaled fragment counts. 
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Differential expression (DE) testing 
 
For DE-testing four different DE-Methods were used, DE-Seq (Anders & Huber, 2010), limma 
(Ritchie et al., 2015), edgeR (Robinson, McCarthy, & Smyth, 2010) or an in house method, a2a. All 
methods test differential expression based on different models with different statistical 
significance testing. If a significant change for an intergenic/intronic region is observed, the change 
might arise as a byproduct of the containing or overlapping gene. In order to find changes directly 
associated to the intergenic/intronic regions it was confirmed if an observed change significantly 
differs from the changes of all overlapping objects. The probability of changes is measured as 
unexpectedness of observed changes with respect to the empirical noise of the changes derived 
from the data. This also allows to compare two changes (double differential view) as they imply 
also a change (the change of the changes). This is then applied to the intergenic and intronic 
differential expression. 
 
2.5.6.2 Analysis of the viral transcriptome 
 
In a second collaboration with the group of Erik Flemington, Cancer Crusaders Bioinformatics Core 
in New Orleans was started to analyze the RNA-Seq reads mapping to the EBV genome (mapping 
to Akata genome) was accomplished. This laboratory published the, until now, most complete 
annotation for the Akata genome by combining different sequencing methods (Lin et al., 2013). 
The Akata EBV strain is non-defective and represents a wild-type virus.  
 
Workflow and Analysis 
 
Reads were mapped using the STAR mapper. Since EBV genome is of dense organization with 
multiple genes overlapping, reads are mapping to multiple genes or isoforms and transcript 
quantification is difficult. Therefore, for counting and differential expression testing, RSEM (B. Li & 
Dewey, 2011) was applied. This package has the advantage to effectively deal with ambiguously-
mapping reads. 
Analysis was performed by the Flemington group. Results were provided as normalized read 
counts. Reads obtained from ChIP-Seq (Glaser, PhD thesis, 2017) were aligned to the Akata 
genome and peaks were called using MACS2 (Y. Zhang et al., 2008). 
 
 
 
 
 
 Material & methods 
33 
 
2.5.6.3 Visualization of RNA-Seq results 
 
For visualization, coverage tracks were generated for sense and antisense strand separately from 
mapped reads (bam files; mapper=STAR) and loaded into the Integrative Genomics Viewer (IGV) 
from the Broad Institute (https://software.broadinstitute.org/software/igv/download). 
 
 
2.5.6.4 Self-performed computational work 
 
For self-performed computational work and visualization, the GALAXY platform of the Backofen 
Lab, Chair for Bioinformatics, Institute for Informatics, University of Freiburg was used 
(https://galaxy.uni-freiburg.de). Heatmaps were generated using the tool “multiBamSummary”, 
which calculated average read coverages for BAM files (mapped reads). For this, the genome was 
split into bins of 1000 bp. For each bin, the number of reads found in each BAM file was counted. 
For coverage calculation, bins with zero or large counts were also included, distance between bins 
= 0 bp. The tool “plotCorrelation” created a heatmap of correlation scores between indicated 
samples obtained by Spearman correlation. 
 
2.6 Gene ontology analysis 
 
For gene enrichment testing, classical ORA (overrepresentation analysis) was conducted by Gergely 
Csaba, using a hypergeometric test. 
We asked for GO-terms of biological processes, for which an enrichment could be calculated for 
the subset of counter-regulated genes (741; strength and direction of regulation was not included). 
The background was defined as all genes, which were detected in any sample/any condition/any 
compartment with ≥ 1 read count. Hits were not filtered for dependency. Significance was limited 
to p < 0.05. Selected GO terms are shown (target genes per term)/ (total genes per term). 
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2.7 Primers  
 
2.7.1 Human chromatin primers 
 
Table 1: Primer pairs for qPCR on human chromatin 
Internal 
Designation 
Target Sequence 
Ampl. 
Length 
in bp 
An-
notation 
Position hg19 
SAR105.1fwd RHOH TSS-
6.749bp 
AGGGAAAGTTAAGACAGGCCTT 110  chr4:40187701 +40187810 SAR105.1rev TAGAGGATTCCAACCCAATGCC 
SAR105.2fwd DNAJB12 
TSS-56.9kb 
CTTGGCACGAACTCTTCCTTC 117  chr10:74057129 +74057245 SAR105.2rev AGATGTGAGAATGATGTGGCCG 
SAR105.4fwd SWAP70 
TSS-62.2kb 
GCTGGGTTTGCGGTTTAATG 100  chr11:9623168 +9623267 SAR105.4rev TTGCTGCTCCCTAAGGTTTG 
SAR92.5fwd POU2F2 TGGCCTCAAGGGAGTGAAC 83  chr19:42633923 +42634005 SAR92.5rev GGCCACCTCTCTTGTTGTG 
SAR92.6fwd CLEC16A AGTGCACATTGGCAGAACTC 80  chr19:42633923 +42634005 SAR92.6rev CTCTGAGCTTGGGTCCTCAC 
SAR92.9fwd CSRNP1 TAGGCAAGCGTGAGAGAAGC 88  chr3:39189615 +39189702 SAR92.9rev CCCGGAAACATCTGTGAGTC 
MH2675fw ADAMDEC1 
TSS 
-16,65 bp 
CTTCATGGCTACAGACTCTTGG 
93 
+ CNTRL 
locus, E2 
binding 
site 
chr8:24224967-
24225059 MH2675rv CCTATGTCTCGCTTCCTGCT 
ST122_F 
RPL30 TSS 
-1,94 bp 
CTGGTCTGACGCTCCTGACT 
120 
- CNTRL, 
no E2 
binding 
site 
chr8:99055763-
99055882 
ST122_R CAGTGCCCAGAATTCCAGAT 
 
 
2.7.2 Human cDNA primers 
 
Table 2: Primer pairs for RT-qPCR on cellular transcripts; *Transcript information based on ENSEMBL 
GrCH75; ◊ only for endpoint PCR 
Internal 
Designation Target Sequence 
Ampl. 
Lengt
h in 
bp 
Annotation Position hg19 
SAR40.3fwd 
MYC* 
CTCTCAACGACAGCAGCTC 
210 
exon-exon-
junct. on 
2nd and 3rd 
exon; 
targets 3/5 
transcripts 
chr8:12875110
1 
+128752686 
 SAR40.3rv CCACAGAAACAACATCGATTTC 
SAR149.3fwd 
PCAT1 
tv1* 
AGAGGCAGAGGATGTTGACAC 
253 
exon-exon-
junct. on 
the 2nd  
and the 4th 
exon of tv1 
chr8:12788991
8 
+128018828 SAR149.3rev AACGTGTGCATCCCAAGAGG 
SAR127.6fwd 
CASC19* 
TCCTTGCCAGTGTCTTCTCC 
210 
exon-exon-
junct. on 
the 1st and 
chr8:12820008
8 
+128209816 SAR127.6rev CCCGTAGATTGCAAACTCCTAG 
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the 3rd 
exon 
SAR127.10fw CASC21* 
(RP11-
382A18.2) 
TGAAACCTCTGCTTCCTGGC 
220 
exon-exon-
junct. on 
the 2nd and 
the 3rd 
exon 
chr8:12833436
9 
+128351642 SAR127.10re
v TGCTGGACGTCTTCTCTTGG 
SAR149.5fwd 
LINC00977*
◊ 
TGCTGGCCTCTTTCTCATGG 
252 
exon-exon 
junct. on 
3rd and 2nd 
exon 
chr8:13022946
0 
+130235525 SAR149.5rev AAGCCAGAAATCCAGGACCC 
SAR179.3fwd 
LINC00977* 
TGGTGGTGGTTGTATCAGGC 
321 
monoexoni
c primer on 
3rd 
exon, gDNA 
same size 
chr8:13022918
7 
+130229507 SAR179.3rev GGGCTTGCTTTCATTCTGTGG 
SAR127.11fw 
CCDC26* 
GCAATGCCTCCTCCTCCTTC 
280 
exon-exon-
junct. on 
the 3rd and 
4th exon; 
targets 3 
/4 
transcripts 
chr8:13036501
5 
+130382620 SAR127.11re
v GGCCTGAGGAGAGAAGACAC 
SAR127.3fwd 
CD84* 
GTCAGCTCTTGGTCCTCAGG 
372 
exon-exon-
junct. on 
2nd and 3rd 
exon; 
targets 4/5 
transcripts 
chr1:16052375
6 
+160535384 SAR127.3rev AGACTCAGAAACAGCACCCG 
SAR156.1fwd 
RP11-
528G1.2*◊ 
GCAGTTCCAGCAAGCATGTC 
371 
exon-exon 
junct 
primer on 
1st and 2nd 
exon 
chr1:16050690
0 
+160541021 SAR156.1rev TGACCCTCCTCTCCTTCACC 
SAR179.2fwd 
RP11-
528G1.2* 
CAGAAATGGCGTGGGTGAAG 
212 
mono-
exonic 
primer on 
2nd exon, 
gDNA 
same size 
chr1:16054098
9 
+160541200 SAR179.2rev ACATCAGTGGCAATCTCCTCC 
SAR127.1fwd 
SLAMF1* 
GTATCAAGGTGCAGGTCCCG 
375 
exon-exon-
junct. on 
the 2nd and 
the 3rd 
exon; 
targets all 
5 
transcripts 
chr1:16060461
9 
+160607286 
SAR127.1rev GGCAGTTGGGAAGCAAAGTG 
SAR127.4fwd 
CD48* 
GTGCCATTCTTGCTGCTCAC 
372 
exon-exon-
junct. on 
the 2nd and 
the 3rd 
exon; 
targets all 
4 
transcripts 
chr1:16065102
1 
+160654804 
SAR127.4rev ACTTGATCCTCAGAGTGGCG 
SAR156.7fwd PPAN-P2RY11* TGCGTGATGTGGTCTCCTC 204 
exon-exon-
junct. on 
the 5th and 
the 6th 
chr19:1022167
6 
+10224625 
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SAR156.7rev TGTAGTCGATGAGGAGGCAG 
exon; 
targets 4 
PPAN 
transcripts 
+ 2 read-
through 
transcripts 
 
SAR156.8fwd  
CTD-
2240E14.4* 
 
GTGGGTCAAGGGTCAGGTTC 
326 
mono-
exonic 
transcript; 
gDNA 
same size 
 
chr19:1020063
6 
-10200961 SAR156.8rev GGACGACCTTATCCCTGCTG 
SAR179.4fwd 
ANGPTL6* 
CAGCCCAGTAGACACCATCC 
200 
 
exon-exon-
junct. on 
the 4th and 
the 6th 
exon ; 
targets 
both 
transcripts 
chr19:1020330 
+10204442 
SAR179.4rev GTGGAGGCTGGACTGTGATC 
SAR127.13fw 
CHMP2A* 
CCCAGCTCATCCAGAACCTG 
374 
exon-exon-
junct. on 
the 2nd and 
the 5th 
exon 
chr19:5906329 
+59065438 
SAR127.13rv AAGAAGATGGCCAAGCAAGG 
JAH31.1Bfwd 
CASC8 
tv3* 
TTGAGTGAGGCTGGAACTGG 
201 
exon-exon 
junct. Fwd-
primer on 
exon 
specific for 
tv3, rev-
Primer on 
exon 6 
chr8:12830216 
+128335320 
JAH31.1Arev AGGATCGACGTTCAAGGTGG 
BS688for 
GAPDH 
GAAGGTGAAGGTCGGAGTC 
 
exon-exon 
junction 
primer 
chr12:6644004 
+6645878 LG90rev TGGGTGGAATCATATTGGAAC 
MH2333fw 
gusB 
CGCCCTGCCTATCTGTATTC 
91 
exon-exon 
junction 
primer 
chr7:65439995
-65441028 MH2333rev TCCCCACAGGGAGTGTGTAG 
MH2682fw 
U6snRNA 
CTCGCTTCGGCAGCACATATAC 
96 
according 
to Didier 
Auboeuf 
Picks up 24 loci; 
It is common in 
vertebrate 
genomes to find 
many copies of 
the U6 snRNA 
gene or U6-
derived 
pseudogenes 
MH2682rev GGAACGCTTCACGAATTTGCGTG 
MH2594fw 
Neat1 
GGGCCATCAGCTTTGAATAA 
149 
mono-
exonic 
transcript; 
gDNA 
same size 
chr11:6519171 
+65191859 
MH2594rev CTTGAAGCAAGGTTCCAAGC 
MH350 fw 
ADAMDEC1 
GAAGAGCACTGACGGGAAAC 
231 
Exon-exon 
junction 
primer 
chr8:24254909 
+24256421 MH350rev ACCAAGGCCACTTGAACATC 
MH199 fw 
BMP4 
TCCACAGCACTGGTCTTGAG 
337 
Exon-exon 
junction 
primer 
chr14:5441735 
-54418645 MH199 rev CGTGTCACATTGTGGTGGAC 
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MH2145fw 
CXCL10 
TGACTCTAAGTGGCATTCAAGG 
239 
Exon-exon 
junction 
primer 
chr4:76943518 
-76944544 MH2145rev CCTTTCCTTGCTAACTGCTTTC 
GS 33.1 for 
DNase1L3 
AGGACACCACGGTGAAGAAG 
202 
Exon-exon 
junction 
primer 
chr3:58178469 
-58183590 GS 33.1 rev GTGAAGGCCCTTGAAGACTG 
      
 
2.7.3 Viral cDNA primers 
 
Table 3: Primer pairs for RT-qPCR on viral transcripts 
Internal 
Designation Target Sequence 
Amplicon 
Length 
in bp 
Annotation 
SAR228.6fwd BGRF1/ 
BDRF1* 
TCAACAAGGAGACCAGCACC 290 exon-exon-junct. on 1st and 2nd exon SAR228.6rev ACTTACCACGTTCAGCAGCC 
SAR228.3 fwd 
BHRF1* 
TGGGCATGTGTTGGAATTGC 
224 
monoexonic isoform; viral DNA 
same size! Fwd- primer in intron 
of late splice variant SAR228.3 rev CAGTGTCCTCTGGCGAAAGG 
SAR228.5fwd BNRF1* TACAGGACCATCAACGCCAC 206 monoexonic transcript; viral DNA same size! SAR228.5rev GCCTGTGCCCATGAACTTTC 
SAR228.10fwd LMP2A* GGGTCCCTAGAAATGGTGCC 391 exon-exon-junct. on 1st and 3rd exon SAR228.10rev GTGGGTCCTCAATCCTCCATG 
MH280fw LMP1 TCCTCCTCTTGGCGCTACTG 490 from Yoshioka et al., 2001; according to Imai et al., 1996 MH280rev TCATCACTGTGTCGTTGTCC 
LG521 fw E2 TCTGCTATGCGAATGCTTTG 255 within one exon LG521 rv CACCGTTAGTGTTGCAGGTG 
     
* Primers were designed using the Akata genome annotation provided by the Flemington Lab and the 
P3HR1 sequence. 
 
 
2.7.4 gDNA primers 
 
Table 4: Primer pairs for qPCR on genomic DNA 
 
Internal 
Designation Target Sequence 
Amplicon 
Length in 
bp 
Position hg19 
LG171for BALF5 CATGCTCTACGCCTTCTTCC 343 - LG171rev ATGCACATCCTCCTTCTTGG 
LG172.Bfor ß2m ATTGGGATTGTCAGGGAATG 266 chr15:45008038+45008303 LG172.Brev GGATGCTAGGACAGCAGGAC 
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3 Results 
 
The following results section is divided into two parts. The first part will focus on the accession of 
E2 to DNA while in the second part, E2 mediated gene regulation is investigated. 
 
3.1 Accession of E2 to DNA: E2 requires EBF1 to bind to its CBF1 
independent binding sites in the human genome 
 
Parts of this work are published in Glaser LV*, Rieger S*, Thumann S, Beer S, Kuklik-Roos C, Martin 
DE, et al. (2017) EBF1 binds to EBNA2 and promotes the assembly of EBNA2 chromatin complexes 
in B cells. PLoS Pathog 13(10): e1006664. https://doi.org/10.1371/journal.ppat.1006664 
 
For this study, a CBF1 deficient human B cell line was used. This cell line was generated by 
homologous recombination in the somatic B cell line DG75 (EBV negative Burkitt’s lymphoma cell 
line), to screen for CBF1 independent functions of E2. The DG75doxHA-E2/CBF1 wt and the DG75doxHA-
E2/CBF1 ko cell lines carry the Dox inducible HA-E2 expression plasmid, thus E2 expression can be 
induced by doxycycline treatment (Figure S2). 
 
3.1.1 Peak selection and characterization 
 
E2 ChIP-Seq experiments conducted in DG75doxHA-E2 CBF1 wt or CBF1 ko B cells in the Kempkes 
laboratory revealed that E2 also binds to chromatin independently of CBF1, therefore the question 
about an alternative DNA anchor that might be used by E2 to bind chromatin arose. A genome wide 
correlation analysis of TF binding patterns uncovered that E2 binding sites highly correlate with 
EBF1 binding sites (Glaser, PhD thesis, 2017). Furthermore, EBF1 appeared to be the only 
significant enriched TF signal at CBF1 independent E2 binding sites.  
Thus, we investigated the impact of EBF1 on the binding pattern of E2 by siRNA-mediated knock 
down of EBF1 and subsequent ChIP-qPCR of E2 and EBF1. CBF1 dependent and independent E2 
binding sites with a moderate signal (50 % < mean signal > 90 % percentile), which are also 
present in LCLs and positive for EBF1 binding in LCLs were selected for qPCR (Figure 7A). To 
characterize CBF1 dependent and independent E2 peaks which meet the described requirements, 
an intersection with predefined clusters of EBNA peaks by correlation was conducted. Cluster 
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analysis for EBNA peaks identified eight distinct clusters of combinations for E2, CBF1, EBF1 and 
CUX1 (Figure S7). These four TFs were chosen based on a preceding genome-wide TF binding 
pattern correlation analysis using 89 TFs. Cluster I for instance, positive for all four investigated 
TFs (Figure S7A/B), shows the strongest enrichment for H3K4me1 as well as for H3K27ac (Figure 
S7C), indicating an association of these binding sites with active enhancers. The majority of E2 
peaks from this cluster reside at strong enhancers (66.7 %) according to CSS by ENCODE in 
GM12878 (Figure S7D). In cluster III to VI, CBF1 is missing, in cluster V to VIII EBF1 is missing and 
in cluster IV, V and VIII, CUX1 is missing. Cluster V is positive for E2 only. We hypothesized that 
CBF1 independent E2 binding sites differ from CBF1 dependent binding sites in their properties. 
Contrarily, CBF1 dependent and independent E2 binding sites only slightly differ in their cluster 
composition (Figure 7B). CBF1 independent compared to dependent peaks are enriched for cluster 
I (from 60% to 70%) and cluster V-VIII are depleted (from ~20% to 8%). Cluster V-VIII are clusters 
without EBF1, while cluster I is EBF1 positive and is accompanied by marks for open chromatin. 
 
The comparison of CBF1 dependent with CBF1 independent E2 peaks in LCLs regarding their 
cluster distribution did not indicate substantial differences. Thus, these binding sites may be 
similar regarding their TF binding pattern and their accompanied chromatin states. However these 
data were obtained in LCLs and the chromatin landscape could differ in DG75. 
 
 
 
Figure 7: Cluster Correlation of E2 peaks selected for EBF1 KO analysis show an enrichment for Cluster I 
and a depletion of Cluster VIII for CBF1 independent E2 peaks. A Scheme of E2 peak selection for ChIP-qPCR 
(from bottom to top): All CBF1 dependent and independent E2 peaks with a 50 % < mean signal > 90 % 
percentile, which were also present in LCLs and EBF1 positive in LCLs were selected for ChIP-qPCR upon 
EBF1 KD. B Donut plots of cluster correlation of selected E2 peaks: intersection of the selected E2 peaks 
with the defined clusters (cluster definition from 7; see Figure S7). 
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3.1.2 Confirmation of knock down and ChIP strategy 
 
The aim was to establish a siRNA-mediated knock down strategy. Furthermore, the established 
ChIP protocol needed to be adapted to the EBF1 antibody. 
The role of EBF1 for CBF1 independent EBNA2 binding events was investigated applying knock 
down experiments. DG75doxHA-E2 CBF1 wt or CBF1 ko B cells were transfected with non-targeting 
siRNAs (siCNTRL) or EBF1 specific siRNAs (siEBF1). 8 h post transfection, E2 transcription was 
induced by 1 µM doxycycline. 24 h post transfection, cells were harvested and analyzed by 
immunoblots and ChIP-qPCR (Figure S4). 
siRNA mediated knock down of EBF1 successfully depleted EBF1 to approximately 35 % of the 
expression in siCNTRL transfected cells (Figure 8A, B). In order to verify the established ChIP 
protocol and to later account for differences in the two cell lines (e.g. much higher E2 protein 
expression level in CBF1 ko cells compared to wt cells), a locus positive and a locus negative for 
E2 binding were investigated (Figure 8C). Both loci were confirmed to be either positive or negative 
for E2 binding by ChIP-Seq. E2 could be precipitated well from the positive locus in CBF1 wt cells 
and it still binds weakly to the positive locus in absence of CBF1. At the negative locus, E2 binding 
is detected on background level. The background level of E2 binding in siCNTRL transfected cells 
in CBF1 wt and ko cells at this locus was used for normalization for the following ChIP-qPCR results. 
 
A siRNA-mediated knock down for EBF1 could successfully be established. The existing ChIP 
protocol could be adapted to the EBF1 antibody and E2 binding could be verified at an established 
positive locus. 
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Figure 8: Confirmation of EBF1 knock down by immunoblotting and ChIP-qPCR of CNTRL loci confirming the 
established ChIP. A,B DG75doxHA-E2 CBF1 wt or CBF1 ko B cells were transfected with a mixture of scrambled 
non-targeting siRNAs (siCNTRL) or EBF1 specific siRNAs (siEBF1). 8 h post transfection, E2 transcription was 
induced. 24 h post transfection, cells were harvested and analyzed by immunoblots and ChIP-qPCR. A 
Representative immunoblots showing expression levels of E2, EBF1, CBF1, and GAPDH before and after 
knock down (n=3). EBF1 negative Jurkat cell lysate served as a negative control. B Protein band intensities 
were quantified by densitometry. The mean change of EBF1 protein expression in siRNA (siEBF1) treated 
compared to control (CNTRL) treated cells is significant according to paired t-test as indicated. Standard 
deviations (SD) are indicated (nbiol. =2). C ChIP-qPCR results for E2 binding to chromatin at a laboratory 
internal established E2 positive (ADAMDEC1 TSS-16,646 bp) and an E2 negative locus (RPL30 TSS-1,936 
bp). % input was calculated relative to negative locus to adjust to divergent E2 inducibility in wildtype and 
knock out cells (ChIP-Seq; percent input at tested locus/percent input of known negative locus). Standard 
errors are indicated (ntech. = 2, nbiol. = 3). 
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3.1.3 siRNA-mediated knock down of EBF1 impairs E2 binding at CBF1 
independent sites 
 
We sought to investigate the contribution of EBF1 to E2 binding to CBF1 dependent and 
independent binding sites. 
E2 and EBF1 were immunoprecipitated from chromatin in DG75doxHA-E2 CBF1 wt or CBF1 ko B cells 
and three CBF1 independent (Figure 9A) and CBF1 dependent (Figure 9B) E2 binding sites were 
analyzed by qPCR. The decrease in E2 binding in CBF1 ko cells compared to CBF1 wt cells can be 
observed at all investigated loci. EBF1 binding is decreased in a similar manner in CBF1 ko cells. 
The siRNA mediated knock down of EBF1 leads to a decrease in EBF1 binding at all probed loci, 
while E2 binding is decreased only at the CBF1 independent sites. 
 
These data clearly shows EBF1 dependent E2 binding at CBF1 independent binding sites. Thus, 
EBF1 is used as an alternative anchor for E2 and this complex formation is important at CBF1 
independent binding sites. 
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Figure 9: E2 requires EBF1 to bind to its CBF1 independent binding sites. E2 binding signals and peak tracks 
as obtained in DG75doxHA-E2 (DG75) and E2, CBF1 and EBF1 binding peaks tracks in LCLs are shown for A 
three CBF1 independent and B three CBF1 dependent E2 binding sites. ChIP-qPCR results for EBNA2 binding 
to chromatin before and after EBF1 knock down are shown below the chromatin profiles. % input was 
calculated relative to a known negative locus. Mean relative input of the wildtype cells treated with siCNTRL 
was set to one. Standard deviation and p-values, based on Student's paired t-test, are indicated (ntech. = 2, 
nbiol. = 2). 
 
3.2 Analyses of cellular and viral genes regulated by E2 and E3A 
 
3.2.1 The cell systems: conditional ER/EB2-5 cells and wt versus ΔE3A LCLs 
 
Previously, in the Kempkes laboratory it could be shown that intergenic genomic regions with high 
chromatin accessibility displayed E3A dependent transcription. As lncRNAs play an important role 
in development and pathogenesis of multiple diseases including cancer (see section 1.3.4, p. 16), 
we examined the capability of EBV to regulate lncRNAs genome wide for the transcription factor 
E3A and the co-expressed master regulator of transcription E2. Therefore, two different cell 
systems were used to study regulation of transcription by E2 and E3A. 
ER/EB2-5 cells express an E2 open reading frame fused to the estrogen receptor (ER) hormone 
binding domain (ER/E2). Estrogen in the cell culture medium of ER/EB2-5 induces nuclear 
localization of ER/E2 and hence E2 can act as transcriptional activator and ensures cell 
proliferation (Figure 10A; see section 2.1.3, p. 21). Estrogen depletion of the cell culture medium 
inactivates ER/E2 and causes cell cycle arrest. Re-addition of estrogen causes rapid re-induction 
of E2 target genes. Cycloheximide (ChX) prevents protein translation and is added to the cells 1 h 
prior to estrogen treatment in order to investigate E2 targets independent of translation (Figure 
S1). E2 targets regulated in the presence of ChX were once operationally defined as direct E2 
target genes (Kaiser et al., 1999). Since LCLs do not express the estrogen receptor endogenously, 
estrogen treatment does not alter gene expression in general (Figure 10B) proved by RT-qPCR at 
three different genes in the CNTRL LCL EB2-3. In contrast, the ER/EB2-5 cell line shows changes 
of expression of the housekeeping genes upon 6 h of estrogen treatment most likely due to the 
impact of E2. We aimed to assess the time point of highest target RNA abundance. After depletion, 
re-activation of ER/EB2-5 cells with estrogen induced a peak in RNA abundance of candidate target 
genes, two cellular (MYC, DNase1L3) and a viral target (LMP1), at 6 h post reactivation of ER/E2 
by estrogen (Figure 10C).  
 
The ER/EB2-5 system was selected as an appropriate system to study E2 dependent gene 
regulation, especially in combination with the treatment of ChX. Side effects of estrogen treatment 
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could be excluded and E2 target genes could be induced with a peak abundance at 6 h post re-
activation. 
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Figure 10: Concept of E2 cell system. A Schematic representation of the ER/EB2-5 system. ER/EB2-5 is an 
EBV immortalized B cell line infected with the mini-EBV plasmid 554-4 and the ∆E2 EBV strain P3HR1. 
ER/EB2-5 cells express ER/E2, where E2 is fused to the hormone-binding domain of the estrogen receptor 
(ER). In the absence of estrogen (estr.), E2 shuttles to the cytoplasm and is virtually inactive. In the presence 
of estrogen, E2 locates in the nucleus and is active as a transcription factor. B Estr. shows effects on ER/EB2-
5 (bottom; ntech. = 3) but no effects on CNTRL cell line EB2-3 (top; ntech. = 3, nbiol. = 3). Quantification of gene 
expression by RT-qPCR of the transcripts of two established housekeeping genes (coding: gusB; non-coding 
U6snRNA) and lncRNA Neat1 is displayed. EB2-3 cells were treated with 1 µM ß-estradiol for 0 h and 6 h, 
ER/EB2-5 cells were depleted for estr. and reactivated for 0 h and 6 h. RNA was isolated from 107 cells and 
1 µg RNA was reverse transcribed to cDNA. Concentration of cDNA copies per 50 ng RNA was obtained by 
absolute quantification. C ER/EB2-5 cells depleted for estr. and reactivated for the indicated hours show a 
peak in RNA abundance of known E2 target genes at 6 h post reactivation of ER/E2 by estrogen. ER/EB2-5 
cells were depleted for estr. and reactivated for the indicated hours (lt= long term cultivation under estrogen). 
RNA was isolated from 107 cells and 2 µg RNA were reverse transcribed to cDNA. 
 
 
To study the regulation of E3A target genes, a wt LCL was compared to a ∆E3A LCL. Both LCLs 
originate from primary B cells of the same donor infected with recombinant EBV, either the wt EBV 
BAC (2089) or a ∆E3A EBV BAC respectively (Be715; Figure 11A). In order to account for eventual 
differences in EBV copy numbers in downstream transcriptome analysis, the copy number of both 
cells was assessed compared to the Namalwa cell line, which is known to carry two EBV genome 
copies per cell (Whitaker, 1985; Figure 11B). As the wt LCL only carries 1.85-fold more EBV copies 
compared to the ∆E3A LCL, this difference was not taken into account for further analyses. Since 
transcriptome variations can accumulate in a mutant cell line due to adaption of the cell, we also 
compared the regulation of candidate genes in this setting (wt versus ∆E3A LCL) to the regulation 
in a dox-inducible E3A cell system by RT-qPCR (Figure 11C). ADAMDEC1 was repressed 1.7 - fold 
in the dox-inducible system, while it was repressed 243-fold in the wt vs. ∆E3A system (Affymetrix 
Array: 44.8 - fold repression), BMP4 was repressed 2.4-fold in the dox-inducible system, while in 
the wt vs. ∆E3A system, it could not be assessed because repression was beyond detection limit 
(Affymetrix Array: 17. 5 - fold repression) and CXCL10 was repressed 5.4 - fold in the dox-inducible 
system, while due to a repression beyond detection limit in the wt vs. ∆E3A system, it could not be 
assessed (Affymetrix Array: 30.2 - fold repression; Affymetrix Data from Hertle et al., 2009). Thus, 
the wt vs. ∆E3A system shows the same trend of regulation than the one observed in the inducible 
system, albeit the effect of repression is much stronger. 
 
Comparing the wildtype with an E3A mutant cell lines was suitable to investigate E3A dependent 
gene regulation. Both cell lines did not differ substantially in their EBV copy numbers and a strong 
trend of regulation can be observed, which could be confirmed in an E3A-inducible cell line. 
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Figure 11: E3A cell system characterization. A Schematic representation of the E3A cell system. Both LCLs 
originate from primary B cells of the same donor infected with recombinant EBV, either the wt BAC (2089) 
or a ∆E3A BAC (Be715. B LCLs appear to have ~ 1.85-fold more EBV copies than ∆E3A LCLs. gDNA was 
isolated from 5 x 106 cells and qPCR of a viral (BALF5; upper panel) and a cellular (ß2m; middle panel) 
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housekeeping gene was performed. Mean and SEM obtained by absolute quantification per 14 ng gDNA 
(nbiol. =3) are displayed. Copy number calculation for wt and mut cell line was normalized to Namalwa cell 
line (bottom panel). C The applied E3A cell system (wt vs ∆E3A LCL) shows same trend of regulation of E3A 
targets as a dox-inducible E3A system ΔE3A-LCLdoxHA-E3A. Quantification of expression level of transcripts of 
three known E3A target genes ADAMDEC1, BMP4 and CXCL10 relative to the expression level of GAPDH is 
shown for two different cell systems, the doxHA-E3A inducible LCL (MH1680-9; left panel) and a wt LCL 
compared to a ∆E3A LCL of the same donor. The doxHA-E3A inducible LCLs were treated for 0 h and 24 h 
with 1 µM dox. RNA was isolated from cell pellets and 2 µg RNA was processed for RT-qPCR. Mean and SEM 
obtained by relative quantification (to GAPDH) is displayed. P-values received by paired t-test as indicated. 
 
3.2.2 Transcriptome analysis by RNA-Seq 
 
To examine the genome-wide transcriptional regulation by E2 and E3A, RNA-Sequencing was 
conducted. The RNA of three biological replicates of several conditions was sequenced:  
 
i) The nucleic and the cytoplasmic compartment of ER/EB2-5 cells depleted from 
estrogen for 4 d and reactivated for 0 h (-estr.) and 6 h (+estr.) or reactivated under 
the treatment of ChX in order to block translation (ChX-estr./ ChX+estr.). The 
cytoplasmic compartment of the ER/EB2-5 cells with absent de novo protein synthesis 
was not analyzed and discussed in the frame of this work due to high variations 
between the biological replicates. 
ii) The nucleic and cytoplasmic compartments of wt LCLs and ∆E3A LCLs.  
 
The cytoplasmic fraction was separated from the nucleic fraction from the same cell batch. 
 
3.2.2.1 78 % of EBVs genes can be differentially expressed by E2 in the ER/EB2-5 
system  
 
Reads obtained from RNA-Sequencing, which didn’t align to the human genome were mapped to 
the viral genome of Akata using the STAR mapper. The Akata EBV strain is non-defective and 
represents a wild-type virus. It has to be mentioned that mapping to this genome is neither perfect 
for the E2 cell system (P3HR1 genome+ p554-4) nor for the E3A cell system (2089 BAC/Be715 
BAC). Up to now, the Akata genome is the most complete annotation for EBV which is available. 
Aiming for high precision in the detection of regulated viral genes, for counting and differential 
expression testing, the RSEM package was applied (B. Li & Dewey, 2011), which effectively deals 
with ambiguously-mapping reads. 
In total, 172 elements were annotated by Lin et al. for the Akata genome, including 92 genes, 43 
miRNAs and 37 regulatory regions (Lin et al., 2013). Upfront, it has to be mentioned that the 
nomenclature for EBV open reading frames (ORF) originates from BamH1-restriction fragments 
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map. The fragments were ordered based on their sizes in descending order (A to Z). The fragment 
on which the ORFs were found and the direction in which they extend was eponymous. The 
numerous ORFs are further divided into latent and lytic genes. EBV genes are consecutively 
expressed in three different phases upon lytic reactivation, the immediate-early, early 
(intermediate) and late phase. The EBV lytic cycle is triggered by the expression of the immediate 
early genes, BZLF1 and BRLF1. They induce the expression of genes encoding the viral 
polymerases and the replication machinery. Late genes encode for structural proteins necessary 
for packaging viral DNA into capsids and the release of infectious virions (reviewed by McKenzie & 
El-Guindy, 2015). 
 
We continued with genes covered with > 20 reads per gene in either of the conditions (-/ +estr., 
ChX-estr./ ChX+estr). The significantly (FDR < 0.05) regulated genes were further analyzed for E2 
regulation in the different subcellular compartments/different conditions. 75 genes were detected 
to be significantly regulated (log2FC > 1 or < -1) by E2 in the cytoplasm, 73 upregulated (log2FCs 
range from 1.46 to 9.85, Table S3) and two downregulated. 47 genes were detected to be 
significantly induced (log2FC > 1) by E2 in the nucleus (log2FCs range from 1.13 to 5.48, Table 
S3) and 68 were detected as significantly induced in the nucleus in absence of de novo protein 
synthesis (+ChX; log2FCs range from 1.02 to 10.53, Table S3). Genes only regulated in absence 
of de novo protein synthesis (+ChX) in the nucleus were ignored in order to exclude false positives. 
46 genes were induced by E2 in both (-ChX/+ChX) conditions. 39 genes were induced by E2 in all 
three states (cytoplasm/ nucleus/ nucleus +ChX). Surprisingly, most of the regulated genes are 
lytic genes. It can be observed that a greater number of genes are significantly regulated in the 
cytoplasm compared to nucleus. Furthermore, the regulation under ChX seems for some genes to 
amplify the induction.  
Comparing E2 regulation of viral genes with E3A regulation, it can be observed that less genes are 
regulated by E3A. Ignoring the genes covered with < 20 reads in either of the conditions (wt/∆E3A), 
42 genes are significantly (FDR < 0.05) regulated (log2FC > 1 or < -1) in the cytoplasm, 41 
upregulated (log2FCs range from 1.08 to 10.82, Table S3) and one gene, the lncRNA EBER1 
downregulated (-1.81). 23 genes were upregulated in the nucleus (log2FCs range from 1.0 to 
11.44, Table S3) and three genes downregulated. The wt versus ΔE3A mutant ratio leads to the 
highest log2FC values for E3A. RPMS1 was regulated by E3A in both compartments. Ten genes, 
including BNRF1 were induced by both TFs in all conditions/compartments. 42 genes were 
induced by both TFs in one of the compartments. 
 
To conclude, E2 induces a great number of EBV genes, including lytic genes. Under the assumption 
that the ER/EB2-5 system resembles the processes during infection, one could suggest that E2 
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induces a lytic cycle. Whether this induction leads to an abortive or a productive lytic cycle needs 
further investigations. E3A regulated most of its target genes in concert with E2. 
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Figure 12: Heatmap displaying the mean normalized read counts of all significantly (p ≤ 0.05) differentially 
expressed genes by E2 in the cytoplasm or the nucleus (- /+ ChX) detected by RSEM. Each horizontal row 
represents a viral gene and every vertical row the mean normalized read counts (nbiol. =3) as indicated. All 
genes sign. differentially expressed by E2 (no log2FC cutoff) in any compartment/condition are listed and 
sorted in descendant manner according to the mean of norm. read counts in the cytoplasmic +estr. 
condition. Genes with < 20 reads in both conditions were excluded. Two different scales were applied for the 
cytoplasmic and the nucleic compartment. Cytoplasm: smallest value= white= 0 read counts, baseline 
value=green=5x 104 read counts, largest value= blue= 1.65x 105 read counts. Nucleus: smallest value= 
white= 0 read counts, baseline value= green= 5x 103 read counts, largest value=blue=1.26 x 105 read 
counts. Graph Pad Prism was used for plotting. 
 
 
In order to confirm candidate target genes of E2 detected by RNA-Seq, BGRF1/BDRF1 (Figure 13), 
BHRF1 (Figure 14) and BNRF1 in the intron of LMP2A (Figure 16) were investigated by RT-qPCR. 
All three candidate loci are characterized by being induced by E2 in cytoplasm, the nucleus, or both 
and being regulated in absence of de novo protein synthesis. For two out of three loci, E2 binding 
sites reside in close genomic proximity.  
The early gene BGRF1/BDRF1 encodes most probably (by sequence homology) for the tripartite 
terminase (TRM) subunit 3 or DNA packaging subunit 3 protein, which belongs to the herpesviridae 
TRM protein family (Figure 13). The three HHV’s terminase subunits are conserved across the HHV 
family. Together they form a complex in the host cytoplasm, the third subunit is relevant for the 
nuclear localization. The DNA packaging complex is responsible for the translocation of the viral 
DNA in empty capsids. TRM3 exerts RNase H-like nuclease activity with which concatemeric viral 
DNA is cleaved into genomes of equal length (https://www.viprbrc.org, https://www.uniprot.org). 
The regulation of a spliced transcript of BGRF1/BDRF1 could be confirmed by RT-qPCR (Figure 15, 
upper panel). The transcript is enriched in the cytoplasm. The log2FC in RNA-Seq under ChX is 
2.14, thus, this target is regulated in the absence of de novo protein synthesis. 
BHRF1 encodes for a homolog of the mammalian B cell leukemia/lymphoma Bcl-2 protein (Figure 
14). BHRF1 might counteract the MYC-induced apoptosis. It binds to a number of pro-apoptotic 
proteins expressed by host cells. BHRF1 expression leads to a resistance to a range of cytotoxic 
agents (Kvansakul et al., 2010). Two isoforms are annotated for BHRF1, a monoexonic transcript 
which is expressed in the early lytic phase and a latent splice variant which consists of two exons. 
Specific primers for the distinct detection of the early lytic variant could be established for RT-
qPCR, the regulation by E2 could be confirmed (Figure 15, lower panel). The transcript is enriched 
in the nucleus. The log2FC in RNA-Seq under ChX is 1.02, thus, this target is weakly regulated in 
the absence of de novo protein synthesis. 
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Figure 13: Overview over BGRF1/BDRF1 locus with pictured E2 dependent induction of transcription in 
ER/EB2-5. Schematic map depicting A Expression based RNA-Seq tracks displaying the coverage in the 
different conditions/fractions as indicated (tracks were set to the stated data range). B Peak track obtained 
from E2 ChIP-Seq (Laura Glaser; mapped to Akata). C Annotation track provided by Flemington Lab. Green 
arrows indicate RT-qPCR primer positions; underneath: color code for annotation track. 
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Figure 14: Overview over BHRF1 locus with pictured E2 dependent induction of transcription in ER/EB2-5. 
Schematic map depicting A Expression based RNA-Seq tracks displaying the coverage in the different 
conditions/fractions as indicated (tracks were set to the stated data range). B Peak track obtained from E2 
ChIP-Seq (Laura Glaser; mapped to Akata). C Annotation track provided by Flemington Lab. Green arrows 
indicate RT-qPCR primer positions; underneath: color code for annotation track. 
 
 
 
Figure 15: RT-qPCR confirmation of transcripts of the viral E2 target genes BGRF1/BDRF1 and BHRF1. Bar 
graphs showing the absolute (left) and the relative (right; rel. to CHMP2A) quantification by RT-qPCR of the 
transcripts two E2 target genes BGRF1/BDRF1 and BHRF1 in different RNA preparations. ER/EB2-5 cells 
were depleted for estrogen and reactivated for 0 h and 6 h partially under ChX treatment. RNA was isolated 
from 107 cells (total) or cell fractions (1.2x 107 cells for cytoplasm and 2x 108 cells for nucleus) and 4 µg 
RNA was reverse transcribed to cDNA. Concentration of cDNA copies per 50 ng RNA as indicated (ntech. =3, 
nbiol. =3). P-values obtained from unpaired t-test indicated if significant (p < 0.05). Underneath the bar graph, 
the raw read counts obtained from RNA-Seq are displayed. Graph Pad Prism was used for plotting. 
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The early gene BNRF1 encodes for the major EBV tegument protein (Figure 16 bottom). BNRF1 is 
important for the EBV invasion of B lymphocytes (López et al., 2005). BNRF1 was reported to have 
a function in the viral transport from the endosomes to the nucleus (Feederle et al., 2006). 
Furthermore, it targets host-cell intrinsic defense proteins and promotes viral early gene activation 
(Tsai, Thikmyanova, Wojcechowskyj, Delecluse, & Lieberman, 2011). The monoexonic transcript 
overlaps with the introns of LMP2A and LMP2B. Both genes are transcribed from the sense strand. 
The primers are specific for BNRF1 transcript but still could detect unspliced intronic LMP2A/B. 
The regulation could be confirmed by RT-qPCR (Figure 17, upper panel). The transcript can be 
detected in the cytoplasm, which supports the identification of BNRF1. Nevertheless, the high level 
of abundance in the nucleus detected by RT-qPCR compared to the cytoplasm could be due to the 
detection of unspliced LMP2A. 
LMP2A is a known direct target gene of E2 (reviewed in Kempkes & Ling, 2015; Figure 16 top). It 
is a latent transmembrane protein that negatively regulates B cell receptor signaling and has been 
furthermore reported to activate (MAPK-, PI3-K/AKT- signaling) or down-regulate (NF-κB- and STAT- 
signaling) several other pathways important for different fundamental events such as proliferation, 
differentiation or transformation (El-Sharkawy, Al Zaidan, & Malki, 2018). Here it is shown as a 
control for E2 regulation. The gene can be identified to be strongly regulated in the cytoplasm. 
Regulation can be confirmed by RT-qPCR (Figure 17, lower panel). Since the housekeeping gene 
CHMP2A was observed to be regulated in these experiments (Figure 18), the relative 
quantifications are also shown. However, since CHMP2A is a protein coding gene enriched in the 
cytoplasm, this normalization leads to an amplification of the signal in the nucleus. The E2 
dependent upregulation of candidate lytic genes detected by RNA-Seq could also be confirmed by 
immunoblotting (data not shown). 
 
In summary, we could observe an E2-dependent regulation of viral genes of the lytic and the latent 
phase of EBV in the ER/EB2-5 cells. Included were genes, which play a role in DNA packaging in 
viral capsids, in the EBV invasion or which have anti-apoptotic capacity. However, the regulation of 
viral target genes by E2 and the importance for EBV biology requires further investigation. 
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Figure 16: Overview over LMP2A locus with pictured E2 dependent induction of transcription in ER/EB2-5. 
Upper panel: LMP2A overview; lower panel: a magnification of the upper panel zooming in on BNRF1. 
Schematic map depicting A Expression based RNA-Seq tracks displaying the coverage in the different 
conditions/fractions as indicated (tracks were set to the stated data range). B Peak track obtained from E2 
ChIP-Seq (Laura Glaser; mapped to Akata). C Annotation track provided by Flemington Lab; underneath: color 
code for annotation track 
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Figure 17: RT-qPCR confirmation of transcripts of the viral E2 target genes BNRF1 and LMP2A. Bar graphs 
showing the absolute (left) and the relative (right; rel. to CHMP2A) quantification by RT-qPCR of the 
transcripts of two E2 targets BNRF1 and LMP2A in different RNA preparations. ER/EB2-5 cells were depleted 
for estrogen and reactivated for 0 h and 6 h partially under ChX treatment. RNA was isolated from 107 cells 
(total) or cell fractions (1.2x 107 cells for cytoplasm and 2x 108 cells for nucleus) and 4 µg RNA was reverse 
transcribed to cDNA. Concentration of cDNA copies per 50 ng RNA as indicated (ntech. =3, nbiol. =3). Mean 
+SEM is displayed. P-values obtained from unpaired t-test indicated if significant (p < 0.05). Underneath the 
bar graph, the raw read counts obtained from RNA-Seq are displayed. Graph Pad Prism was used for plotting. 
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Figure 18: Housekeeping gene as control for RT-qPCR. Bar graphs showing the absolute quantification of RT-
qPCR of a transcript of housekeeping gene CHMP2A in different RNA preparations. ER/EB2-5 cells were 
depleted for estrogen and reactivated for 0 h and 6 h partially under ChX treatment. RNA was isolated from 
107 cells (total) or cell fractions (1.2x 107 cells for cytoplasm and 2x 108 cells for nucleus) and 4 µg RNA was 
reverse transcribed to cDNA. Concentration of cDNA copies per 50 ng RNA as indicated (ntech. =3, nbiol. =3). 
P-values obtained from unpaired t-test indicated if significant (p < 0.05). Underneath the bar graph, the raw 
read counts obtained from RNA-Seq are displayed. Graph Pad Prism was used for plotting. 
 
 
3.2.2.2 E2 manipulates the host transcriptome 
3.2.2.2.1 Efficiency of read alignment is compartment and mapper dependent 
 
In order to assess the coverages of our samples, reads obtained from RNA-Seq were aligned to the 
human genome hg19.  
We aimed to compare four different mapping algorithms, HISAT (D. Kim et al., 2015), STAR (Dobin 
et al., 2013), ContextMap2 (Bonfert et al., 2015), and TopHat2 (D. Kim et al., 2013). Mapping was 
conducted by Gergely Csaba. Investigating the whole genome, transcriptome, intergenic and 
intronic regions and known and novel junctions, the alignment performance varied. As expected, 
in average ~80% of all reads aligned to hg19 (Figure S8). HISAT performed poorly for the samples 
derived from the E3A system (Figure S8B) and mapped incomparably more reads of the cytoplasm 
to intergenic junctions (Figure S13). Therefore, this mapper was excluded from all further analyses. 
More reads from the cytoplasmic compartment could be mapped to annotated transcripts 
(ENSEMBL GRCh37.75; Figure S9), known (Figure S12) and intergenic (novel) junctions (Figure 
S13). As expected, more reads from the nuclear compartment could be mapped to intergenic 
(Figure S10) and intronic (Figure S11) regions.  
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Taken together, the sequencing was successful (the majority of reads could be mapped) and the 
quantity of mapped reads is compartment and mapper dependent.  
 
3.2.2.2.2 Strategy for identification of unannotated intergenic and intronic genes 
 
In order to define potential novel genes, regions not overlapping any ENSEMBL annotation were 
subjected to further analysis. The analysis of nucleic RNAs was difficult due to the nature of 
immature transcripts. It was not possible to de novo assemble transcripts. Since the application of 
de novo assembly tools like StringTie were not feasible for the nucleic fraction of the cells, Gergely 
Csaba sought to develop a bypassing strategy. 
The determination of detected intergenic/intronic transcribed genes consist of multiple steps 
(Figure 19). First, candidate intergenic/intronic regions were derived from each sample 
independently. These regions were given by proximal (≤ 50 bp from closest fragment ends) or 
overlapping fragments (read pairs) not mapping to any ENSEMBL gene (intergenic) or exon 
(intronic). Since sequencing was conducted strand specific, also regions antisense to overlapping 
known genes were collected. The second step was, to combine these “raw“ intergenic/ intronic 
regions to replicate-consistent ones. To this end, the derived regions from all mappers and all 
replicates for each condition were used in a joined analysis: all intergenic/intronic candidates 
having ≥ 50 supporting reads were merged and the part of the intergenic/intronic region 
consistently detected by all mappers in all biological replicates for the same condition was 
extracted. The discovered intergenic genes were classified by their genomic overlap with annotated 
ENSEMBL genes (intergenic if no overlap, a combination of sense/antisense 
genebody/3_PRIME/5_PRIME/FULL otherwise). As a result, a purified set of observed non-
annotated (ENSEMBL) regions was obtained. As these regions could still be a byproduct of 
transcription of gene-overlapping regions, we corrected for noise by comparing the changes to the 
changes of the overlapped gene in the differential analysis. 
 
Thus, a different strategy to investigate unannotated differentially expressed genes could be 
developed and was used in the following analyses. 
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Figure 19: Simplified scheme on the inference of intergenic and intronic genes from extracted read covered 
regions not consistent with ENSEMBL gene or exon annotation. Two major steps were performed: intergenic 
(between two genes annotated by ENSEMBL) and intronic (between two exons annotated by ENSEMBL) 
regions, which were covered with reads were extracted from each sample (condition/replicate). The 
extracted regions covered with ≤ 50 reads are joined for each condition separately and the common region 
detected in all biological replicates of the same condition by all used mappers was defined as a new 
intergenic or intronic gene. Blue boxes= simplified read pairs (=fragments). Green boxes= extracted regions. 
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3.2.2.2.3 Biological replicates show high similarity in RNA-Sequencing 
 
In order to validate the quality of the biological replicates, two quality controls were conducted. On 
the one hand, the raw read counts of the replicates were compared with each other after mapping 
(conducted by Gergely Csaba). The samples of cytoplasmic (Figure S14) and nuclear compartment 
(Figure S15) of ER/EB2-5 cells - / + estr. were similar as they lined up on the diagonal and the 
samples of cytoplasmic (Figure S17) and nuclear (Figure S18) compartment of wt/∆E3A cells were 
highly similar as well as. In contrast, the samples of the nuclear compartment of ER/EB2-5 cells 
ChX-estr./ ChX+estr. show high variations compared to each other also at high read counts (Figure 
S16). On the other hand, a Spearman correlation of average read coverages of the replicates was 
calculated (Figure 20 to Figure 22) proving, that overall biological replicates of same treatment or 
condition and same compartment show high similarities and form clusters. In general, all prepared 
samples (not only replicates) show a high correlation (rmin= 0.75). Interestingly, in the E2 system, 
the samples corresponding to the same compartments form a cluster of high correlation while the 
samples deriving from the same treatment form a higher order cluster (Figure 20). In contrast, in 
the E3A system, the samples of the same cell line form a high correlation cluster while the samples 
corresponding to the same compartment show a higher order cluster (Figure 22), demonstrating 
the stronger diversity between +/- E3A as compared to +/- E2. All the samples of the nuclear 
compartment of ER/EB2-5 cells ChX-estr./ ChX+estr. show a high correlation (r= 0.83-0.92; Figure 
21). The clustering here is a bit diffuse probably due to the high variations between the biological 
replicates of the same condition (Figure S16). ChX-treated samples form a higher order cluster 
independent of estrogen treatment, indicating a high impact of ChX on the transcription, only 
exception is the first replicate of ChX+estr. 
 
Taken together, the biological replicates used in this study exhibited acceptable similarity. 
However, ChX-treated replicates show higher variations which have to be considered in further 
analysis. 
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Figure 20: Biological replicates of the same condition and the same subcellular location cluster by correlation 
analysis. Average read coverages for BAM files (mapped reads) were calculated. The genome was split into 
bins of 1000 bp. For each bin, the number of reads found in each BAM file was counted. Unsupervised 
hierarchical clustering was performed by Spearman correlation and visualized in a heatmap; scale from 0.6 
to 1.0. GALAXY platform was used for computation and visualization. 
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Figure 21: Excluding replicate 1 +estr. , biological replicates of the same condition cluster by correlation 
analysis. Average read coverages for BAM files (mapped reads) were calculated. The genome was split into 
bins of 1000 bp. For each bin, the number of reads found in each BAM file was counted. Unsupervised 
hierarchical clustering was performed by Spearman correlation and visualized in a heatmap; scale from 0.6 
to 1.0. ChX- samples were reactivated for E2 for 0 h and 6 h by estrogen (-estr. and +estr., respectively) 
under the treatment of ChX (1 h before estrogen addition) leading to the inhibition of de novo protein 
synthesis. GALAXY platform was used for computation and visualization. 
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Figure 22: Biological replicates of the same cell line, +/- E3A, and same subcellular location cluster by 
correlation analysis. Average read coverages for BAM files (mapped reads) were calculated. The genome was 
split into bins of 1000 bp. For each bin, the number of reads found in each BAM file was counted. 
Unsupervised hierarchical clustering was performed by Spearman correlation and visualized in a heatmap; 
scale from 0.6 to 1.0. GALAXY platform was used for computation and visualization. 
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3.2.2.2.4 Four dimensional (4D)- combinatorics promise a high reliability in detection of 
regulated genes 
 
Following mapping, aligned read pairs (fragments) had to be counted on the chosen count feature 
(genomic element). Subsequently, the features were tested for differential expression in a 
compared condition pair. 
Aiming for high reliability in the detection of regulated genes and to circumvent biases by the 
selection of one certain tool setup, combinatorics using four different dimensions were applied 
(Figure 23). Three different mapper (STAR, ContextMap2, TopHat2), combined with two different 
read origins (gene, gene with transcript supporting reads), combined with three different count 
modes and four different DE-Methods resulted in 72 possible combinations (=setups). For DE-
testing four different DE-Methods were used, DE-Seq (Anders & Huber, 2010), limma (Ritchie et 
al., 2015), edgeR (Robinson et al., 2010) or an in house method, a2a. Regarding the detected 
amount of significant regulated genes, all combinations using ContextMap2 (*) as a mapper were 
not advantageous for the samples of the cytoplasmic compartment of ER/EB2-5 cells - /+ estr. 
(Figure 24A). All combinations using a2a (*) as DE-method yielded slightly better results for the 
samples of the nuclear compartment of ER/EB2-5 cells ChX-estr./ ChX+estr (Figure 24C). In 
contrast, the entire setups result in similar outputs for the samples of the nuclear compartment of 
ER/EB2-5 cells - /+ estr. (Figure 24B), and for the samples of both compartments of wt/∆E3A cells 
(Figure 25). We determined to use the common amount of genes consistently detected by the most 
beneficial setups for the downstream analysis. As a consequence, the combinations using 
ContextMap2 for the cytoplasmic samples of ER/EB2-5 cells - /+ estr. were disregarded for the 
downstream analysis. Furthermore, only combinations using a2a for nuclear samples of ER/EB2-
5 cells ChX-estr./ ChX+estr were included in downstream analysis. For the nuclear samples of 
ER/EB2-5 cells ChX-estr./ ChX+estr, our aim was to detect in the most sensitive way, for all other 
samples our aim was to be most specific.  
 
The detection of differentially expressed genes was not dependent on a certain tool set. We 
continued to analyze the consistently detected genes by multiple setups which promised a high 
reliability in the resulting data. 
 Results 
65 
 
 
 
Figure 23: 4D- matrix of mapper, count type, sampling and DE-method combinatorics. Scheme of 
combinatorics used to circumvent biases in the detection of differentially expressed genes: Three different 
mapper combined with two different count types combined with three different sampling styles and four 
different DE-Methods resulting in 72 possible combinations (=setups); ContextMap2, STAR and TopHat2 
were applied as mapper. Read origin: Either read pairs aligning completely to a gene were considered (read 
origin = gene) or read pairs aligning to a gene were only considered, if any gene derived transcript was 
covered by reads (read origin = gene with transcript support). Different count modes were performed: i) reads 
were counted ii) reads were downsampled on fragment level iii) downsampling (ds) to decrease impact of 
highly amplified fragments (for detailed explanation please see section 2.5.6.1, p. 29). *ContextMap2 was 
excluded for cytoplasmic samples; *a2a was the only DE-Method used for ChX-treated samples 
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Figure 24: Different setups leading to different (A, C) or similar (B) results regarding the number (#) of 
significantly regulated genes in the E2 cell system. Bar graphs displaying the number of detected significantly 
regulated genes in the different setups for A regulation by E2 (+estr./-estr.) in the cytoplasm (highlighted in 
blue are the worst cases, the combinations with ContextMap2as mapper), B regulation by E2 (+estr./-estr.) 
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in the nucleus and C regulation by E2 (+estr./-estr.) in the nucleus in absence of de novo protein synthesis 
(ChX; highlighted in blue are the best cases, the combinations with a2a as DE-Method). Gene with transc. 
supp.: gene with transcript support. Ds: downsampling (for detailed explanation please see section 2.5.6.1, 
p. 29). Graph Pad Prism was used for plotting. 
 
 
 
 
 
Figure 25: Different setups leading to similar results regarding the number (#) of significant regulated genes 
in E3A cell system. Bar graphs displaying the number of significantly regulated genes in the different setups 
for A regulation by E3A (wt/∆E3A LCL) in the cytoplasm B regulation by E3A (wt/∆E3A LCL) in the nucleus. 
Gene with transc. supp.: gene with transcript support. Ds: downsampling (for detailed explanation, see 
section 2.5.6.1, p. 29). Graph Pad Prism was used for plotting. 
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3.2.2.2.5 Protein coding and non-coding genes are regulated by E2 and E3A  
 
In the following, the common set of genes, consistently detected by the most beneficial setups, are 
described. The number of detected genes is dependent on the cutoffs/thresholds for read 
coverage, fold change (FC) and significance (FDR). 
To further increase the reliability in the detection of differential expressed genes, we agreed to 
choose the worst FDR and the worst fold change detected by one of the setups for all following 
analyses. The worst FDR corresponds to the FDR, which is the worst called FDR by one of the 
setups and the worst log2FC corresponds to the log2FC closest to zero detected by one of the 
setups. The result of the selection was exemplified for the ENSEMBL genes. Using the cutoffs FDR 
≤ 0.05 and log2FC ≥ 1 or ≤ -1, 48 setups for the cytoplasmic ER/EB2-5 samples - /+ estr. resulted 
in the consistent detection of 6,524 ENSEMBL genes (Figure 26A), all 72 setups for the nuclear 
ER/EB2-5 samples - /+ estr. led to the consistent detection of 5,360 ENSEMBL genes (Figure 26B) 
and 18 setups for nuclear samples of ER/EB2-5 cells ChX-estr. / ChX+estr led to the consistent 
detection of 262 ENSEMBL genes (Figure 26C). An additional cutoff was introduced, only genes, 
which were covered with > 20 reads in one of the compared conditions were considered. This cutoff 
selected genes which were sufficiently covered to study regulation. The number of reads chosen 
for this cutoff was the result of RT-qPCR confirmation of candidate genes. Genes with 20 reads 
could be repeatedly detected by RT-qPCR. 
The ENSEMBL annotation categorizes genes and transcripts into different biotypes, which can be 
grouped into protein coding, pseudogene, long non-coding and short non-coding. Long non-coding 
genes can be subclassified into, for instance, 3’ overlapping ncRNA, antisense RNA, lincRNA, sense 
intronic RNA or sense overlapping RNA. In the following, these last-mentioned biotypes were 
filtered and termed lncRNAs, the remaining biotypes were pooled (residual biotypes). RNAs smaller 
than 200 bp were lost to a great extent during the RNA preparations (kit retains only RNAs > 200bp 
according to the manufacturer), so we excluded small RNAs (< 200 bp) from downstream analyses. 
In the cytoplasm, application of strengthened cutoffs (read counts > 20, FDR < 0.05 and log2FC 
>1 or < -1) resulted in the isolation of 5,578 genes that are significantly differentially expressed, 
including 999 lncRNAs. In the nucleus, 4,562 genes are significantly differentially expressed, 
including 646 lncRNAs. 226 genes are significantly differentially expressed in the nucleus when 
de novo protein synthesis is blocked, including 55 lncRNAs (Figure 27). For further analysis, the 
cutoff for the log2FC of ENSEMBL genes was set to > 0.85 or < -0.85 in ER/EB2-5 samples, since 
the variance was minor and the majority of known target genes of E2 could be detected with these 
cutoffs. 
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Figure 26: Downstream, consistently by the different setups detected E2-dependently regulated ENSEMBL 
genes with were analyzed. The miniaturized 4D-matrix indicates the combinatorics for the particular 
regulation analysis. The left panel shows a cumulative plot with the number of significantly (FDR ≤ 0.05) 
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regulated (log2FC ≥ 1 or ≤ -1) genes in ≥ x setups and the right panel shows a plot with the log2FCs of the 
amount of genes which were consistently detected by all setups. A Regulation by E2 (+estr. /-estr.) in the 
cytoplasmic compartment of ER/EB2-5: 6,524 genes were consistently detected by 48 setups. B Regulation 
by E2 (+estr. /-estr.) in the nucleic compartment of ER/EB2-5: 5,360 genes were consistently detected by 
72 setups. C Regulation by E2 (+estr./-estr.) in the nucleic compartment of ER/EB2-5 in absence of de novo 
protein synthesis: 262 genes were consistently detected by 18 setups (plots were created by Gergely Csaba). 
 
 
 
Figure 27: E2-dependent regulation of ENSEMBL annotated genes. Volcano plots displaying the log2FC vs 
the worst common FDR detected by all reasonable (48 for cytoplasmic samples, 72 for nucleic samples and 
18 for nucleic ChX-treated samples) setups for E2 regulated genes. Black= all genes with > 20 reads, 
orange= log2FC > 1 or < -1, red= cutoff for FDR < 0.05, green= all biotypes without lncRNAs with the cutoff 
for FDR < 0.05 and log2FC > 1 or < -1, purple= all lncRNAs with the cutoff for FDR< 0.05 and log2FC > 1 or 
< -1. This definition resulted in 5,578 regulated genes in the cytoplasm including 999 lncRNA genes (upper 
left), 4,562 regulated genes in the nucleus including 656 lncRNA genes (upper right) and 226 regulated 
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genes in the nucleus in absence of de novo protein synthesis including 55 lncRNA genes (lower right). For 
plotting, filtered gene lists were input for R. 
 
 
In addition to the ENSEMBL annotated genes, according to our strategy, differentially regulated 
genes were identified in intergenic (Figure 28) and intronic (Figure 29) regions. Similarly, the 
common amount of genes consistently detected by all 72 setups was further analyzed in the 
following (process not shown). As these regions could still be a byproduct of transcription of gene-
overlapping regions, we corrected for noise by comparing the changes to the changes of the 
overlapped gene in the differential analysis (=depcorr.). The same cutoffs were applied as for the 
ENSEMBL genes. In the cytoplasm, these thresholds resulted in 133 intergenic and no intronic 
genes regulated significantly. In the nucleus, 483 intergenic and 8 intronic genes are regulated 
significantly. 10 intergenic and no intronic genes are regulated significantly in the nucleus when 
de novo protein synthesis is blocked. 
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Figure 28: E2-dependent regulation of intergenic transcription. Volcano plots displaying the corrected log2FC 
(depcorr. = noise corrected log2FC) vs the worst common FDR detected by all setups for E2 regulated genes. 
Black= all genes with > 20 reads, orange= log2FC > 1 or < -1, red= cutoff for FDR < 0.05, green= all genes 
with the cutoff for FDR < 0.05 and log2FC > 1 or < -1. This definition resulted in 133 regulated genes in the 
cytoplasm (upper left), 483 regulated genes in the nucleus (upper right) and ten regulated genes in the 
nucleus in absence of de novo protein synthesis (lower right). For plotting, filtered gene lists were input for 
R. 
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Figure 29: E2-dependent regulation of intronic transcription. Volcano plots displaying the corrected log2FC 
(depcorr. = noise corrected log2FC) vs the worst common FDR detected by all setups for E2 regulated genes. 
Black= all genes with > 20 reads, orange= log2FC > 1 or < -1, red= cutoff for FDR < 0.05, green= all genes 
with the cutoff for FDR < 0.05 and log2FC > 1 or < -1. This definition resulted in zero regulated genes in the 
cytoplasm (upper left), eight regulated genes in the nucleus (upper right) and zero regulated genes in the 
nucleus in absence of de novo protein synthesis (lower right). For plotting, filtered gene lists were input for 
R. 
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The result of the selection on the E3A cell system was exemplified for the ENSEMBL genes. Using 
the cutoffs FDR ≤ 0.05 and log2FC ≥ 1 or ≤ -1, all 72 setups for the cytoplasmic wt/ΔE3A cell 
samples resulted in the consistent detection of 3,200 ENSEMBL genes (Figure 31A) and all 72 
setups for the nuclear wt/ΔE3A cell samples lead to the consistent detection of 3,783 ENSEMBL 
genes (Figure 30B). In the cytoplasm, application of strengthen cutoffs (read counts > 20, FDR < 
0.05 and log2FC >1 or < -1) resulted in 2,788 significantly regulated genes, this includes 518 
lncRNAs. In the nucleus, 3,367 genes are regulated significantly, comprising 785 lncRNAs (Figure 
31). 
 
 
 
 
Figure 30: Downstream, consistently by the different setups detected E3A-dependently regulated ENSEMBL 
genes were analyzed. The miniaturized 4D-matrix indicates the combinatorics for the particular regulation 
analysis. The left panel shows a cumulative plot with the number of significantly (FDR ≤ 0.05) regulated 
(log2FC ≥ 1 or ≤ -1) genes in ≥ x setups and the right panel shows a plot with the log2FCs of the amount of 
genes which were consistently detected by all setups. A Regulation by E3A (wt/∆E3A LCL) in the cytoplasmic 
compartment of LCLs: 3,200 genes were consistently detected by 72 setups. B Regulation by E3A (wt/∆E3A 
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LCL) in the nucleic compartment of LCLs: 3,783 genes were consistently detected by 72 setups (plots were 
created by Gergely Csaba). 
 
 
 
 
Figure 31: E3A-dependent regulation of ENSEMBL annotated genes. Volcano plots displaying the log2FC vs 
the worst common FDR detected by all setups for E3A regulated genes. Black= all genes with > 20 reads, 
orange= log2FC > 1 or < -1, red= cutoff for FDR < 0.05, green= all biotypes without lncRNAs with the cutoff 
for FDR < 0.05 and log2FC > 1 or < -1, purple= all lncRNAs with the cutoff for FDR < 0.05 and log2FC > 1 or 
< -1. This definition resulted in 2,788 regulated genes in the cytoplasm including 518 lncRNA genes (left) 
and 3,367 regulated genes in the nucleus including 785 lncRNA genes (right). For plotting, filtered gene lists 
were input for R. 
 
 
Equally to the E2 regulation, differentially regulated genes were identified in intergenic (Figure 32) 
and intronic (Figure 33) regions. In the cytoplasm, chosen thresholds resulted in 478 intergenic 
and 347 intronic significantly regulated genes. In the nucleus, 1,239 intergenic and 369 intronic 
genes are regulated significantly. 
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Figure 32: E3A-dependent regulation of intergenic transcription. Volcano plots displaying the corrected 
log2FC (depcorr. = noise corrected log2FC) vs the worst common FDR detected by all setups for E3A 
regulated genes. Black= all genes with > 20 reads, orange= log2FC > 1 or < -1, red= cutoff for FDR < 0.05, 
green= all genes with the cutoff for FDR < 0.05 and log2FC > 1 or < -1. This definition resulted in 478 
regulated genes in the cytoplasm (left) and 1,239 regulated genes in the nucleus (right). For plotting, filtered 
gene lists were input for R. 
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Figure 33: E3A regulation of intronic transcription. Volcano plots displaying the corrected log2FC (depcorr. = 
noise corrected log2FC) vs the worst common FDR detected by all setups for E3A regulated genes. Black= 
all genes with > 20 reads, orange= log2FC > 1 or < -1, red= cutoff for FDR < 0.05, green= all genes with the 
cutoff for FDR < 0.05 and log2FC > 1 or < -1. This definition resulted in 347 regulated genes in the cytoplasm 
(left) and 369 regulated genes in the nucleus (right). For plotting, filtered gene lists were input for R. 
 
 
Taking the 20 best significant regulated genes in each condition pair (10 conditions, 45 condition 
pairs, 380 significant regulated genes) and performing a PCA (Principle Component Analysis; 
conducted by Gergely Csaba), it could be observed that the condition pairs cluster to some extent 
(Figure 34) together, despite the fact that the biological replicates show a quite high variation. 
Samples of same estrogen treatment cluster together (Figure 34A) and samples of same estrogen 
and ChX treatment cluster together (Figure 34B). ER/EB2-5 cells +estr. cluster to wt LCLs, 
confirming, that these cell lines express similar genes and cells depleted for E2 separate in 
opposite direction to cells depleted for E3A (Figure 34C, D). This result demonstrates that samples 
can be separated based on their regulated genes and cluster according to their biological 
affiliation. 
 
In conclusion, we were able to detect differentially expressed annotated protein-coding and lncRNA 
genes as well as genes, so far not incorporated in the ENSEMBL annotation which were regulated 
dependently on E2 and E3A. 
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Figure 34: PCA based on the 20 best (highest log2FCs) significantly (FDR ≤ 0.05) regulated genes in each 
condition pair showing how the conditions behave towards each other. A Conditions without estrogen 
treatment group together on the left and conditions with estrogen treatment group together on the right; the 
compartment has no effect. B Conditions without estrogen treatment group on the left and conditions with 
estrogen treatment group on the right, while the ChX treated samples group at the bottom (nucleic 
compartment). C Samples of wt LCLs group together with samples of ER/EB2-5 LCLs while samples of cells 
without active E2 group on the left bottom and samples of cells without E3A group on the right top in the 
cytoplasm. D Samples of wt LCLs group together with samples of ER/EB2-5 LCLs while samples of cells 
without active E2 group on the left top and samples of cells without E3A group on the right bottom in the 
nucleus (PCA was performed by Gergely Csaba; for plotting, results were input for R; black lines and color 
fields without mathematical importance, only for visual isolation of groups). 
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3.2.2.2.6 EBV regulates its target genes in gene blocks 
 
Genes within a contact domain or TAD are co-regulated, either they are active or repressed. We 
sought to recognize co-regulated gene blocks by E2 or E3A. 
We noticed that the set of identified cellular target genes of E2 contained to a great extend co-
regulated genes which were in physical proximity regarding their genomic position. To investigate, 
whether this is coincidence or can be observed genome-wide, Gergely Csaba tested all significantly 
(FDR ≤ 0.05) E2 (- ChX) regulated (log2FC ≥ 0.85) genes versus randomly selected regulated genes 
for clustering in blocks (Figure 35). A co-regulated gene block (CRGB) was defined by a genomic 
region of genes regulated in the same direction (or not regulated) and had to contain ≥ 2 genes. 
The borders of a CRGB were defined by a gene regulated in the opposite direction. There were no 
genomic size limitations for the CRGB. We excluded mitochondrial genes, chromosomes with less 
than 5 regulated genes from the analysis and EBV genes. Investigating the length of CRGBs, we 
found that 80 % of all E2 regulated CRGB were ≤ 2 Mb (in both, cytoplasm and nucleus) and 70 % 
of all E3A regulated blocks were ≤ 2 Mb (in both, cytoplasm and nucleus; Fig. S19). TADs are 
defined to be up to 2 Mb in size, this was used as a benchmark (Dixon et al., 2012).  For the 
cytoplasmic compartment for example, around 75% of the involved 6,132 E2 target genes can be 
found in blocks of up to ten genes (Figure 35 upper left). More genes were clustered in blocks in 
the cytoplasm compared to the nucleus (Figure 35 upper panel). For E3A block regulation can also 
be observed (Figure 35 lower panel). Rao et al. published 2014 so called contact domains for 
GM12878. They claimed to investigate with the highest resolution, however, in their investigation 
TAD-defined boundaries were not detected. They came up with smaller contact domains than TADs 
(Rao et al., 2014; see section 1.1.4, p. 10). Intersecting 2,038 CRGB regulated by E2 in the nucleus 
with the 9,273 contact domains published, we found 33 % (673) of CRGBs completely overlapping 
with the published contact domains (not shown). Thus, the majority of CRGB are only partially 
overlapping with contact domains.  
 
These data indicate that EBV regulates its target genes in blocks of various sizes of consecutive 
similar regulated genes. 
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Figure 35: E2 regulates its target genes block wise. Cumulative plots displaying the % of genes in block size 
of ≤ x, minimum genes per block = 2 compared to 5 runs of randomly selected genes. 6,132 genes were 
involved in the block regulation by E2 in the cytoplasm (upper left), 5,019 genes were involved in the block 
regulation by E2 in the nucleus (upper right), 2,991 genes were involved in the block regulation by E3A in 
the cytoplasm (lower left) and 3,636 genes were involved in the block regulation by E3A in the nucleus (lower 
right); mtDNA (mitochondrial DNA) and chromosomes containing < 5 regulated genes are excluded. For all 
comparisons of real to random, p-values (by Kolmogorov–Smirnov test) = 0 (plots were created by Gergely 
Csaba using genes with FDR ≤ 0.05 and log2FC ≥ 0.85). 
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3.2.2.2.7 Regulated blocks of cellular target genes consist of protein coding and non-coding 
genes with cancer links  
 
Next, we aimed to confirm candidate target blocks by RT-qPCR and intended to characterize these 
blocks by integration of public available data on LCLs. 
Three of these E2 target blocks in the neighborhood of MYC (Figure 36, Figure 37), SLAMF1 (Figure 
40) and PPAN (Figure 42) were investigated further by integrating public available data for the LCL 
GM12878 included in the ENCODE project and confirmed by RT-qPCR. These loci were chosen 
since they all contain reviewed protein coding E2 target genes (described in the following). All three 
candidate loci are characterized by the presence of at least two genes being induced by E2 in 
cytoplasm, the nucleus, or both and being regulated in absence of de novo protein synthesis, 
implicatory for a “direct” induction. Furthermore, the blocks are characterized by locally increased 
GRO-Seq signals indicating ongoing transcription, active chromatin marks like H3K27ac, 
H3K4me1, increased PolII binding indicatory for active transcription and local CTCF binding sites 
signaling possible TAD boundaries (coverage tracks obtained by ChIP-Seq data for H3K27ac, 
H3K4me1, RNA PolII and CTCF were sourced as BigWig files from ENCODE). In fact, TADs were 
described for these loci (as indicated), indicating that EBV potentially regulates its targets TAD-
wide. Additionally, DNA-loops were published for GM12878 obtained by capture Hi-C experiments, 
connecting either two fragments containing each a promoter (promoter of genes annotated by Ref-
Seq gene annotation) or a promoter-fragment with a non-promoter-fragment (=”other”; Mifsud et 
al., 2015). Worthy of note here is that there are loops generated in GM12878 at these loci and 
all/most of the loops are connecting fragments of the surrounding with MYC, SLAMF1 or PPAN. 
Furthermore, all these loci contain at least one annotated lncRNA that is co-regulated together with 
protein coding genes. Intriguingly, these lncRNAs identified by RNA-Seq as E2 targets can all be 
linked to cancer as discussed in the following section. 
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MYC 
 
MYC was defined as a direct target of E2 (Kaiser et al., 1999; Figure 36, Figure 37). MYC (C-MYC) 
is a proto-oncogene which encodes a transcription factor. MYC responsive genes are involved in 
almost every important cellular function. Most importantly, MYC is involved in the regulation of 
various growth-promoting signal transduction pathways. Interestingly, almost all cancer-associated 
genetic changes in MYC are linked to non-coding regulatory regions (Miller, Thomas, Islam, 
Muench, & Sedoris, 2012). E2 is published to activate multiple MYC enhancers and to rearrange 
the MYC locus by hijacking long-range enhancer-promoter loops (Wood et al., 2016; Figure 36). 
Moreover, two bidirectionally transcribed eRNAs were already described to be targets of E2 and to 
influence MYC transcription (Liang et al., 2016; Fig 29. at the bottom). This group used short 
hairpin RNA (shRNA)-mediated knock down to investigate the impact of those eRNAs on MYC. 
shRNA target sites and RT-qPCR primer products reside in CASC19/21. In the environment of MYC, 
several non-coding RNA genes were detected as E2 targets by RNA-Seq in this study, four of them 
at the 3’ of the TSS of MYC, PCAT1 (two transcript variants (tvs) according to GRCh37.75; both 
multiexonic; sense transcripts), CASC8 (four tvs according to GRCh37.75; all multiexonic; 
antisense transcripts), CASC19 (one transcript according to GRCh37.75; multiexonic; antisense 
transcript) and CASC21 (= RP11-382A18.2; one transcript according to GRCh37.75; multiexonic; 
sense transcript), and two of them 5’ of the TSS of MYC, LINC00977 (one transcript according to 
GRCh37.75; multiexonic; antisense transcript) and CCDC26 (four tvs according to GRCh37.75; all 
multiexonic; antisense transcripts). The eRNAs published by Liang et al. reside in the introns of 
CASC19 and CASC21 (Figure 37). The CASC (CAncer suSCeptibility) genes are related to pancreatic 
cancer (Wolpin et al., 2014). PCAT1 is implicated in disease progression of prostate cancer and is 
claimed to control HRR (homologous recombination repair) in all sorts of cancer (Prensner et al., 
2011). CCDC26 contributes to tumorigenesis in pancreatic cancer (Peng & Jiang, 2016) and is 
dysregulated in AML (Hirano et al., 2015). LINC00977 is also linked to pancreatic cancer (Wolpin 
et al., 2014). In fact, the region 5’ of MYC was identified to contain multiple cancer susceptibility 
loci (Grisanzio & Freedman, 2010; Huppi, Pitt, Wahlberg, & Caplen, 2012; Wolpin et al., 2014). All 
of these non-coding RNA genes are co-regulated together with MYC by E2 as confirmed by RT-qPCR 
(Figure 38, Figure 39). Their spliced transcripts could be detected in the total, cytoplasmic or 
nucleic RNA preparation, - /+ ChX. For the transcript of the non-coding gene LINC00977, 
unfortunately no exon-exon-junction primer could be established for RT-qPCR. Nevertheless, the 
spliced transcript could be repeatedly detected by RT-PCR from cDNA templates of different RNA 
preparations (Figure S20). The log2FCS in RNA-Seq under ChX for this locus ranges from 2.03 to 
5.01, thus, the targets are well regulated when de novo protein synthesis is blocked. 
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Figure 36: Overview of the MYC gene locus with pictured E2 dependent induction of transcription in ER/EB2-
5 and references for active chromatin and looping activity in GM12878. Schematic map depicting A 
Expression based RNA-Seq tracks displaying the coverage in the different conditions/fractions as indicated 
(coverage encoded in bigwig files; converted from BAM files, mapping by STAR mapper; set to the indicated 
data range) and a GRO-Seq track showing the coverage in GM12878 (Core LJ, et al. 2014; data range set to 
auto scale). B Tracks obtained from ChIP-Seq (H3K27ac, H3K4me1, RNA PolII and CTCF sourced from 
ENCODE for GM12878; data range set to auto scale). C Annotation track (only names of relevant genes and 
different tvs specified). D Additionally displayed are CTCF-mediated TADs and promoter-to-promoter loops 
(grey= loops directing to E2 target genes) in GM12878 as well as MYC-loops in B cells, where -E2 4C-Seq 
reads were subtracted from +E2 4C-Seq reads (green= E2 induced loops, purple= E2 repressed loops). 
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Figure 37: Overview of the region 3’ of the TSS of MYC with pictured E2 dependent induction of transcription 
in ER/EB2-5 and references for active chromatin in GM12878. Schematic map depicting A Expression based 
RNA-Seq tracks (1-12) displaying the coverage in the different conditions/fractions as indicated (coverage 
encoded in bigwig files; converted from BAM files, mapping by STAR mapper; set to the indicated data range) 
and a GRO-Seq track showing the coverage in GM12878 (Core LJ, et al. 2014; data range set to auto scale). 
B Tracks obtained from ChIP-Seq (H3K27ac, H3K4me1, RNA PolII and CTCF sourced from ENCODE for 
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GM12878; data range set to auto scale). C Annotation tracks (only names of relevant genes and different 
tvs specified). D Annotation of published eRNAs and used shRNAs for knock down confirmation of these 
eRNAs (1, 5= shRNAs for knock down of eRNA428; 2, 3= shRNA for knock down of eRNA525; s= “sense” 
amplicon investigated by RT-qPCR; as= “antisense” amplicon investigated by RT-qPCR. 
 
 
 
 
Figure 38: RT-qPCR confirmation of E2 target genes in the MYC neighborhood 3’ of the TSS of MYC. Bar 
graphs showing the absolute quantification by RT-qPCR of four non-coding transcripts, PCAT1 (tv1), CASC19, 
CASC21 and CASC8 in different RNA preparations. ER/EB2-5 cells were depleted for estrogen and 
reactivated for 0 h and 6 h, with a subpopulation under ChX treatment. RNA was isolated from 107 cells 
(total) or subcellular fractions (1.2x 107 cells for cytoplasm and 2x 108 cells for nucleus) and 4 µg RNA was 
reverse transcribed to cDNA. Concentration of cDNA copies per 50 ng RNA as indicated (ntech. = 3, nbiol. = 3). 
P-values obtained from unpaired t-test indicated if significant (p < 0.05). Underneath the bar graph, the raw 
read counts obtained from RNA-Seq aligned to ENSEMBL genes are displayed. Graph Pad Prism was used 
for plotting. 
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Figure 39: RT-qPCR confirmation of E2 target genes in the MYC neighborhood 5’ of the TSS of MYC. Bar 
graphs showing the absolute quantification by RT-qPCR of MYC transcripts and the two non-coding 
transcripts LINC00977 and CCDC26 in different RNA preparations. The primer pair for CCDC26 detects three 
of four tvs. ER/EB2-5 cells were depleted for estrogen and reactivated for 0 h and 6 h with a subpopulation 
under ChX treatment. RNA was isolated from 107 cells (total) or subcellular fractions (1.2 x 107 cells for 
cytoplasm and 2 x 108 cells for nucleus) and 4 µg RNA was reverse transcribed to cDNA. Concentration of 
cDNA copies per 50 ng RNA as indicated (ntech. = 3, nbiol. = 3). P-values obtained from unpaired t-test 
indicated if significant (p < 0.05). Underneath the bar graph, the raw read counts obtained from RNA-Seq 
aligned to ENSEMBL genes are displayed. Graph Pad Prism was used for plotting. 
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SLAMF1 
 
SLAMF1 is also an already known target of E2 (Maier et al., 2006; Figure 40). SLAM-family 
receptors are well described in the literature to be expressed in diverse immune cell types. They 
contain two immunoglobulin-like domains in their extracellular region and exert important 
functions in immune cells (Veillette, 2006). SLAMF1 (CD150) cell surface molecule is upregulated 
in B cell lymphoma cell lines with type III EBV latency (Takeda, Kanbayashi, Kurata, Yoshiyama, & 
Komano, 2014). In SLAMF1’s environment, the genes of two other cell surface molecules, CD48 
and CD84, belonging to the SLAM-family receptors (SLAMF2 and SLAMF5, respectively) and a non-
coding RNA gene, RP11-528G1.2, were detected as E2 targets by RNA-Seq in this study. RP11-
528G1.2 (one transcript according to GRCh37.75; multiexonic; sense transcript) is transcribed 
antisense to CD84. It was observed to be misregulated in gastric cancer (Song et al., 2016). This 
non-coding RNA gene is co-regulated together with the three SLAM-family receptors by E2, 
confirmed by RT-qPCR (Figure 41). The spliced transcripts of the protein coding genes could be 
detected in the total, the cytoplasmic or the nucleic RNA preparation, - /+ ChX. For the transcript 
of the non-coding RP11-528G1.2, unfortunately no exon-exon-junction primer could be established 
for RT-qPCR. Nevertheless, the spliced transcript could be detected by RT-PCR from cDNA 
templates of different RNA preparations (Figure S20). The log2FCS in RNA-Seq under ChX for this 
locus ranges from 1.21 to 1.75, thus, the targets are weakly regulated when de novo protein 
synthesis is blocked. 
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Figure 40: Overview of the SLAMF gene locus with pictured E2 dependent induction of transcription in 
ER/EB2-5 and references for active chromatin and looping activity in GM12878. Schematic map depicting 
A Expression based RNA-Seq tracks (1-12) displaying the coverage in the different conditions/fractions as 
indicated (coverage encoded in bigwig files; converted from BAM files, mapping by STAR mapper; set to the 
indicated data range) and a GRO-Seq track showing the coverage in GM12878 (Core LJ, et al. 2014; data 
range set to auto scale). B Tracks obtained from ChIP-Seq (H3K27ac, H3K4me1, RNA PolII and CTCF sourced 
from ENCODE for GM12878; data range set to auto scale). C Annotation tracks (only names of relevant genes 
and different transcript variants specified). D Additionally displayed are CTCF-mediated TADs and promoter-
to-promoter loops (grey=loops directing to E2 target genes)/promoter-to-other loops (red= loops directing to 
E2 target gene) in GM12878. 
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Figure 41: RT-qPCR confirmation of E2 target genes in the SLAMF neighborhood. Bar graphs showing the 
absolute quantification by RT-qPCR of transcripts of CD48, SLAMF1, CD84 and the non-coding transcript 
RP11-528G1.2 in different RNA preparations. ER/EB2-5 cells were depleted for estrogen and reactivated 
for 0 h and 6 h, with a subpopulation under ChX treatment. RNA was isolated from 107 cells (total) or 
subcellular fractions (1.2 x 107 cells for cytoplasm and 2 x 108 cells for nucleus) and 4 µg RNA was reverse 
transcribed to cDNA. Concentration of cDNA copies per 50 ng RNA as indicated (ntech. = 3, nbiol. = 3). P-values 
obtained from unpaired t-test indicated if significant (p < 0.05). Underneath the bar graph, the raw read 
counts obtained from RNA-Seq aligned to ENSEMBL genes are displayed. Graph Pad Prism was used for 
plotting. 
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PPAN 
 
Peter Pan (PPAN) is a reported target of E2 (Spender et al., 2006; Figure 42). The neighborhood of 
PPAN contains genes with diverse functions in proliferation and immune response. PPAN encodes 
the Suppressor of SW14 1 (SSF1) homolog, which is a conserved protein (SSF1 in yeast and PPAN 
in drosophila]. It is published to be essential for cell growth and proliferation (Welch et al., 2000). 
P2RY11 encodes a purinergic receptor and among other roles it is described to exert a role in 
immune response with cell type-specific effects (Vitiello, Gorini, Rosano, & la Sala, 2012). PPAN-
P2RY11 is a read-through product and the fusion protein shares sequence identity with each 
individual gene product (provided by RefSeq, Nov 2010; 
https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=692312). In the 
neighborhood resides ANGPTL6 which functions as a chemokine enhancing proliferation in blood 
cells (CD34+ cord blood cells; Fatrai et al., 2011). These protein coding genes were detected as E2 
targets by RNA-Seq in this study together with a non-coding RNA gene CTD-2240E14.4. CTD-
2240E14.4 (one transcript according to GRCh37.75; monoexonic; antisense transcript) was found 
to be misregulated in 13 different cancer types (Yan et al., 2015). The read-through transcript 
PPAN-P2RY11, ANGPTL6 and the non-coding RNA CTD-2240E14.4 are co-regulated by E2 as 
confirmed by RT-qPCR (Figure 43). Specific primers for the detection of distinct transcripts of only 
P2RY11 or only the read-through transcript PPAN-P2RY11 could not be established for RT-qPCR. 
Specific primers for only PPAN transcripts are not feasible. The exon-exon junction primers used 
detect the spliced transcripts of both, PPAN and PPAN-P2RY11. The spliced transcripts of ANGPTL6 
and the monoexonic transcript of CTD-2240E14.4 could be detected in the total, the cytoplasmic 
and the nucleic RNA preparation, - /+ ChX. However, the regulation of ANGPTL6 observed by RT-
qPCR appears to be not so convincing, particularly because it seems to be regulated by ChX. The 
log2FCS in RNA-Seq under ChX for this locus ranges from 1.12 to 1.45, thus, the targets are weakly 
regulated when de novo protein synthesis is blocked. 
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Figure 42: Overview of the PPAN gene locus with pictured E2 dependent induction of transcription in ER/EB2-
5 and references for active chromatin and looping activity in GM12878. Schematic map depicting A 
Expression based RNA-Seq tracks (1-12) displaying the coverage in the different conditions/fractions as 
indicated (coverage encoded in bigwig files; converted from BAM files, mapping by STAR mapper; set to the 
indicated data range) and a GRO-Seq track showing the coverage in GM12878 (Core LJ, et al. 2014; data 
range set to auto scale). B Tracks obtained from ChIP-Seq (H3K27ac, H3K4me1, RNA PolII and CTCF sourced 
from ENCODE for GM12878; data range set to auto scale). C Annotation tracks (only names of relevant genes 
and different transcript variants specified). D Additionally displayed are CTCF-mediated TADs and promoter-
to-other loops (red= loops directing to E2 target gene) in GM12878. 
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Figure 43: RT-qPCR confirmation of E2 target genes in the PPAN neighborhood. Bar graphs showing the 
absolute quantification by RT-qPCR of the PPAN-P2RY11 readthrough transcript, ANGPTL6 and the non-
coding transcript CTD-2240E14.4 in different RNA preparations. ER/EB2-5 cells were depleted for estrogen 
and reactivated for 0 h and 6 h, with a subpopulation under ChX treatment. RNA was isolated from 107 cells 
(total) or subcellular fractions (1.2 x 107 cells for cytoplasm and 2 x 108 cells for nucleus) and 4 µg RNA was 
reverse transcribed to cDNA. Concentration of cDNA copies per 50 ng RNA as indicated (ntech. =3, nbiol. =3). 
P-values obtained from unpaired t-test indicated if significant (p < 0.05). Underneath the bar graph, the raw 
read counts obtained from RNA-Seq aligned to ENSEMBL genes are displayed. Graph Pad Prism was used 
for plotting. 
 
 
 
 
 
 
 Results 
93 
 
It was not necessary to perform a relative quantification, since a housekeeping (non-coding) gene 
did not show major regulation. However, the protein-coding housekeeping gene showed a slight 
regulation in the cytoplasm upon E2 reactivation, in contrast to the results of RNA-Sequencing 
(Figure 44).  
 
Together, these RT-qPCR data support the RNA-Sequencing results on gene blocks regulated by 
E2 in presence and absence of de novo protein synthesis. 
 
 
 
 
 
Figure 44: Transcripts of housekeeping genes as control for RT-qPCR. Bar graphs showing the absolute 
quantification by RT-qPCR of transcripts of the non-coding gene U6snRNA and the protein-coding gene 
CHMP2A in 4 in different RNA preparations. ER/EB2-5 cells were depleted for estrogen and reactivated for 
0 h and 6 h with a subpopulation under ChX treatment. RNA was isolated from 107 cells (total) or subcellular 
fractions (1.2 x 107 cells for cytoplasm and 2 x 108 cells for nucleus) and 4 µg RNA was reverse transcribed 
to cDNA. Concentration of cDNA copies per 50 ng RNA as indicated (ntech. = 3, nbiol. = 3). P-values obtained 
from unpaired t-test indicated if significant (p < 0.05). Underneath the bar graph, the raw read counts 
obtained from RNA-Seq aligned to ENSEMBL genes are displayed. Graph Pad Prism was used for plotting. 
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3.2.2.2.8 Protein coding and non-coding targets are regulated by E2 during establishment of 
latency 
 
Post infection, latency is established (Fig. 1). E2 is one of the first viral genes expressed post 
infection. Since the transcriptional analysis described so far is conducted in established cell 
systems, we wondered whether the ER/EB2-5 system recapitulates the physiological events during 
the establishment of latency and whether the protein coding and non-coding target genes of E2 
are regulated in a similar or different manner.  
Therefore, primary B cells were isolated from adenoids of three individual donors and infected with 
the EBV strain B95.8. At different time points post infection, cells were harvested, RNA was isolated 
and specific E2 targets were quantified by RT-qPCR. Different strategies for quantification of 
transcript levels were performed. Usually, absolute quantification is based on the RNA amount 
which is input in reverse transcription. Since the RNA content per cell differs dramatically during 
the time course of infection due to cell growth (Table S1), an absolute quantification based on the 
cell number submitted to reverse transcription was performed in addition. Because of changes of 
the protein coding and non-coding housekeeping gene RNA levels (Figure 45), the absolutely 
quantified copy numbers per cell number of the candidate E2 targets were normalized to the 
housekeeping gene of same biotype. It can be appreciated that E2 itself increases dramatically 
during infection, peaks at day three post infection and then decreases slightly (Figure 46, bottom 
right). MYC increases after infection, peaks at day three post infection and decreases again until it 
almost reaches its pre-infection levels (Figure 47, bottom right). One of the non-coding targets in 
the MYC neighborhood, CASC21, increases after infection with a peak at day 6 post infection (Fig. 
Figure 48, bottom right). SLAMF1 quickly increases in the first hours post infection, reached a 
plateau with a minimal local peak at 24 h post infection and then decreases slightly (Figure 49, 
bottom right). The non-coding target in the SLAMF1 neighborhood, RP11-528G1.2, increases after 
infection with a peak at day 6 post infection (Figure 50, bottom right). PPAN-P2RY11 slowly 
increases after infection, peaks at day three post infection and then decreases (Figure 51, bottom 
right). The non-coding targets in the PPAN neighborhood, CTD-2240E14.4, increases after infection 
with a peak at day 6 post infection (Figure 52, bottom right).  
 
Summing up, E2 coding and non-coding targets are already regulated during establishment of 
latency, indicating that the ER/EB2-5 system recapitulates the infection and latency establishment 
process. 
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Figure 45: RT-qPCR of housekeeping genes during the establishment of latency. Line plots showing different 
analyses of RT-qPCR of transcripts of the housekeeping genes CHMP2A (protein coding) and U6snRNA (non-
coding) at different time points post infection. Primary B cells were isolated from adenoids of three different 
donors and infected with B95.8 viral supernatant. RNA was isolated from 5 x 106 or 107 cells and 1 µg of 
RNA was reverse transcribed to cDNA (ntech. = 2). A Absolute quantification based on RNA amount used for 
cDNA preparation for both genes, concentration of cDNA copies per 50 ng RNA as indicated. B Absolute 
quantification based on cell number of both genes, concentration of cDNA copies per 106 cells as indicated. 
C Mean over three donors (of quantification shown in B) of both genes, concentration of cDNA copies per 
106 cells as indicated. Graph Pad Prism was used for plotting. 
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Figure 46: RT-qPCR of E2 during the time course of infection showing a peak in abundance at 3 d p.i. and a 
steady increase of RNA abundance. Line plots showing different analyses of RT-qPCR of E2 at different time 
points post infection. Primary B cells were isolated from adenoids of three different donors and infected with 
B95.8 viral supernatant. RNA was isolated from 5 x 106 or 107 cells and 1 µg of RNA was reverse transcribed 
to cDNA (ntech. = 2). A Absolute quantification based on RNA amount, concentration of cDNA copies per 50 ng 
RNA as indicated. B Absolute quantification based on cell number, concentration of cDNA copies per 106 
cells as indicated for all three donors (left) and the mean over three donors (right). C cDNA copies 
(quantification shown in B) normalized to the coding housekeeping gene CHMP2A for all three donors (left) 
and the mean over three donors (right). Graph Pad Prism was used for plotting. 
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Figure 47: RT-qPCR of MYC during the time course of infection showing a peak in abundance at 3 d p.i.. Line 
plots showing different analyses of RT-qPCR of MYC at different time points post infection. Primary B cells 
were isolated from adenoids of three different donors and infected with B95.8 viral supernatant. RNA was 
isolated from 5 x 106 or 107 cells and 1 µg of RNA was reverse transcribed to cDNA (ntech. = 2). A Absolute 
quantification based on RNA amount, concentration of cDNA copies per 50 ng RNA as indicated. B Absolute 
quantification based on cell number, concentration of cDNA copies per 106 cells as indicated for all three 
donors (left) and the mean over three donors (right). C cDNA copies (quantification shown in B) normalized 
to the coding housekeeping gene CHMP2A for all three donors (left) and the mean over three donors (right). 
Graph Pad Prism was used for plotting. 
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Figure 48: RT-qPCR of non-coding CASC21 at MYC locus during the time course of infection showing a peak 
6 d p.i. and a steady increase of RNA abundance. Line plots showing different analyses of RT-qPCR of 
CASC21 at different time points post infection. Primary B cells were isolated from adenoids of three different 
donors and infected with B95.8 viral supernatant. RNA was isolated from 5 x 106 or 107 cells and 1 µg of 
RNA was reverse transcribed to cDNA (ntech. = 2). A Absolute quantification based on RNA amount, 
concentration of cDNA copies per 50 ng RNA as indicated. B Absolute quantification based on cell number, 
concentration of cDNA copies per 106 cells as indicated for all three donors (left) and the mean over three 
donors (right). C cDNA copies (quantification shown in B) normalized to the coding housekeeping gene 
CHMP2A for all three donors (left) and the mean over three donors (right). Graph Pad Prism was used for 
plotting. 
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Figure 49: RT-qPCR of SLAMF1 during the time course of infection showing a peak in abundance at 24 h p.i.. 
Line plots showing different analyses of RT-qPCR of SLAMF1 at different time points post infection. Primary 
B cells were isolated from adenoids of three different donors and infected with B95.8 viral supernatant. RNA 
was isolated from 5 x 106 or 107 cells and 1 µg of RNA was reverse transcribed to cDNA (ntech. = 2). A Absolute 
quantification based on RNA amount, concentration of cDNA copies per 50 ng RNA as indicated. B Absolute 
quantification based on cell number, concentration of cDNA copies per 106 cells as indicated for all three 
donors (left) and the mean over three donors (right). C cDNA copies (quantification shown in B) normalized 
to the coding housekeeping gene CHMP2A for all three donors (left) and the mean over three donors (right). 
Graph Pad Prism was used for plotting. 
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Figure 50: RT-qPCR of non-coding RP11-528G1.2 at SLAMF locus during the time course of infection 
showing a peak 6 d p.i. and a steady increase of RNA abundance. Line plots showing different analyses of 
RT-qPCR of RP11-528G1.2 at different time points post infection. Primary B cells were isolated from 
adenoids of three different donors and infected with B95.8 viral supernatant. RNA was isolated from 5 x 106 
or 107 cells and 1 µg of RNA was reverse transcribed to cDNA (ntech. = 2). A Absolute quantification based on 
RNA amount, concentration of cDNA copies per 50 ng RNA as indicated. B Absolute quantification based on 
cell number, concentration of cDNA copies per 106 cells as indicated for all three donors (left) and the mean 
over three donors (right). C cDNA copies (quantification shown in B) normalized to the coding housekeeping 
gene CHMP2A for all three donors (left) and the mean over three donors (right). Graph Pad Prism was used 
for plotting. 
 Results 
101 
 
 
 
Figure 51: RT-qPCR of PPAN-P2RY11 during the time course of infection showing a peak in abundance at 
3 d p.i.. Line plots showing different analyses of RT-qPCR of SLAMF1 at different time points post infection. 
Primary B cells were isolated from adenoids of three different donors and infected with B95.8 viral 
supernatant. RNA was isolated from 5 x 106 or 107 cells and 1 µg of RNA was reverse transcribed to cDNA 
(ntech. = 2). A Absolute quantification based on RNA amount, concentration of cDNA copies per 50 ng RNA as 
indicated. B Absolute quantification based on cell number, concentration of cDNA copies per 106 cells as 
indicated for all three donors (left) and the mean over three donors (right). C cDNA copies (quantification 
shown in B) normalized to the coding housekeeping gene CHMP2A for all three donors (left) and the mean 
over three donors (right). Graph Pad Prism was used for plotting. 
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Figure 52: RT-qPCR of non-coding CTD-2240E14.4 at PPAN locus during the time course of infection showing 
a peak 6d p.i. and a steady increase of RNA abundance. Line plots showing different analyses of RT-qPCR of 
CTD-2240E14.4 at different time points post infection. Primary B cells were isolated from adenoids of three 
different donors and infected with B95.8 viral supernatant. RNA was isolated from 5 x 106 or 107 cells and 
1 µg of RNA was reverse transcribed to cDNA (ntech. = 2). A Absolute quantification based on RNA amount, 
concentration of cDNA copies per 50 ng RNA as indicated. B Absolute quantification based on cell number, 
concentration of cDNA copies per 106 cells as indicated for all three donors (left) and the mean over three 
donors (right). C cDNA copies (quantification shown in B) normalized to the coding housekeeping gene 
CHMP2A for all three donors (left) and the mean over three donors (right). Graph Pad Prism was used for 
plotting. 
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3.2.2.2.9 Regulation of non-coding genes correlates positively with the regulation of the 
neighboring protein coding genes 
 
A mark of an active enhancer is its transcription, and an active enhancer is associated with the 
activation of transcription of remote gene loci. eRNAs were once claimed to rather act in cis in 
contrast to lincRNAs (W. Li et al., 2013). Next, we questioned whether the detected non-coding 
genes (ncg) were regulated alongside with protein coding genes (pcg). Furthermore, we 
investigated whether an enhancer chromatin state of the lncRNA has a substantial impact on 
activation of remote genes and whether the assignment of trans-/cis- mode of action for 
eRNAs/lincRNAs is obsolete. 
For eRNA assignment, the chromatin state segmentation published by Ernst et al. in the context of 
the ENCODE project was used (Ernst et al., 2011). If the TSS flanking region (TSS -1000 bp 
+100 bp) of the lncRNAs intersected ( ≥ 1 bp) with one of the four enhancer chromatin states (two 
weak enhancer and two strong enhancer states), the lncRNAs was considered as eRNA in the 
following investigations. The lncRNA could have originally another classification. The classifications 
are not mutually exclusive (see section 1.3.2.1, p. 13). 
We calculated the frequencies of distances of an expressed and significantly regulated eRNA to 
the closest expressed and significantly regulated pcg and compared this setting with the distances 
of other lncRNAs to their pcg partner. We observed that surprisingly, other lncRNAs were closer in 
proximity to pcgs than eRNAs (Figure 53A, left). This finding was intensified by the limitation of the 
distance to 2000 kb and the selection of only pairs with no interjacent unregulated gene (Figure 
53A, right). TADs are claimed to be up to 2 Mb in size (Dixon et al., 2012), this was used as a 
comparison. We expected shorter distances between the regulated eRNAs to the closest pcg. In 
order to test, whether eRNAs compared to other lncRNAs were co-regulated with pcgs in their 
neighborhood, the correlation of log2FCs between eRNAs and other lncRNAs with their closest pcg 
partner was assessed (Figure 53B). As a control, randomly selected regulated RNAs were chosen. 
Since we were concerned to bias the result by selecting a specific subcellular compartment (pcgs 
are enriched in the cytoplasm and lncRNAs might be enriched in the nucleus) the analysis was 
carried out for lncRNAs in the cytoplasm versus pcgs in the cytoplasm (Figure 53B, right) for 
lncRNAs in the nucleus versus pcgs in the cytoplasm (Figure 53B, top right) and for lncRNAs in the 
nucleus versus pcgs in the nucleus (Figure 53B, bottom right). While the log2FCs of the control 
group of RNAs did not correlate with the log2FCs of their closest pcg neighbor, the log2FCs of 
eRNAs correlated with the log2FCs of their closest pcg neighbor. The “other lncRNAs” correlated 
slightly better (r=0.75 versus r=0.8) than eRNAs. The selection of a specific subcellular 
compartment for the biotypes did not result in a substantial difference in the correlation. 
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These data show that despite a long range distance of regulated lncRNA to the closest regulated 
pcg, their regulation strength and direction correlated positively. The enhancer chromatin state at 
the TSS flanking region of the transcripts of the defined eRNA genes did increase neither the 
proximity nor the correlation of the lncRNA-pcg pairs. 
 
 
 
Figure 53: E2 significantly (FDR < 0.05) regulated (log2FC > 1 or <-1) lncRNAs and pcgs are not in next 
proximity, but the regulation of these target genes correlates positively. 4,480 genes which are similarly 
regulated by E2 in both subcellular compartments and are covered with > 20 reads in both compartments 
(= expr+ reg.) were selected for this analysis (3,653 pcgs, 232 eRNAs and 373 other lncRNAs) A Cumulative 
plots displaying the frequency of distances from lncRNA to pcg (left) and the frequency of distances restricted 
to max. 2,000 kb (right). B The log2FCs of eRNA and other lncRNAs correlate positively with the log2FCs of 
pcgs in comparison to random selected RNAs. Pearson correlation on the log2FCs of two compared groups 
(given by x- and y-axes); line displays result of linear regression on these groups (selection of gene subsets 
was conducted by me; plots were created by Gergely Csaba). 
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3.2.2.2.10 Genome-wide characterization of E2 regulated genes 
 
Aiming to comprehensively characterize E2 regulated genes with focus on lncRNAs in detail, 
several existing data on LCLs were integrated to delineate different subsets of E2 regulated genes. 
In the following, two groups of genes were subject to the investigations  
i) ENSEMBL genes and  
ii) intergenic genes (with regards to ENSEMBL gene annotation).  
 
ENSEMBL annotated genes for hg19/GrCh37 from the release 75 (Feb 2014, latest update 
available for hg19/GrCh37 at beginning of this thesis; 63,677 annotated genes), which resembles 
the Gencode V19 annotations (GENCODE consortium within the framework of the ENCODE project) 
were further analyzed. All for our cells relevant genes, for which ≥ 1 read was detected in any 
sample, where input for a giant “filter tree”. This resulted in 31,192 human genes. According to 
the ENSEMBL biotype categorization (see section 3.2.2.2.5 p. 68) these genes consisted of 17,611 
protein coding genes (pcgs), 7,676 lncRNAs and 5,905 genes of heterogeneous biotypes 
(pseudogenes, polymorphic_pseudogenes, IG_C_gene, IG_V_gene IG_V_pseudogene, 
IG_C_pseudogene TR_V_gene, TR_C_gene, TR_V_pseudogene, processed_transcript, misc_RNA, 
snoRNA, snRNA, miRNA). The assigned biotype of a gene corresponds presumably to the biotype 
of the first detected transcript for this gene, there might be more transcripts belonging to a gene 
assigned with different biotypes. It has to be mentioned, that in this analysis, of all the 17,611 
protein coding genes there are ~700 genes, for which the biotype of the transcript with highest 
Frank (explanation see below) is a non-coding biotype. 
 
The second group covers differentially expressed regions, which have not been annotated by 
ENSEMBL (for determination see section 3.2.2.2.2, p. 58). The discovered 8,918 regions were 
designated as genes. Assuming that all protein coding genes are already uncovered, these genes 
might all be lncRNAs genes. Regulated intronic regions were not further analyzed due to the 
uncertainty of their genesis. 
Where genes regulated in the same direction after comparing two different datasets were 
encountered, we designated them as co-regulated. 
 
E2 targeted lncRNA genes are found in nucleus and cytoplasm 
 
First, the question arose in which subcellular compartment, nucleus (nucl) or cytoplasm (cyto), E2 
regulated RNAs are predominantly located. Particularly interesting for us were E2 regulated 
lncRNAs and their location with regard to their function. In the following, genes regulated by E2 
with regard to the two compartments are analyzed. 
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ENSEMBL genes 
 
The 31,192 ENSEMBL genes were filtered for their read coverage (Figure 54A). 19,154 genes, 
covered with > 20 reads per gene in either of the two compartments (nucleus or cytoplasm) or in 
either of the two conditions (-/+estr.) were considered as expressed. The remaining genes were 
subsequently selected for significant (worst FDR < 0.05) regulation (log2FC > 0.85 or < - 0.85) in 
either of the two subcellular compartments (decision [1] in the filter tree, Figure 54A). 7,599 genes 
remained, which were then screened for genes which were regulated in the same direction (co-
regulated) by E2 in the cytoplasm and the nucleus, leaving 5,104 genes (decision [2] in the filter 
tree, Figure 54A, Figure 54B). Among those are 797 lncRNAs (Figure 54B). 2,495 genes are not 
significantly co-regulated. The 5,104 genes can be significantly co-regulated in both 
compartments, but the threshold of the read coverage at the very beginning was set in regard to 
one of the four samples. Demanding > 20 reads in the nucleic samples left 4,620 genes 
considered expressed here, hence, 484 genes are enriched solely in the cytoplasm (Figure 54C). 
Demanding > 20 reads in the cytoplasmic samples remained 4,964 genes considered expressed 
here, consequently are 140 genes enriched solely in the nucleus. 4,480 genes were covered with 
> 20 reads in both compartments. 
Wondering, whether the nucleic compartment is enriched for lncRNA genes, the biotypes were 
demanded for the genes co-regulated in the nucleus and expressed or enriched there (Figure 
54Figure 54D, upper panel first two graphs l.t.r) and for the genes being regulated solely in the 
nucleus (with > 20 reads; Figure 54D, lower panel left). The biotype of lncRNAs was further split 
up in lncRNAs, which emanate from chromatin with enhancer state (> 1 overlap with enhancer 
state according to CSS HMM; Ernst et al., 2011) and are for this thesis defined as eRNAs and other 
lncRNAs (all other ENSEMBL annotated lncRNA, whose TSS flanking region did not overlap with an 
enhancer state). Since eRNAs are thought to have mainly gene regulatory functions, they were 
expected to reside in the nucleus. Comparing the nucleic lncRNAs with their cytoplasmic 
counterparts, it can be observed that there is quasi no difference in biotype composition regarding 
the genes which are expressed in nucleus and cytoplasm (Figure 54D, upper panel, middle), most 
likely because of the huge overlap of genes residing in both subcellular compartments (Figure 
54C). Strikingly, the set of genes enriched in both the cytoplasm and nucleus contains more 
lncRNAs compared to the total amount of expressed genes. Furthermore, more co-regulated 
lncRNAs reside in the nucleus than in the cytoplasm (Figure 54D, upper panel, edges). Against all 
expectations, eRNAs were augmented in the cytoplasm enriched subset. Equally, examining the 
specifically in the nucleus and cytoplasm regulated genes, eRNAs and other lncRNAs are 
augmented in the cytoplasm (Figure 54D, lower panel). Summing up, our data indicate that E2 
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regulated lncRNAs and especially eRNAs reside in both compartments and are according to our 
methods augmented in the cytoplasm of ER/EB2-5 cells. 
Next, we investigated if the lncRNAs in the different gene subsets of the two subcellular 
compartments differed in length or splice status. Assuming that eRNAs are rather short and 
monoexonic transcripts, which are not spliced and transported out of the nucleus, we expected the 
whole population of lncRNAs in the nucleus to be rather short and monoexonic, whereas the longer, 
multiexonic transcripts could reside in both compartments according to our assumptions. For this 
analysis, we examined the underlying transcripts of the different gene subsets. In order to 
determine the most likely differentially expressed transcripts for each gene, ranking analysis by F-
statistics was conducted. For all transcripts belonging to a gene, a F-measure was assessed, the 
transcripts were ranked according to their F measure and as a cutoff, only transcripts with Frank ≤ 2 
were considered for further analysis. Investigating the median length of the transcripts of lncRNAs 
in the different gene subsets with this as requirement, we observed that in general the transcripts 
of all expressed lncRNAs (mean ~1.0 to 1.5 kb) differed in length from the transcripts of all 
expressed pcgs (mean= 3.4 kb; Figure 54E). However, the length of the transcripts deriving from 
lncRNA genes is similar comparing subsets in the nucleus to cytoplasm. eRNAs were augmented 
in the cytoplasm enriched genes (Figure 54D), which does not impact the transcript length in this 
subset. Transcripts of lncRNA genes enriched in the nucleus occur to be shorter (mean= 960 bp) 
compared to the transcripts of all expressed lncRNA genes (mean= 1.3 kb). One has to bear in 
mind that the subset of genes enriched in the nucleus is the smallest. The length of transcripts of 
lncRNA genes specifically regulated in the nucleus or cytoplasm is similar.  
In order to study the splice status of the transcripts, the number of exons of the transcripts (Frank 
≤ 2) per regulated lncRNA gene was assessed. We determined that overall, the transcripts of all 
expressed lncRNAs have less exons (mean= 2.5 exons) than transcripts of all expressed pcgs 
(mean= 10.4 exons; Figure 54F). Nevertheless, the number of exons of transcripts deriving from 
lncRNA genes does not differ significantly comparing subsets in the nucleus to cytoplasm. eRNAs 
were augmented in the cytoplasm enriched genes, which has no impact on the number of exons 
in this subset compared to the same subset in the nucleus. The transcripts of lncRNA genes 
specifically regulated in the cytoplasm appear to have less exons. In conclusion, the lncRNAs in 
the different gene subsets of the two compartments do not differed in length or splice status. 
 
We found that E2 regulated lncRNAs including eRNAs reside in both subcellular compartments, 
the nucleus and the cytoplasm and the lncRNAs in both compartments are largely similar regarding 
their transcript length and splice status. 
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Figure 54: Characterization of E2 regulated ENSEMBL genes. A Decision tree on subsets of genes to be 
further analyzed: All genes with > 20 reads in any compartment or any condition were considered to be 
expressed and filtered for 1. significant (worst FDR < 0.05) regulation (log2FC > 0.85 or <- 0.85) by E2 in 
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any compartment and 2. significant (worst FDR < 0.05) regulation (log2FC > 0.85 or <- 0.85) in the same 
direction (co-regulation) in both subcellular compartments. B 67 % of E2 target genes in one of the 
compartments are co-regulated in both subcellular compartments. Scatterplot showing the positive 
correlation of log2FCs of the E2 co-regulated (5,104 genes out of the 7,599) genes in the cytoplasm vs. 
nucleus (not filtered for significance in both compartments for plotting). Log2FCs of filtered genes were 
plotted using R. C 88 % of co-regulated genes (4,480) are expressed (>20 reads) in both compartments. 
Venn diagram displaying the localization of regulated genes. The intersection of co-regulated genes 
expressed in both compartments was plotted using R. D The number of lncRNAs is increased in the subset 
of genes enriched in the nucleus. Vertical slices showing the fraction of biotypes (eRNAs defined as RNAs 
with ≥ 1 bp overlap with enhancer signature -1000 bp +100 bp around TSS) of co-regulated genes (upper 
panel) and not co-regulated genes (lower panel) in the cytoplasm and the nucleus (> 20 reads). Plots were 
created using Graph Pad Prism. E The lncRNA transcripts of most gene subsets don’t differ in their length. 
Box plots showing the median length of all transcripts (Frank ≤ 2) derived from E2 regulated genes in the 
different gene subsets (mean indicated); p-values of interesting comparisons indicated, obtained from 
unpaired t-test with Welch’s correction. Plots were created using Graph Pad Prism. F The lncRNA transcripts 
of most gene subsets don’t differ in their number of exons. Box plots showing the average number of exons 
of transcripts (Frank ≤ 2) regulated by E2 in the different gene subsets; mean indicated; p-values of interesting 
comparisons indicated, obtained from unpaired t-test with Welch’s correction. Plots were created using 
Graph Pad Prism. 
 
 
Intergenic genes  
 
As before, the 8,918 intergenic (interjacent to ENSEMBL annotated genes) transcribed genes were 
filtered for their read coverage (Figure 55A). 4,772 genes, covered with >20 reads per gene in 
either of the two compartments (nucleus or cytoplasm) in either of the two conditions (-/+estr.) 
were considered as expressed. The remaining genes were subsequently selected for significant 
(worst FDR <0.05) regulation (log2FC > 1 or < - 1) in either of the two compartments (decision [1] 
in the filter tree, Figure 55A). 603 genes remained which were then screened for genes, which 
were co-regulated by E2 in the cytoplasm and the nucleus, leaving 360 genes (decision [2] in the 
filter tree, Figure 55A, Figure 55B). 243 genes are not significantly co-regulated. In the nucleic 
samples, 288 genes remained after demanding a gene coverage of > 20 reads (=considered 
expressed in the nucleus), hence, 72 genes are enriched in the cytoplasm only (Figure 55C). In the 
cytoplasmic samples, 233 genes remained after demanding gene coverage of > 20 reads 
(considered as expressed in the cytoplasm), consequently, 127 genes are only enriched in the 
nucleus. 161 genes were covered with > 20 reads per gene in both compartments. It can be 
appreciated, that more intergenic genes are located in the nucleus than in the cytoplasm. 
We questioned whether novel lncRNAs can be identified in the different gene subsets. For this, we 
intersected the E2 regulated, intergenic genes detected in ER/EB2-5 with the entries of the lncRNA 
Atlas LNCat (Figure 55D). This comprehensive database combines lncRNAs from 24h resources 
including GENCODE, LNCipedia and NONCODE. If the smaller of the two compared genomic 
intervals (gene entry LNCat versus detected intergenic gene) overlapped > 50% with the other data 
set, the intergenic gene was considered as already known. If the smaller of the two compared 
intervals overlapped < 50 % with the other data set, the intergenic gene was considered as 
potentially novel. If there was no overlap at all, the intergenic gene was considered as novel. The 
 Results 
110 
 
request for an overlap for the genes co-regulated and enriched or expressed in the nucleus or in 
the cytoplasm (Figure 55D, upper panel) and for the genes being regulated solely in the nucleus or 
cytoplasm (with >20 reads; Figure 55D, lower panel) resulted in remarkable 20-35 % of novel 
intergenic genes in the different subsets. Up to 10 % of the intergenic genes are already recorded 
and 65-70 % of the genes partly overlap with entries of LNCat. Altogether, there is evidence for 
identification of novel lncRNA genes. This would need to be confirmed by the search for ORFs. 
Furthermore, we investigated the length of all E2 regulated intergenic genes in the different gene 
subsets of the two compartments (Figure 55E). Due to the enrichment of immature transcripts in 
the nucleus, the outer borders of a gene were difficult to infer. The average length of all detected 
intergenic genes is 3 kb, intergenic genes enriched in the cytoplasm (mean= 1.7 kb) and specific 
for the cytoplasm (mean= 1.4 kb) were observed to be significantly shorter than their nucleic 
counterparts (mean= 2.4 and 2.5 kB, respectively). The intergenic genes of the remaining subsets 
don’t differ substantially. The intron-exon structure of the intergenic genes could not be reliably 
predicted, also due to the nature of the data (many intronic reads; Figure S22). Introns could not 
be reliably inferred even with increasing sensitivity. Furthermore, no convincing data could be 
collected to infer the required number of fragments as evidence for a junction, since increasing 
the number of fragments required for the acceptance of a junction did not substantially alter the 
number of inferred introns. 
Last, we wanted to determine the chromatin state at the flanking region (-1000 bp, +100 bp) of 
the transcription start side (TSS) of the intergenic genes (Figure 55F; > 1 bp overlap of TSS flanking 
region with enhancer state according to CSS HMM; Ernst et al., 2011) in order to investigate, 
whether E2 predominantly activates eRNAs. Most of the intergenic genes had no chromatin state 
assigned (55-77 %). The majority of the detected intergenic genes with an assigned chromatin 
state harbor marks of transcription (TxN; Figure 55F, top left). The distribution of chromatin states 
is similar in all gene subsets except for the subsets of genes which are specifically regulated in the 
cytoplasm, most of the genes are not assigned with a chromatin state. H3K36me3 and H4K20me1 
are marks associated with transcriptional activation.  
 
Taken together, novel (with regards to the ENSEMBL annotation) intergenic transcribed genes can 
be enriched in the nucleus. Up to 30 % of the intergenic genes seem to be entirely novel since they 
do not overlap with genes of the comprehensive database LNCat. Intergenic transcribed genes in 
the cytoplasm were found to be shorter than the intergenic transcribed genes in the nucleus. As 
expected, intergenic transcribed genes were shown to exhibit marks of active transcription, 
however they were not enriched for enhancer marks. 
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Figure 55: Characterization of E2 regulated intergenic genes. A Decision tree on subsets of genes to be 
further analyzed: All genes with > 20 reads in any compartment or any condition were filtered for 1. 
significant (worst FDR < 0.05) regulation (log2FC > 1 or < - 1) by E2 in any compartment and 2. significant 
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regulation (worst FDR < 0.05) regulation (log2FC > 1 or < - 1) in the same direction (co-regulation) in both 
compartments B 60 % of E2 target genes in one of the compartments are similarly regulated (co-regulated) 
in both subcellular compartments. Scatterplot showing the positive correlation of log2FCs of the E2 co-
regulated (360 genes out of the 603) genes in the cytoplasm vs. nucleus (not filtered for significance in both 
compartments for plotting). Log2FCs of filtered genes were plotted using R. C 45 % of co-regulated genes 
(161) can be found in both compartments. Venn diagram displaying the localization of regulated genes. The 
intersection of co-regulated genes expressed in both compartments was plotted using R. D The number of 
novel intergenic RNAs is increased in the subset of genes enriched in the nucleus. Vertical slices showing 
the fraction of intergenic genes not, partly (< 50 % of the smaller compared interval) or entirely (> 50 % of 
the smaller compared interval) overlapping with entries in the LNCat (upper panel= co-regulated genes, lower 
panel= not co-regulated genes) in the cytoplasm and the nucleus (> 20 reads). Plots were created using 
Graph Pad Prism. E The genes of most subsets do not significantly differ in their median length. Box plots 
showing the median length of genes regulated by E2 in the different gene subsets. Plots were created using 
Graph Pad Prism. F 55-76 % of the genes don’t hold an assigned CSS, genes specifically regulated in the 
nucleus are enriched for marks for transcription (TxN). Donut plots showing the fractions of genes with 
different CSS at their TSS flanking region (-1000 bp +100 bp; ≥ 1 bp overlap of TSS flanking region with 
chromatin state). CSS in GM12878 based on the definition by Ernst et al, 2011 (ENCODE project; other= 
insulator, polycomb repressed, heterochromatin, repetitive/CNV). Since multiple chromatin states can be 
associated per transcript, an exclusive classification was conducted (enhancer>promoter>TxN>other). Plots 
were created using Graph Pad Prism. 
 
 
E2 regulates 174 genes in the absence of de novo protein synthesis 
 
To identify direct target genes of E2, the translation inhibitor ChX was applied. However, it has to 
be pointed out that this strategy only targets protein coding target genes. Here, the inhibition of 
the following translation prevents any downstream effect of the gene.  
 
ENSEMBL genes 
 
31,192 ENSEMBL genes were again filtered for their read coverage in the samples +/- estr. and 
ChX+estr/ ChX- estr. (Figure 56A). 16,227 genes were covered with > 20 reads per gene in either 
of the conditions. The remaining genes were subsequently selected for significant (worst FDR 
< 0.05) regulation (log2FC > 0.85 or < - 0.85) in the nucleus in the absence of ChX (decision [1] in 
the filtertree, Figure 56A). 4,679 genes remained, which were then screened for regulation in the 
presence of ChX (decision [2] in the filter tree, Figure 56A, Figure 56B). Among the remaining 178 
genes are already described direct E2 targets like MYC, DNase1L3 and CR2 (Figure 56B). 4,501 
genes are not significantly regulated under ChX (Figure 56C). Of the 178 genes regulated by E2 in 
both ChX conditions, 174 are co-regulated. We continued only with genes which are regulated by 
E2 -/+ChX in the same direction (either up- or downregulation). 
Examining the biotype composition of the E2 regulated genes -/+ ChX, we observed that 38 of the 
co-regulated genes are lncRNAs, among them also 11 eRNAs (Figure 56D, right). There is a slight 
enrichment for lncRNAs under ChX (from 12.2 % to 21.8 %). Since E2 is known to preferably bind 
to open chromatin, especially to enhancers, we speculated whether this is mirrored in the 
chromatin state of the “directly” regulated genes. We aimed to determine the chromatin state at 
the TSS flanking region of the transcripts belonging to the E2 regulated ENSEMBL genes in 
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presence and absence of translation (Figure 56E; > 1 bp overlap of TSS flanking region with 
enhancer chromatin state according to CSS HMM). With or without the treatment of ChX, the 
enhancer chromatin state at the TSS flanking regions of transcripts of E2 regulated genes is 
increased compared to the general distribution of CSS of the transcripts of all genes detected in 
our data sets. Nevertheless, the TSS flanking regions showed enriched promoter CSS for cells 
without ChX treatment compared to ChX treated cells, whereas genes with “other” or no assigned 
CSS at the TSS flanking region of their derived transcripts are enriched with ChX (other= insulator, 
polycomb repressed, heterochromatin, repetitive/CNV). However, these data have to be 
interpreted cautiously, since the CSS of GM12878 might differ compared to the CSS of ER/EB2-5 
cells + estr. as well as –estr. 
 
These data show, that in presence and absence of de novo protein synthesis, E2 regulates a 
substantial amount of genes, including lncRNAs, which largely emanate from enhancer marked 
chromatin. 
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Figure 56: Characterization of E2 regulated ENSEMBL genes in absence of de novo protein synthesis 
A Decision tree on subsets of genes to be further analyzed: All genes with > 20 reads in both conditions (- 
and + ChX) were filtered for 1. significant (worst FDR < 0.05) regulation (log2FC > 0.85 or <- 0.85) by E2 in 
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the nucleus in presence of de novo protein synthesis (- ChX) and 2. significant regulation (worst FDR < 0.05) 
regulation (log2FC > 0.85 or <- 0.85) by E2 in absence of de novo protein synthesis in the nucleus (+ ChX) B 
178 of E2 target genes are significantly regulated in presence and absence of de novo protein synthesis. 
Scatterplot showing the positive correlation of log2FCs of the E2 co-regulated (among them the 178 
significantly regulated genes +ChX out of the 4,679) genes in the cytoplasm vs. nucleus (not filtered for 
significance in the samples + ChX for plotting). Log2FCs of filtered genes were plotted using R. C Only 4 % 
(178) of E2 target genes are also regulated in absence of de novo protein synthesis. 174 genes are regulated 
in absence of de novo protein synthesis in the same direction (co-regulated) as with normal translation. Venn 
diagram showing the proportion of co-regulated genes. The intersection of regulated genes expressed in 
presence and absence of de novo protein synthesis was plotted using R. D The number of lncRNAs is 
increased in the subset of genes which are co-regulated. Vertical slices showing the fraction of biotypes 
(eRNAs defined as RNAs with ≥ 1 bp overlap with enhancer signature -1000 bp +100 bp around TSS) of 
regulated genes in presence of translation (left) and co-regulated genes in presence and absence of 
translation (right). Plots were created using Graph Pad Prism. E E2 regulated genes are enriched for 
enhancer marks independent of ChX. Donut plots showing the fractions of genes with different CSS at the 
TSS flanking region of their derived transcripts (-1000 bp +100 bp; transcripts with Frank ≤ 2; ≥ 1 bp overlap 
of TSS flanking region with chromatin state). Genes not regulated by E2 in the nucleus (left) compared to 
genes regulated by E2 in the nucleus (right). CSS in GM12878 based on the definition by Ernst et al, 2011 
(ENCODE project; other= insulator, polycomb repressed, heterochromatin, repetitive/CNV). Since multiple 
chromatin states can be associated per transcript, an exclusive classification was conducted 
(enhancer>promoter>TxN>other). Plots were created using Graph Pad Prism. 
 
 
Next, we investigated whether the E2 regulated genes can be associated with E2 binding sites 
(computationally called peaks based on enrichment of aligned ChIP-Seq reads) and in which TF 
clusters these peaks reside. In order to do so, we intersected the E2 peaks obtained by ChIP-Seq 
(Glaser, PhD thesis, 2017) with i) the TSS flanking region [1], ii) the genebody [2], iii) a fragment 
looping to the TSS flanking region [3], iv) a TSS flanking region of another gene within the same 
TAD [4] or v) a related TAD [5] of the transcripts (Frank ≤ 2) derived from the E2 regulated genes 
(Figure 57A). The looping data is sourced from Mifsud et al. (Mifsud et al., 2015). It has to be 
mentioned that the promoter and “other” (not promoter) fragments are very large (Figure S22), 
more than the half are >10kb. This implies that the chance of a positive intersection of one of 
these fragments with an interval (genomic region) of choice is increased. Since possibly multiple 
E2 peaks exist per transcript, classification was exclusive (i>ii>iii>iv>v). Two control subsets of 
genes were examined, genes which are not covered with > 20 reads in the nucleus in presence of 
translation (Figure 57A top, 14,335 genes, not shown), and genes not significantly regulated by E2 
in the nucleus in absence and presence of translation (Figure 57A bottom left). It can be observed 
that the number of genes not harboring a peak associated to their related transcripts decreases 
and the number of genes harboring a peak associated to the TSS flanking region or the genebody 
of their related transcripts increases. Comparing this to the genes significantly regulated by E2 in 
presence (Figure 57A, bottom middle) or presence/absence (Figure 57A, bottom right) of 
translation, it can be noticed that the proportion of genes not harboring a peak associated to their 
related transcripts further decreases to a minimum of 16 % for the co-regulated genes and the 
proportion of genes harboring a peak at the TSS flanking region or at the genebody of their related 
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transcripts further increased to over 60 % for the co-regulated genes -/+ ChX. Thus, E2 regulation 
can be linked to E2 binding in presence and even better in absence of de novo protein synthesis.  
Intersecting the E2-peaks associated with the transcripts (Frank ≤ 2) of E2 regulated genes with the 
cluster-assigned panEBNA peaks (E2, E3A and E3C peaks), we intended to reveal, which anchors 
E2 possibly utilizes to regulate their target genes (Figure 57B). The cluster distribution of all peaks 
associated in one of the investigated modes (i-v) with transcripts of the genes in our data sets 
shows that 26 % of the peaks reside in cluster I, 16 % in cluster V and 13 % in cluster VIII to name 
the three biggest clusters (Figure 57B, top left). 11 % of the peaks associated with the related 
transcripts were not assigned to a cluster. The cluster allocation was done for the peaks associated 
with transcripts derived from E2 regulated genes –ChX (Figure 57B, middle panel) or -/+ ChX 
(Figure 57B, right panel) for all genes (top) for other lncRNAs (middle) and eRNAs (bottom; eRNAs= 
lncRNAs with enhancer chromatin state at their TSS flanking region). “No ass. cluster” (no assigned 
cluster) means no associated peaks which could be assigned to a cluster. Tracking cluster I across 
the different subsets, it can be recognized that for most of the genes (35-73 %) the peaks 
associated with the related transcripts can be allocated to this cluster. The treatment with ChX 
enhances this occurrence as well as the selection for eRNAs in both ChX conditions. From these 
data we can speculate that for the regulation of most of the “direct” target genes, especially the 
eRNAs, E2 occupies binding sites of cluster I, positive for CBF1, EBF1 and CUX1 and high for 
H3K4me1 and H3K27ac.  
 
From these data we can conclude that only a minority (4 %) of E2 target genes can be regulated 
with absent de novo protein synthesis. Among the potentially directly regulated genes are also 
lncRNAs, which largely emanate from enhancer marked chromatin. E2 regulation can be linked to 
E2 binding in presence and, even better, in absence of de novo protein synthesis. As expected, E2 
occupied binding sites of cluster I, positive for CBF1, EBF1 and CUX1 and high for H3K4me1 and 
H3K27ac, may be responsible for the regulation of E2 target genes. 
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Figure 57: Characterization of E2 regulated ENSEMBL genes in absence of de novo protein synthesis 
A Transcripts of genes co-regulated in presence and absence of de novo protein synthesis are enriched for 
E2 binding (at TSS flanking region or in genebody). Donut plots showing the fraction of genes with different 
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associated E2 binding sites at their derived transcripts in different gene subsets. Genes with ≤ 20 reads or 
not regulated by E2 in the nucleus (left) compared to genes regulated by E2 in the nucleus (right). For a 
positive connection, E2 peaks had to overlap ≥ 1 bp with the investigated genomic positions clarified in the 
following: We differentiated between [1] genes with a peak in the TSS flanking region of the derived 
transcripts (Frank ≤ 2), [2] genes with a peak in the genebody of the derived transcripts (Frank ≤ 2), [3] genes 
with a peak on a fragment looping to the promoter of the derived transcripts (Frank ≤ 2; Mifsud et al., 2015), 
[4] genes located in the same contact domain with a transcript occupied by a peak at the TSS flanking region 
and [5] genes located in the same contact domain with a peak. Since multiple peaks can possibly be 
associated per transcript, an exclusive classification was conducted ([1]>[2]>[3]>[4]>[5]; g.o.i= gene of 
interest). B E2 peaks associated with genes co-regulated in presence and absence of de novo protein 
synthesis are enriched for Cluster I. Donut plots displaying the cluster distribution of E2 peaks associated 
with transcripts (Frank ≤ 2) corresponding to genes in the different gene subsets. Intersection of E2 peaks 
connected to E2 regulated genes in (A) with EBNA peaks in cluster analysis (Glaser, PhD thesis, 2017). 
Cluster distribution of all E2 peaks connected to transcripts derived from genes covered with ≥ 1 peak in our 
data set (left) compared to peaks associated with regulated gene subsets (right; upper panel= all genes, 
middle panel= all other lncRNAs and lower panel= eRNAs). E2 peaks were identified by ChIP-Seq conducted 
in our lab (Glaser, PhD thesis 2017). Graph Pad Prism was used for plotting. 
 
 
Intergenic genes 
 
For the intergenic genes, the 8,918 intergenic genes were filtered for their read coverage in the 
samples +/- estr. and ChX+estr/ChX- estr. (Figure 58A). 3,623 genes were covered with >20 reads 
per gene in either one of both conditions. The remaining genes were subsequently selected for 
significant (worst FDR < 0.05) regulation (log2FC > 1 or < -1) in the nucleus in the absence of ChX 
(decision [1] in the filter tree, Figure 58A). 372 genes remained, which were then screened for 
regulation in the presence of ChX (decision [2] in the filter tree, Figure 58A, Figure 58B). Only 9 
genes withstood the filtering, all of them are co-regulated.  
Also for these genes, we investigated whether the E2 regulated genes can be associated with E2 
binding sites (Figure 58C). For the control subset of genes, genes which are not covered with > 20 
peaks in the nucleus with present de novo protein synthesis (Figure 58C top, 14,335 genes, not 
shown), and genes not significantly regulated by E2 in the nucleus (Figure 58C bottom left), it can 
be observed that the distribution of classes of genes with peaks associated to their related 
transcripts looks similar. Comparing this to the genes significantly regulated by E2 in presence 
(Figure 58C, bottom middle) or presence/absence (Figure 58C, bottom right) of translation, it can 
be noticed that the proportion of genes not harboring a peak associated to their related transcripts 
decreased slightly for the regulated genes and the proportion of genes harboring a peak at the TSS 
flanking region slightly increased. For the nine co-regulated genes, the transcripts of all of the 
genes can be linked with a peak, six of them via the same TAD. The chromatin state at the TSS 
flanking region (-1000 bp, +100 bp) of the transcripts belonging to the E2 regulated intergenic 
genes in presence and absence of translation was also determined (data not shown), however, the 
majority of genes were not assigned with a chromatin state, the other genes were enriched for the 
TxN chromatin state as the ENSEMBL genes. 
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Using these stringent cutoffs, we detected only nice intergenic transcribed genes regulated by E2 
in the presence of ChX. E2 regulation can be linked to E2 binding in presence and even better in 
absence of de novo protein synthesis. 
 
 
 
 
Figure 58: Characterization of E2 regulated intergenic genes in absence of de novo protein synthesis 
A Decision tree on subsets of genes to be further analyzed: All genes with >20 reads in both conditions (-
+ChX) were filtered for 1. significant (worst FDR < 0.05) regulation (log2FC > 1 < - 1) by E2 in the nucleus 
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and 2. significant (worst FDR < 0.05) regulation (log2FC > 1 < - 1) by E2 in absence of de novo protein 
synthesis in the nucleus B Nine (of 24 regulated) E2 target genes are significantly regulated in presence and 
absence of de novo protein synthesis. Scatterplot showing the positive correlation of log2FCs of the E2 co-
regulated (among them the 9 significantly regulated genes +ChX out of the 4,679) genes in the cytoplasm 
vs. nucleus (not filtered for significance in the samples + ChX for plotting). Log2FCs of filtered genes were 
plotted using R. C Genes co-regulated in presence and absence of de novo protein synthesis are slightly 
enriched for E2 binding. Donut plots showing the fraction of genes with different associated E2 binding sites 
in different gene subsets. Genes with < 20 reads or not regulated by E2 in the nucleus (left) compared to 
genes regulated by E2 in the nucleus (right). For a positive connection, E2 peaks had to overlap ≥ 1 bp with 
the investigated genomic positions clarified in the following: We differentiated between [1] genes with a peak 
in the TSS flanking region [2] genes with a peak in the genebody, [3] genes with a peak on a fragment looping 
to their promoter (Mifsud et al., 2015), [4] genes located in the same contact domain with a transcript 
occupied by a peak at the TSS flanking region and [5] genes located in the same contact domain with a peak. 
Since multiple peaks can possibly be associated per transcript, an exclusive classification was conducted 
([1]>[2]>[3]>[4]>[5]; g.o.i.= gene of interest). 
 
 
The majority of E2 and E3A regulated genes are counter-regulated 
 
Since E2 is a well characterized transactivator of various genes and E3A is known to antagonize 
E2, we aimed to investigate this incidence genome wide. We want to emphasize that we are 
comparing a conditional cell system with a static cell system which can eventually lead to 
misinterpretations. Data for the nuclear compartment are reported in the following, the analysis of 
the cytoplasmic compartment lead to similar results (not shown). 
 
ENSEMBL genes 
 
For this analysis, again the 31,192 ENSEMBL genes were filtered for their read coverage in both 
systems, E2/E3A presence/absence (Figure 59A). 15,751 genes were covered with > 20 reads 
per gene in the nucleus of either of the two systems (+/- estr. or wt/mut). The remaining genes 
were subsequently selected for significant (worst FDR < 0.05) regulation (log2FC > 1 or < -1) by E2 
in the nucleus (decision [1] in the filter tree, Figure 59A). 4,071 genes remained, which were then 
screened for regulation by E3A (decision [2] in the filter tree, Figure 59A). 1,058 genes are 
significantly regulated by E3A, 3,013 are not. Of the 1,058 genes, which are regulated by both TFs, 
741 are counter-regulated, that are remarkable 70 % of shared targets (Figure 59B, C). The 
strongest by E2 induced gene (log2FC= 9.4) counter-regulated by E3A (log2FC= - 5.2) encodes the 
interleukin 1 receptor, type II (IL1R2). As expected, among the strongest E3A repressed (log2FC= 
- 8.2), counter-regulated by E2 (log2FC= 3.4) encodes for the chemokine CXCL10 (well-studied by 
the Kempkes laboratory). The 741 significantly counter-regulated genes can be separated in 118 
lncRNAs and 623 other genes (mostly pcgs). Of the 118 lncRNAs, 99 genes as also expressed 
(> 20 reads) in the cytoplasm. Of the 99 genes residing in both compartments, 61 are also 
significantly counter-regulated in both compartments, 38 are nucleus specific (Figure 59B). To re-
emphasize a special lncRNA in the MYC neighborhood, CCDC26 is one of the counter-regulated 
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lncRNAs. It was reported to play a role in different cancer types (Hirano et al., 2015; Peng & Jiang, 
2016). 
E2 is expressed early during infection, while E3A expression follows later, potentially repressing 
genes activated by E2. Under this assumption, the co-regulated genes should be all expressed 
(> 20 reads) in wt LCLs. Furthermore, if E2 and E3A operate in a competitive way and the genes 
are expressed (> 20 reads) in wt LCLs, it can be assumed that E2 prevailed over E3A (or both TFs 
exert an activating function on these genes). In contrast, if E3A showed a stronger repressive 
function than E2 activation (or both TFs exert a repressive function on the genes) genes are not 
expressed (< 20 reads) in wt LCL. Thus, most interesting for us was the question, if the detected 
co- and counter-regulated genes are expressed in wt LCLs. Of the not significantly counter-
regulated genes (genes can be co-regulated or not regulated by one of the two TFs), 260 genes are 
indeed expressed in wt LCLs. The remaining 57 genes are repressed by E2 and even stronger 
repressed by E3A, that might be why they are not expressed in wt LCLs. For the 741 counter-
regulated genes, 559 genes are still expressed in wt LCLs, while 182 are not expressed. We 
reasoned that for the 559 genes, E2’s activation prevailed over E3A’s repression and for 182 
genes, E3A’s repression prevailed E2’s activation. 
We wondered, whether the result of the 559 counter-regulated genes present in LCLs (genes 
regulated by both TFs, but E2 “won”) can be mirrored in the binding behavior of both TFs, we tested 
the transcripts of those genes for E2 and E3A peaks (Figure 59D). Ideally, it should be possible to 
associate the 559 counter-regulated genes present in LCLs with both TFs. For 367 of the 559 
genes, the transcript can be associated (at TSS flanking region, etc.) with at least one of both TFs, 
which equals 66 %. The transcripts of 215 genes are linked to an E2 binding site and 152 are 
linked to an E3A binding site, for 116 genes, the transcripts can be associated to both TFs. 
However, only at 27 of those 116 genes, both TFs reside in the TSS flanking region of the 
transcripts. The 741 counter-regulated genes were subjected to a GO-Analysis (Gergely Csaba), 
where we tested for an enrichment of biological processes compared to a background set of genes. 
Interestingly, we observed a substantial amount of GO terms linked to development or 
morphogenesis as well as differentiation and proliferation (Table S2). Only a small amount of terms 
are linked to immune response. 
 
Taken together, we found 70 % (741) of the E2 and E3A shared target genes to be counter-
regulated, which includes 118 lncRNAs. 75 % of the counter-regulated genes are expressed in wt 
LCLs, which could indicate that E2’s activation prevailed over E3A’s repression. For 66 % of the 
counter-regulated genes expressed in wt LCLs, a transcript can be associated with at least one of 
both TFs. The counter-regulated genes were enriched for processes such as development or 
morphogenesis as well as differentiation and proliferation. 
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Figure 59: Characterization of E2 and E3A counter-regulated genes in the nucleus. A Decision tree on subsets 
of genes to be further analyzed: All genes with >20 reads in any condition were filtered for 1. significant 
(worst FDR < 0.05) regulation (log2FC > 1 or < -1) by E2 in any compartment and 2. significant (worst FDR 
< 0.05) regulation (log2FC > 1 or < -1) by E3A in the nucleus. B 70% of shared E2 and E3A target genes are 
counter-regulated and the majority are expressed (> 20 reads) in wt LCLs. Sunburst plot displaying different 
gene subsets indicated in the legend. C Scatterplots showing the anti-correlation of log2FCs of the shared 
E2 and E3A target genes (741 genes out of 1,058) in the nucleus (not filtered for significance) Log2FCs of 
filtered genes were plotted using R. D 30% (116) of in wt LCL expressed, counter-regulated genes associated 
with a binding site (367) are occupied by both TFs. Venn diagram displaying the occupation of counter-
regulated genes, expressed (>20 reads) in wt, by E2 and E3A. 559 of 741 counter-regulated Genes are 
covered with > 20 reads in wt LCLs, for 65% binding sites were detected, 59% of them are E2 binding sites 
an 41% are E3A binding sites. 
 
 
 
 
 
 Results 
123 
 
Intergenic genes 
 
The 8,918 intergenic genes were also tested for counter-regulation. They were also filtered for their 
read coverage in both systems, E2/E3A presence/absence (Figure 60A). 3,084 genes were 
covered with > 20 reads per gene in either of the conditions. The remaining genes were 
subsequently selected for significant (worst FDR < 0.05) regulation (log2FC > 1 or < - 1) by E2 in 
the nucleus (decision [1] in the filter tree, Figure 60A). 309 genes remained, which were in the last 
step screened for regulation by E3A (decision [2] in the filter tree, Figure 60A). 64 genes are 
significantly regulated by E3A (Figure 60C). Of the 64 genes which are regulated by both TFs, 44 
(~70 %) are counter-regulated. Of the 44 counter-regulated genes, 38 have transcripts linked to 
an E2 peak and 37 have an E3A peak linked to their transcripts (data not shown). 
 
To conclude, also intergenic (towards ENSEMBL annotation) transcribed genes were observed to 
be counter-regulated by E2 and E3A up to 70 % of their shared target genes. Almost 90 % of the 
counter-regulated genes are occupied by E2 and E3A.  
 
 
Figure 60: Characterization of E2 and E3A counter-regulated intergenic genes in the nucleus A Decision tree 
on subsets of genes to be further analyzed: All genes with >20 reads in any condition were filtered for 1. 
significant (worst FDR < 0.05) regulation (log2FC > 1 and < - 1) by E2 in any compartment and 2. significant 
(worst FDR < 0.05) regulation (log2FC > 1 and < - 1) by E3A in the nucleus. B 70 % of the shared intergenic 
target genes are counter-regulated by E2 and E3A. Scatterplots showing the anti-correlation of log2FCs of 
E2 regulated genes vs. E3A regulated genes in the nucleus. Log2FCs of filtered  
genes were plotted using R. 
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4 Discussion 
 
4.1 E2 requires EBF1 to bind to its CBF1 independent binding 
sites 
 
Microarray analysis revealed that E2 regulates cellular gene expression in absence of CBF1. ChIP-
Seq investigations in DG75doxHA-E2/CBF1 wt and CBF1 ko cells demonstrated that E2 binds to 
chromatin in absence of CBF1 (CBF1 independent binding). CBF1 is the most well studied binding 
anchor of E2. Bioinformatics predict EBF1 to act as an alternative E2 anchor to facilitate its CBF1 
independent binding to chromatin. To confirm the computational predication we sought to 
determine the biochemical underpinnings. Molecular characterization of the contribution of EBF1 
to CBF1 independent E2 binding will shed considerable light on E2 mediated transcriptional 
regulation. 
 
To this end, we performed a siRNA-mediated knock down of EBF1 and immunoprecipitated EBF1 
and E2 from isolated chromatin obtained from DG75doxHA-E2 CBF1 wt or CBF1 ko B cells. 
Subsequently, the recovered genomic DNA was analyzed by RT-qPCR and three CBF1 dependent 
and independent E2 binding sites with certain requirements were investigated.  
We observed EBF1 to be decreased at all investigated loci upon EBF1 knock down, while E2 binding 
was decreased only at CBF1 independent sites. This indicates that E2 requires EBF1 for chromatin 
interaction at CBF1 independent sites. More general, EBF1 binding is decreased in CBF1 ko cells 
compared to wt cells (E2 binding is decreased in a similar manner). Furthermore, the decreased 
binding of EBF1 upon EBF1 knock down was more profound in CBF1 wt cells compared to ko cells 
(Figure 9). As positive control, we confirmed the decrease of EBF1 binding upon its knock down 
(Figure 9A/B). E2 binding is diminished in CBF1 ko cells, since CBF1 is the key adaptor for E2 
binding to chromatin. Our observation that in CBF1 deficient cells EBF1 chromatin binding was 
reduced at all tested loci indicates that CBF1 could be important in EBF1-E2 complex formation. 
The decrease in E2 binding of CBF1 independent sites upon EBF1 knock down suggest, that EBF1 
is required for E2 binding to the CBF1 independent binding sites, thus, E2 binding to CBF1 
independent sites appears partially EBF1 dependent. However, E2 binding could not be depleted 
completely upon EBF1 knock down at CBF1 independent binding sites. The incomplete knock down 
of EBF1, as seen in Figure 8A/B, may account for some of the E2 binding to CBF1 independent 
sites (Figure 9). Another reason could be an alternative TF. Unsurprisingly, the CBF1 independent 
E2 binding sites are depleted in clusters V to VII, since EBF1 binding is absent in clusters V to VII 
(Figure 7B, Figure S7). However, CBF1 independent E2 binding sites are enriched for cluster I, 
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which contains all correlated TFs (CBF1, EBF1 and CUX1) represented (Figure S7). Thus, CUX1 
could be an alternative TF mediating E2 binding to CBF1 independent sights following EBF1 knock 
down. Furthermore this cluster was characterized as highly associated with the chromatin state of 
an enhancer in LCLs, as it shows high signals for H3K4me1 and H3K27ac. This may indicate that 
the CBF1 independent/EBF1 dependent binding of E2 to chromatin leads to increased enhancer 
binding (Figure S7). 
It was revealed by our group that E2 binding to chromatin is strongly dependent on CBF1, since 
86.4% of E2 binding sites are lost in CBF1 ko cells compared to the wt cells. Indeed, E2 signal 
strengths are much stronger at E2 binding sites in CBF1 wt than in ko cells (Glaser et al., 2017). 
Our observation of E2 binding loss in CBF1 ko cells is in line with previous findings indicating that 
CBF1 is the major anchor for E2 (reviewed in Kempkes & Ling, 2015). At CBF1 independent peaks, 
EBF1 was the only significant motif enriched as discovered by motif search (Glaser et al., 2017). 
Hence, we investigated E2 chromatin binding upon EBF1 knock down. The result that EBF1 
promotes E2 chromatin assembly and that CBF1 might contribute to this assembly is consistent 
with a recent study (Lu et al., 2016), which found that the formation of EBF1-CBF1 co-occupied 
binding sites are promoted by E2 and that E2 recruits CBF1 and EBF1 to its target sites. 
Furthermore, EBF1 has been implicated as one of several cellular factors associated with the 
maintenance of latency of EVB (Davies et al., 2010).  EBF1 is a crucial TF in defining B cell lineage 
specificity during differentiation (reviewed in Boller, Li, & Grosschedl, 2018). EBF1 was found to 
regulate genes associated to B cell function and most recently, it was shown to act as pioneer 
factor establishing chromatin accessibility (Boller et al., 2016). These findings support our 
hypothesis that E2 uses EBF1 to establish access to B cell enhancers to drive B cell activation. 
We were not able to connect E2 target genes to E2 binding sites. E2 activates gene expression 
predominantly by binding to enhancers and not to the promoters (Glaser, PhD thesis, 2017; Zhao 
et al., 2011). Enhancers can influence transcription through long-range chromatin interactions 
(reviewed in Plank & Dean, 2014). Therefore, association of E2 target genes with E2 binding sites 
is highly challenging. The data for peak selection and cluster analysis were obtained from 
experiments in LCLs and we transferred this information to the DG75 cell line. The differences in 
E2 binding patterns observed between LCL and DG75 cell lines may be in part explained by 
differences in the chromatin landscape between cell lines. Since we lacked EBF1 ChIP-Seq data in 
DG75 cells, we only included binding sites which were positive for E2 and EBF1 in LCLs, assuming 
a similar chromatin landscape in DG75. 
The correlation of genes regulated by CBF1 independent binding of E2 needs to be investigated by 
chromosome conformation capture techniques. Such would aide in revealing CBF1 independent 
biological pathways which E2 might regulate. Furthermore, although we could functionally link 
EBF1 to E2 binding we could not answer the question about a co-occupation of CBF1 and EBF1 by 
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E2. However, the role of E2 in CBF1 and EBF1 co-occupation has been explored by Lu et al. (Lu et 
al., 2016). The binding order of the involved TFs remains to be unraveled. 
 
While, E2 has been previously identified to drive the genome-wide cooperative binding of EBF1 and 
CBF1 (Lu et al., 2016), this work demonstrates the major contribution of EBF1 at sites of CBF1 
independent E2 binding. Our work has uncovered a previously unreported and significant role for 
EBF1 in E2 transcriptional regulation. 
 
4.2 Analyses of cellular and viral genes regulated by E2 and E3A 
 
The recent developments in transcriptional analysis by high-throughput RNA sequencing has 
provided extensive and rapid expanding catalogues of lncRNA. While significant advances have 
been made recently, much remains unknown about the expression and functional activity of 
lncRNAs. The highly tissue specific expression of lncRNA along with the ongoing co-evolution of 
high-throughput sequencing and bioinformatics algorithms are powering this rapid expansion of 
knowledge in the area. Microarray analysis revealed E2 dependent regulation of lncRNAs. The 
genome-wide regulation of lncRNAs by E2 remains an understudied area. E2 is the master 
regulator of transformation and maintenance of latency following EBV infection. Developing an 
understanding of the genome-wide E2 regulation of lncRNAs would extend our understanding of 
the regulatory network of E2 considerably. 
 
The overall aim of the second part of this thesis was the genome-wide identification of E2 and E3A 
viral and cellular target genes by comparing the transcriptomes of E2 or E3A proficient and 
deficient human B cell lines. We have shown E2 to regulate the expression of several lncRNAs. To 
determine the sub-cellular localization of E2 regulated lncRNAs and to enrich for lncRNAs in the 
nucleoplasm, harvested cells were fractionated into cytoplasm and nucleoplasm. E2 is renowned 
to induce targets which are themselves strong transcriptional regulators, which adds complexity to 
transcriptomic analysis of E2 induced gene expression. To address this, we conduced RNA-Seq of 
cells with induced E2 in the presence or absence of the translational inhibitor cycloheximide (ChX), 
allowing us to distinguish between E2 targets requiring competent de novo protein synthesis for 
induction. RNA was isolated from the desired cell line and conditions and cDNA libraries were 
prepared. Transcriptional changes were investigated by RNA-Seq experiments with subsequent 
confirmation of candidate targets by RT-qPCR.  
 
 
 
 
 Discussion 
127 
 
4.2.1 78 % of EBVs genes can be regulated by E2 in the ER/EB2-5 system  
 
An additional benefit of the transcriptome analysis of LCLs is the integrated EBV transcriptome. 
Thus, we briefly identified all viral target genes especially regulated by E2 with RNA-Seq. The 
analysis of the data provided by RNA-Seq regarding viral target gene regulation was conducted in 
collaboration with the Cancer Crusaders Next Generation Sequence Analysis Core, Tulane 
University, New Orleans, USA.  
 
In the ER/EB2-5 system, the proliferation of the cells was blocked for 4 days and reinduced again. 
For E3A regulation, two static systems were compared. But yet under these unphysiological 
conditions, we sought to identify E2 and E3A regulated viral genes. Therefore, reads were aligned 
to the Akata genome using the STAR mapper. For counting and DE-testing, the RSEM package was 
utilized.  
We found 73 out of 92 genes upregulated by E2 in the cytoplasm, 47 in the nucleus. 46 genes 
were regulated with blocked de novo protein synthesis. Intriguingly, regulated genes included lytic 
genes, which are usually not expressed during latency. Surprisingly, almost 80 % of the viral 
transcriptome was modified by E2 (Figure 12). Provided that the ER/EB2-5 system resembles the 
process during infection, it may be that E2 is able to induce the lytic cycle, since the genes, 
responsible for the lytic switch, BZLF1 and BRLF1 are also induced by E2 (Figure 12, Table S3). 
Preliminary data indicate E2-dependent induction of these genes as confirmed by Western Blot 
analysis on protein level (data not shown; n=1). Attempts to infect and transform primary B cells 
with ER/EB2-5 supernatants failed, which would have supported the assumption of a productive 
lytic cycle (data not shown). This may indicate that E2 induces an abortive lytic cycle. A lytic cycle 
is considered as abortive, if the cycle was not completed resulting in induced cell lysis and the 
release of novel infective viral particles. In order to confirm the detection of regulated viral genes, 
three genes induced by E2 were investigated by RT-qPCR. RNA was prepared of total and 
fractionated cell lysates and reverse transcribed. We confirmed that all genes were regulated by 
E2, independent of an E2 binding site in proximity, both with present or absent de novo protein 
synthesis (Figure 13 to Figure 18). While BGRF1/BDRF1 (Figure 15 upper panel) and LMP2A 
(Figure 17 lower panel) transcripts are enriched in cytoplasm, BHRF1 is enriched in nucleus (Figure 
15, lower panel), the localization for BNRF1 determined by RNA-Seq and RT-qPCR is contradictory 
(Figure 17 upper panel). The involved RNAs are linked to important processes throughout the entire 
life cycle of EBV. These data support the results obtained by RNA-Seq, where we observed 
immediate early, early, intermediate, late and latent genes to be regulated by E2. Here, we confirm 
the upregulation of genes involved in EBV invasion, virus production, prevention of apoptosis and 
mimicry of B cell signaling. LCLs are known to express lytic genes (see above), but it is unknown 
whether this expression is directly induced by E2. Co- and counter-regulation of viral genes by E2 
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and E3A was determined by comparing the datasets obtained by RNA-Seq analysis of both TFs. We 
observed that E3A acts as a transcriptional activator of viral genes. 42 genes were induced by both 
TFs, thus, more than 50 % of E2 targets are additional upregulated by E3A (Table S3). It appears 
that the induction of lytic genes by E2 is amplified by E3A. E2 induces E3A (log2FC in cytoplasm 
6.4) and they regulate lytic genes, like BZLF1, BRLF1 or BNRF1 in concert. Thus, both latency 
associated TFs are involved in regulation of genes which could promote tumorigenesis. E3A is 
considered an oncogene and might play a role in cell cycle regulation. It is controversial, if E3A is 
essential for B cell transformation, since E3A mutants can still give rise to LCLs. However, it is 
important to the transformation process (Allday et al., 2015) and we observe a strong upregulation 
by E2.  
Recently, evidence has emerged that the lytic cycle can contribute to EBV-induced oncogenesis. It 
was reported that tumor growth could be promoted by low numbers of lytically infected cells. 
Additionally, BZLF1 can provoke genomic instability. Furthermore, several lytic genes, such as 
BILF1, BALF4 and BHLF1, have been shown to be expressed at a high level in cell lines and tumor 
biopsies (reviewed in Young et al., 2016). We found all three genes to be induced by E2. A recent 
review suggests, that “an abortive lytic cycle would reconcile the need of lytic expression for viral 
tumorigenesis” (Morales-Sánchez & Fuentes-Panana, 2018). Nevertheless, LCLs can also undergo 
some level of spontaneous lytic reactivation, with rates varying among LCLs (Adhikary et al., 2007). 
Furthermore, it has been observed that LCLs express detectable levels of transcripts for early lytic 
genes. Davies et al. propose that each line of Latency III-transformed B cells has a characteristic 
frequency of EBV lytic reactivation (Davies et al., 2010), which would be in line with a productive 
lytic cycle. It does not, however, mean that E2 triggers this reactivation. Whether E2 induces a 
productive lytic cycle or whether the cycle is abortive remains to be determined.  
 
This may indicate that by upregulation of lytic genes during establishment and maintenance of 
latency, EBV promotes a tumorigenesis. Alternatively, the transient expression of viral lytic genes 
upon infection could be initiated by E2. 
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4.2.2 E2 regulates lncRNA which are contained in co-regulated gene blocks 
(CRGB), are associated with malignancies and could regulate protein 
coding and non-coding genes. 
 
Microarray analysis of E2 regulation and E3A regulation was conducted and revealed numerous 
cellular target genes of E2 and E3A. Furthermore, shared gene subsets of E2 and E3A were already 
uncovered. Nevertheless, the identification of all cellular coding and non-coding target genes of 
E3A and especially E2 by deep sequencing is still pending. 
 
4.2.2.1 Analytic approach is fundamental for the identification of differentially 
expressed genes 
 
The analysis of the cellular target gene regulation data generated by RNA-Seq was performed in 
collaboration with the Teaching and Research Unit Bioinformatics of LMU University Munich. 
Analysis of RNA-Seq requires a concatenation of different tasks, basically mapping, counting and 
DE- testing. In order to align the obtained reads with their corresponding genomic origin, alignment 
was performed using four different splice aware mapper ContextMap2, STAR, HISAT, and TopHat2, 
all of which allow inference of introns. The primary RNA-Seq data obtained for all technical 
replicates displayed good quality, mirrored by the percentages of mapped reads in general aligned 
with the human genome hg19 (Figure S8). We observed variations in alignment of reads towards 
different genomic regions between nucleic and cytoplasmic regions, as well as variations between 
the mapper for some samples (Figure S8- Figure S13). In keeping with our expectations, the 
nucleoplasm was enriched for immature unspliced transcripts and the cytoplasm is enriched for 
mature, spliced transcripts which is reflected in the percentages of reads mapping to complete 
transcripts (Figure S9) and junctions (Figure S12/ Figure S13) or intronic and intergenic regions 
(Figure S10/ Figure S11). The variation between mappers is most likely due to differences in their 
algorithms and underpinning assumptions.  
The comparison of biological replicates on read aligned level showed high similarity, indicating that 
the cells were not altered substantially between 0 h and 6 h post E2 reactivation or by E3A 
expression (Figure 20- Figure 22). Focusing on the E2 conditions, nuclear samples were highly 
correlated (r~0.8) between 0 h and 6 h estrogen. This was particularly profound in samples 0 h 
and 6 h post E2 reactivation where de novo protein synthesis was inhibited (r~0.9; Figure 21), 
indicating that fewer changes occur. Furthermore, the disorganized clustering of the ChX- treated 
samples may indicate a substantial impact of ChX on the samples. However, clustering was 
observed dependent on E2 and E3A proficiency and according to the sub-cellular compartments. 
Interestingly, in the E2 system diversity between the compartments is responsible for the major 
clusters, while for E3A diversity between the cell lines is responsible for the major cluster. This may 
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be explained in one or more ways. For the E3A system, two different cell lines were compared, 
which could result in E3A independent differences. Furthermore, selection following E3A knock out 
may have resulted in a cell population transcriptionally adapted to the loss of E3A. In contrast, 
treatment with estrogen for 6 h did not lead to dramatic changes. The ER/EB2-5 cells may reflect 
a heterogeneous population of not entirely synchronized cells which could further impact 
clustering. 
To assess the number of reads deriving from each gene, reads were counted using an in-house 
tool. Genes served as counting features in two ways: either, all gene aligned reads were simply 
counted or reads were only counted for genes which are supported by reads aligning to a derived 
transcript. This is a very sensitive approach and bears advantages and disadvantages as discussed 
below. The read counts were down-sampled to account for PCR amplification. By PCR amplification, 
multiple identical copies (duplicates) can arise. For example, smaller fragments are easier to PCR 
amplify and end up over-represented without biological meaning. Therefore, the fraction of PCR 
duplicates were kept low. When comparing the biological replicates by read count level (Fig, S14-
S18) we again observed high read count variations between the biological replicates for the ChX-
treated samples.  
Initially, we expected to dissect direct and indirect E2 targets by the treatment of the cells with the 
translation blocker ChX. Since non-coding targets do not undergo translation, their functions are 
not affected by ChX and they still can mediate the transcription of secondary targets. Hence the 
clear dissection of direct (primary) and indirect (secondary) targets by ChX has become unfeasible. 
Additionally, ChX seems to have a major impact on RNA metabolism, leading to high variations 
between the biological replicates.  
ChX, originally isolated from Streptomyces griseus, is the most common used chemical reagent to 
inhibit protein synthesis. It is reported to block the elongation phase of eukaryotic translation by 
binding to the “E site” of the 60 S ribosome and prevents eEF2-mediated translocation (Schneider-
Poetsch et al., 2010). Usually, mRNA is post-translationally degraded after deadenlyation of the 
PolyA-tail. Once the tail is shortened, mRNA is subject to decay by exosome (3’  5’) or decapping 
and (5’  3’) Xrn1p digestion. Reduction in mRNA translation upon intrinsic stimuli normally 
potently induces mRNA decay. However, extrinsic inhibition of translation due to stress can result 
in mRNA stabilization. Numerous studies reported reduced mRNA decay following ChX treatment, 
suggesting that ribosomal association of mRNA inhibited mRNA degradation. ChX affects mRNA 
decay by indirectly preventing mRNA decapping (reviewed in Huch & Nissan, 2014). The variation 
between the cytoplasmic samples were so high we excluded them from this analysis. The variation 
of samples from the nuclear compartment was acceptable. However, we observed stabilization of 
certain mRNAs upon ChX treatment in the nucleus in the RNA-Seq results. One could imagine 
backlog, where transcripts accumulate also in the nucleus since they are not exported due to 
blocked processing. Critically, this could also hold true for cytoplasmic lncRNAs. Very recently it 
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was shown that lncRNAs are associated with active ribosomes. Approximately half of all expressed 
lncRNAs were detected in the cytoplasm with most of them associated with ribosomes. These 
lncRNAs have further be shown to be stabilized in response to ChX, in a similar fashion to mRNAs 
(Carlevaro-Fita, Rahim, Guigó, Vardy, & Johnson, 2016). The ER/EB cells may not be exactly 
synchronized. Thus, stabilization of different transcripts at different levels by ChX could be the 
reason for variations between the replicates. Furthermore, it has to be considered that slight 
variances in the treatment of the cells of the different biological replicates can be responsible for 
variances in the transcriptome. 
DE- testing was conducted by applying four different DE-methods: edgeR, limma, DE-Seq and a2a, 
each using different normalizing steps or different statistical models. For each required task of 
RNA-Seq analysis, a variety of tools exist, which all have different approaches and therefore 
different outputs. The detection of a set of differentially expressed genes could thus be dependent 
on the selected tools (reviewed by Costa-Silva, Domingues, & Lopes, 2017). All methods are tested 
using modelling, simulations and benchmarks (default values). Every individual experiment needs 
adjustments, there are no clear instructions to find the "optimal" method. One approach is to 
analyze the results in depth and make decisions one-by-one (here gene-by-gene) or - if one looks 
for the clearest signals  - one can take the "robust" approach and combining multiple methods and 
taking only results if proposed by all (or all reasonable) combinations. We used the consensus from 
72 combinations (Figure 23) in order to identify differentially expressed genes tool-independently. 
Only for the cytoplasmic samples of the ER/EB2-5 cells, use of the mapper ContextMap2 was 
disregarded because it resulted in a huge decrease in detected genes (48 combinations), we have 
no explanation for this (Figure 24A). The DE-method a2a was most effective in addressing the large 
variation between the ChX-treated samples, thus we relied only on this DE-method for this condition 
(18 combinations; Figure 24C. By applying this consensus-technique, we robustly detected E2 and 
E3A regulated protein coding and non- coding genes as displayed in volcano plots (Figure 
27/Figure 31). Furthermore we were able to extract differentially expressed genes in intergenic 
and intronic transcribed regions of ENSEMBL annotated genes after mapping (Figure 28/Figure 
29, Figure 32/Figure 33). These were also submitted to DE-testing. To exclude reads from any 
other origin, correction for background and proximal transcribed genes was performed as 
described in section 3.2.2.2.2 p. 58. Many more transcripts were upregulated than downregulated 
by E2, in line with results from microarray analysis conducted in estrogen dependent E2- inducible 
DG75 cell lines (Glaser et al., 2017). In line with results from microarray analysis performed using 
the same cell lines as in this study, the numbers of up- and downregulated E3A target genes were 
similar (Hertle et al., 2009). However, upregulation of cellular genes by E3A is not well studied. 
Usually, one would use de novo synthesis algorithms to identify novel transcripts. These tools 
predict novel transcripts based on the read coverage. Applying these tools was not possible for the 
nucleic samples due to the large number of immature transcripts which leads to the prediction of 
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myriad isoforms. This is why we came up with an alternative strategy to infer unannotated 
differentially expressed genes as mentioned in section 3.2.2.2.2, p. 58. 
Detection of regulated genes is generally strictly dependent on applied thresholds and definitions. 
During analysis we encountered two major definition related difficulties, i) the definition of read 
origins and ii) the thresholds for detection of novel regulated loci.  
 
i) First, one has to define the reads which shall be counted for a specific feature. Both, 
read pairs mapping entirely to the region of a gene and read pairs mapping to a gene 
plus read pairs mapping to the corresponding transcripts (if any transcript with 
supporting reads is available) were counted. Taking all reads into account, the 
detection achieved is sensitive and comprehensive. Generally, introns and exons of the 
same transcript are transcriptionally well correlated and since introns are typically 
much longer, many reads may be distributed over the whole intron. Thus, introns count 
can be utilized as an approach for gene coverage estimation where transcribed introns 
are the byproduct of gene transcription. Nevertheless, if intronic regions are 
transcribed without exonic regions, these reads would be lead to false positive gene 
transcript determination. Indeed, it is likely that to some degree such intronic 
transcription was regulated by E2 and E3A at certain loci in our studies. Such 
transcription lead to over-estimation of transcript levels, e.g. ART3 shows intronic 
transcription with few reads aligning to the transcript, leading to over-estimation of 
expression. This could be corrected by only selecting those genes which reach a certain 
threshold of reads on the gene and on the transcript level for further analysis. 
 
ii) Since the thresholds for detection of novel intergenic or intronic genes were 
tremendously conservative, our false positive detection rate of novel loci will be very 
low. However, it is likely that a significant false negative rate was apparent in our 
analysis. This is exemplified in the missing detection of novel genes from chromosome 
four to nine, since no region was detected consistently differentially expressed by all 
tool combinations. 
We did the following, as described in section 3.2.2.2.2 obenp.on page 58: 
First, candidate intergenic regions were derived from each sample independently. 
These regions were defined by proximal (≤ 50 bp from closest fragment ends) or 
partially overlapping fragments not mapping to any ENSEMBL gene. Since strand 
specific sequencing was conducted, regions antisense to overlapping known genes 
were also collected. The second step was to combine these „raw“ intergenic regions to 
build a replicate-consistent panel. All intergenic candidates having ≥ 50 supporting 
reads were merged and the part of the intergenic region consistently detected by all 
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mappers in all biological replicates for the same condition was extracted. If two regions 
from different conditions overlapped (≥ 1 bp), one of them was discarded defining 
them as not sufficient different. One of the mappers used did not align the required ≥ 
50 reads to any region of chromosomes four to nine.  
Furthermore, we corrected for transcriptional regulation of other known genomic 
elements by comparing the changes of the novel intergenic/intronic regions to the 
changes of the overlapped gene in the differential analysis. Therefore, we dismiss 
alternative explanation for regulation, concluding that the expression changes we 
detect in intergenic/intronic regions were indeed specifically induced by E2 or E3A. In 
this thesis, we corrected for background based on gene level. This is more stringent 
compared to transcript level correction. On the gene level, reads also mapping to 
intronic regions of the gene were counted. For example, the ART3 gene appears to be 
regulated, since its intron is regulated. Over estimation of gene expression by 
determinations utilizing intronic counts has been discussed in i). Since an intronic 
region was corrected for background transcription on gene level and the underpinning 
gene is similarly regulated, the significant regulation of the intronic region was 
annihilated. Enhancer derived intronic (ART3) transcription was readily detected by RT-
qPCR at the model locus CXCL9/10 (see Introduction), thus the stringency has to be 
relaxed for future analysis. Using a dependency correction on transcript level data it 
should be possible to detect the intergenic (CXCL9/10) and intronic (ART3) transcripts 
at our model locus of CXCL9/10. For future analysis we recommend the use of less 
stringent thresholds for read coverage and correction on transcript level on transcript 
level. 
 
In summary, the thresholds applied in this work resulted in a very stringent and conservative 
determination of intergenic and intronic transcripts, which lead to false negative rate for novel 
transcripts but at the same time to a high reliability for the differentially detected genes. The 
assumption, that intronic transcription has to be derived from already confirmed genes is 
misleading and has to be reassessed for single genes on transcript level. 
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4.2.2.2 Discovery of co-regulated gene blocks (CRGBs) 
 
Higher order chromatin structures can result in domain-wide transcriptional activation of genes. 
There is evidence that E2 binds superenhancers residing within TADs. Furthermore, it was 
reported, that EBV has local effects on the chromatin organization. Whether EBV exploits other 
higher order chromatin structures to regulate its target genes remains to be elucidated. 
To investigate the potential global regulation of whole chromatin domains block-like by EBV, all E2 
and E3A significantly regulated genes were screened in silico for clustering. We observed that 
approximately 80 % of E2 and E3A regulated genes are organized in blocks of up to ten genes 
(Figure 35). Approximately 80 % of the blocks regulated by E2 and approximately 70 % of gene 
blocks regulated by E3A genes are smaller than 2 Mb (Fig. S19). These findings may indicate that 
E2 and E3A regulate genes on a higher level of genome organization. This would mean that EBV 
makes use of higher order chromatin units by binding there to open chromatin and regulating whole 
associated chromatin domains genome-wide. E2 local action has been shown to activate a 
chromatin domain in the neighborhood of MYC by rearranging enhancer-promoter loops (Wood et 
al., 2016). To determine the role of E2 in regulating gene expression via chromatin 
rearrangements, a study could map intergenic E2 binding sites to E2 up-regulated genes using the 
HiC-technique (Zhao et al., 2011). It has also been reported for E3A that it can repress a whole 
chromatin domain in the neighborhood of CXCL10 (Harth-Hertle et al., 2013). However, when 
intersecting the detected E2 regulated CRGB with the published contact domains by Rao et al., we 
observed only 30 % of the CRGB residing entirely in contact domains (data not shown). This 
indicates that CRGB and contact domains may differ in their nature. The hierarchy of genome 
organization contains from large cell type specific chromosome territories, intermediate tissue 
invariant TADs, down to chromatin looping. In contrast to the tissue invariant TADs, the chromatin 
states within the TADs are highly diverse in different cell types or conditions, leading to a 
modulation of activity and compartment association, as well as differential chromatin loop 
formation (Dekker & Heard, 2015). The size of the detected by E2 and E3A regulated blocks fits 
the published size of TADs ranging between 40 kb and 2 Mb when they were first discovered in 
embryonic stem cells (Dixon et al., 2012), but the genomic intervals are different to published 
contact domains in GM12878 (Rao et al., 2014). However, contact domains observed by Rao et 
al. do not resemble reported TAD size. Different data on architectural structure exists for LCLs 
(GM12878) on different hierarchical level. This includes the CTCF-mediated architecture obtained 
by ChIA-PET (Tang et al., 2015a), “chromosome territories” detected by Hi-C (Selvaraj, R Dixon, 
Bansal, & Ren, 2013) “contact domains” (median length 185 kb; Rao et al., 2014) and chromatin 
looping between promoters and enhancers (Mifsud et al., 2015). Regarding EBV it has been shown 
that EBNA occupied super-enhancers reside with their corresponding gene in the same TAD. They 
used the low-resolution Hi-C data from Selvaraj et al.  
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We compared the EBNA regulated genes to randomly selected genes and found that they cluster 
in groups, which we named co-regulated gene blocks (CRGB). CRGBs are defined by gene 
regulation while TADs or contact domains are defined on a structural level.  However, this 
observation could be a general mode of action of TFs and would be needed to compare to other 
TFs to resolve this question. Furthermore, one could investigate whether each block contains a 
“direct” target gene (regulated with absent de novo protein synthesis) or intriguingly, a lncRNA 
which could induce looping and activation of the whole CRGB. 
 
Whether our block regulation data correlates with any of these datasets remains to be determined. 
Datasets were obtained regarding 3D genome organization using different techniques resulting in 
different interpretations. A most informative approach to the question of whether EBV exploits any 
kind of higher level chromatin order would certainly be provided by applying a Hi-C method in 
different LCLs, proficient and deficient for defined viral TFs. 
 
4.2.2.3 Potential role for E2 regulated lncRNAs in the establishment of lymphomas 
and other cancer types 
 
Differentially expressed genes detected by RNA-Seq and subsequent analysis required 
confirmation of candidate genes.  
To confirm the detection of regulated protein coding and non-coding genes, three chromatin blocks 
of co-regulated genes were investigated by RT-qPCR. RNA was prepared of total and fractionated 
(cytoplasm and nucleoplasm) cell lysates and reverse transcribed. We could confirm that all 
investigated blocks contained genes regulated by E2, both with present or absent de novo protein 
synthesis (Figure 36- Figure 44). Studying the chromatin features, we noticed locally enriched 
marks for open chromatin and nascent RNA transcription (Figure 36, Figure 37, Figure 40, Figure 
42). All the involved genes reside in the same or neighboring CTCF-mediated TADs or are linked by 
loops. The regulated blocks are rich in E2 binding sites. The involved lncRNAs are linked to cancer 
studies in the literature. 
We picked these loci as representatives of target genes, co-regulated in blocks containing well-
known E2 target protein coding genes and so far unknown non-coding targets. MYC appears to 
reside in a “desert” of non-coding transcriptional activity (Huppi et al., 2012). E2 regulates together 
with MYC several of the 3‘ and 5‘ of the TSS transcribed non-coding genes. Some of them were 
enriched in the nucleus (PCAT1, CASC21, CASC8, LINC00977), while a few were enriched in the 
cytoplasm (CASC19, CCDC26). This holds true for the other two investigated loci, where both 
lncRNA transcripts are enriched in the nucleus. Liang et al. described E2 regulated eRNAs 5’ of the 
MYC TSS, eRNAs MYC-428 and MYC-525 which are derived from ESEs and regulate MYC 
expression (Liang et al., 2016). These eRNAs are in close proximity to CASC19 TSS (eRNA-428, 
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which is -525 bps away from MYC TSS) and sense/antisense overlapping of the intron of CASC21 
(eRNA525, which is -428 bps away from MYC TSS; Figure 37). The sites for their shRNA-mediated 
knock down seem not to target their eRNAs but rather the transcripts of CASC19/21. Thus, it may 
be that the described eRNAs and CASC19/21 exert a similar or identical function. The fold change 
profile obtained by RNA-Seq was recapitulated by RT-qPCR generally, although one has to bear in 
mind that the two methods cannot be compared directly with each other, since in library 
preparation there are many more steps involved which can affect the outcome. Moreover, the RNAs 
for RT-qPCR were not depleted for rRNAs. Furthermore, it must be remembered that despite the 
identical amounts of RNA subjected to both, reverse transcription or library preparation, the RNA 
from the nuclear fraction is obtained from 20 times more cells than the RNA of the cytoplasmic 
fraction in order to detect low abundance transcripts in the nucleus. Nevertheless, the enrichment 
in the nucleus or cytoplasm could reveal information about the primary localization of the lncRNAs 
and give hints towards their possible functional implications. Indeed, it has been reported that the 
function of lncRNAs can be associated with their unique subcellular localization (L.-L. Chen, 2016). 
All the regulated protein coding genes have important roles in different biological processes which 
can be associated with infection (SLAM-family receptors/P2RY11 in immune response) and 
transformation (MYC and PPAN for proliferation); the two major events describing EBVs life cycle. 
This chapter investigated lncRNAs (PCAT1, CASC8, CASC19, CASC21, LINC00977, CCDC26, RP11-
528G1.2 and CTD-2240E14.4) regulated by E2 in blocks together with protein coding genes linked 
to cancer (see section 3.2.2.2.6, p. 79). Many lncRNAs have been reported to be uniquely 
expressed in differentiated tissues or specific cancer types (Iyer et al., 2015). Dysregulation is 
common in cancer and despite most lncRNAs showing a dysregulated expression are a cancer type 
specific, some are also shared among different cancer types  (Yan et al., 2015). Intriguingly, we 
did not observe EBV to dysregulate lncRNAs with known roles in the hematopoietic system. 
However, browsing the Leukemia Atlas (expression profiles of 12 distinct blood cell populations) 
from the public available database www.lncScape.de, which represents a comprehensive resource 
for the non-coding RNA landscape in the human hematopoietic system (Schwarzer et al., 2017), 
most of the lncRNAs associated with the three loci MYC, SLAMF or PPAN are recorded. All of these 
lncRNAs were differentially expressed between the different blood cell populations, suggesting they 
may play important roles in immune cell function or differentiation. This is most intriguing given 
the fact that EBV regulates lncRNAs linked to cancer indicating a potential role for these lncRNAs 
in the establishment of lymphomas and other cancer types. Further, EBV is also associated with 
epithelial cancers, such as gastric (Iizasa, Nanbo, Nishikawa, Jinushi, & Yoshiyama, 2012) and 
pancreatic cancer (Samdani, Hechtman, O’Reilly, DeMatteo, & Sigel, 2015).  
Interestingly, lncRNAs uncovered in our analysis as regulated by EBV have been linked with these 
types of cancer, indicating a potential mechanism through which EBV may promote these cancers. 
Intrinsically, EBV solely aims to initiate, establish and maintain persistent infection and not induce 
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transformation (Thorley-Lawson, 2015). Thus, despite the association of EBV with a variety of 
cancers, the fact that the majority of human adults are asymptomatically infected implies that EBV 
is not a typically oncogenic virus. 
 
Hence, our work in uncovering cancer associated lncRNAs regulated by EBV may provide important 
clues as to how EBV virus transitions from asymptomatic to oncogenic in some subjects.  
 
4.2.2.4 E2 induced pcgs and ncgs are regulated during the establishment of 
latency 
 
E2 is one of the first viral coding genes expressed post infection and acts as a potent transcriptional 
regulator. We identified coding and non-coding target genes of E2 using the ER/EB2-5 system. We 
sought to address, whether the physiological events during the establishment of latency in vitro 
are recapitulated in the ER/EB2-5 cell system. Furthermore, the fact that EBV regulates lncRNAs 
linked to cancer could indicate that these lncRNAs contribute to the transformation of primary B 
cells. Besides, we wanted to assess whether protein coding and non-coding target genes are 
regulated similar by E2. 
 
To test this, during the establishment of LCLs from primary B cells infected with strain B95.8 EBV, 
at several time points cells were harvested. Coding and non-coding candidate E2 targets 
(MYC/CASC21, SLAMF1/ RP11-528G1.2 and PPAN/ CTD-2240E14.4) were quantified by RT-qPCR 
based on the cell number harvested at each time point. In order to account for changes in cell 
growth, we normalized to coding and non-coding housekeeping genes. We observed that E2 shows 
a peak in transcript abundance 72 h p.i, (Figure 46). Protein coding genes are regulated earlier 
during the establishment of latency than non-coding genes, peaking between 24 h and 72 h p.i. 
(Figure 47, Figure 49, and Figure 51). The lncRNA transcripts however increase progressively 
during the establishment of latency, peaking 6 d p.i. (Figure 48, Figure 50, and Figure 52). The 
protein coding genes are closely regulated following E2 induction. SLAMF1 peaks earlier than E2 
and the other protein-coding genes, potentially because it is involved in immune response and thus 
required earlier. Protein coding genes are regulated earlier during establishment of latency than 
non-coding genes. A possible reason for the late transcription may be that the transcription of the 
lncRNA appear later as a consequence of the activation of chromatin domains (Figure 47 to Figure 
52). A hallmark of herpesvirus infection is the establishment of latency, with several strategies 
adopted to evade recognition by the host immune system during this period. Many reports exist 
detailing immune-related lncRNAs regulated by herpesviruses to affect immune response 
mechanisms in the cell (reviewed in Ahmed & Liu, 2018). It is possible that E2 regulated lncRNAs 
identified in our studies may play a role in such processes during progression towards latency. 
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Comparison of the transcriptomes of infected versus control cells revealed distinct changes of 
lncRNAs, thus the expression of the viral proteins altered expression of lncRNAs (Fortes & Morris, 
2016). Additionally, the regulation of lncRNA transcription could provide signals of malignant 
transformation (Schmitt & Chang, 2016). Alternatively, the transcription of lncRNAs may be a host 
response to pathogen infection, as critical functions for lncRNAs have been identified in the innate 
immune response (Y. G. Chen, Satpathy, & Chang, 2017). 
Investigation of additional regulated genes would confirm this pattern of regulation. Upon infection, 
the primary B cell transforms into a LCL and increase in size, which is accompanied by 
transcriptional changes adding complexity to the analysis. The distinction of direct E2 driven 
changes and changes which result from cell growth is intricate. The induced cell growth is 
accompanied with increased protein and RNA content per cell (Table S1). Hence, the RNA 
quantification was based on the cell number and in parallel based on the amount of RNA how it is 
commonly performed. The differences arising between both analyses are displayed (Figure 45 to 
Figure 52). As shown, the housekeeping genes undergo strong regulation. In order to correct for 
the changes arising from cell growth and increasing RNA content, and to determine the specific 
changes induced by E2 relative quantification was done. Of note, protein coding transcripts of 
interest were related to a coding housekeeping transcript, and non-coding transcripts of interest 
were related to a non-coding housekeeping gene. These housekeeping transcripts were not 
transcribed by the same Polymerase (PolIII instead of PolII) and were transcribed from multiple loci 
in the genome. Variations between the donors are observable, which is anticipated. All these 
circumstances may affect the results and subsequently the interpretation; hence, our 
interpretation must be treated with caution. 
 
4.2.2.5 E2 induced lncRNAs may regulate remote protein-coding genes 
 
The question arouse whether lncRNAs are regulated together with their protein coding neighbors. 
To address this question, we calculated the frequencies of distances of an expressed significantly 
regulated eRNA or lncRNA to the closest expressed significantly regulated pcg and a Pearson 
correlation was calculated for the log2FCs of a neighboring eRNA/lncRNA-pcg pair.  
90 % of the distances between the pairs were ≤ 100 kb (Figure 53A). Additionally, eRNAs (by 
definition) were not observed closer in genomic proximity than other lncRNAs. The fold changes of 
the lncRNAs and pcg partner correlated positively (ranging from r= 0.72- 0.82), independent of the 
chromatin state at the TSS flanking region (Figure 53B). Here, we have shown that the lncRNAs 
appear to be co-regulated by E2 with protein coding genes, since their fold changes correlate 
positively, despite a huge distance between these pairs. The huge distance implies long-range 
interactions play an important role in this co-regulation. Since enhancer–promoter loops are 
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thought to not cross TAD borders (Dekker & Heard, 2015), this genomic limitation might be a hint 
that in some cases we did not detect enhancer promoter interactions here. Furthermore, 
enhancers are reported to directly affecting genes in physical proximity. The enhancer chromatin 
state neither promoted proximity nor increased the correlation, suggesting that the enhancer 
chromatin state at the TSS flanking region is not sufficient for the definition of an enhancer derived 
RNA (as discussed below). A similar investigation was conducted by Ilott et al., they too did not find 
a difference in distances between eRNAs and other lncRNAs to their pcg partner. However, they 
observed a much stronger correlation between the fold changes of eRNAs with the closest pcg 
compared to other lncRNA. Furthermore, their observed distances between A and B ranged from 
0 to 100 kb, while for a certain amount of pairs the observed distances exceeded 2000 kb (Ilott et 
al., 2014). Long-distance intra- and inter-chromosomal interactions could be the result of co-
localization of unlinked genomic regions to a common nuclear compartment (Bateman, Johnson, 
& Locke, 2012). It has been hypothesized that ncRNAs and coding genes belonging to the same 
biological pathways are coordinately regulated („guilt-by-association“ approach Schwarzer et al., 
2017; Guttman et al., 2009). The correlation of fold changes could further be analyzed following 
the exclusion of all ncg-pcg relationships exceeding distances of 2000 kb in order to enhance 
investigations regarding TAD-related gene regulation. 
 
 
4.2.2.6 E2 regulated lncRNAs: cellular localization, impact of blocked de novo protein synthesis 
and counter-regulation by E3A 
 
4.2.2.6.1 E2 regulated lncRNAs, located in both nucleus and cytoplasm 
Further examination of E2 target genes was conducted by filtering all genes with a detected read 
coverage of >1 read using a decision based filtering application (implemented by Gergely Csaba) 
for properties regarding coverage, significance and strength of regulation. E2 target genes were 
then assigned to subgroups which could be characterized more in detail based on localization, 
biotype, length, splice status, novelty, chromatin state, TF binding cluster and E2 binding relation. 
Where genes regulated in the same direction after comparing two different datasets were 
encountered, we designated them as co-regulated. If genes were regulated in opposing directions, 
we designated them as counter-regulated regarding the underlying investigation. 
As discussed above, enrichment in the nucleus or cytoplasm may indicate the primary localization 
of the lncRNAs and hints towards their possible functional implications. Generalization of this logic 
may be transferred to different biotypes. The localization of lncRNAs was addressed by the 
fractionation of the cells in their compartments before RNA isolation. Two classes of genes were 
further characterized, the ENSEMBL annotated genes and novel detected intergenic lncRNAs.  
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Then, by RNA-Seq analysis, genes were filtered according to indicated thresholds. This resulted in 
two subgroups (Figure 54A). The majority of genes were similarly regulated in both compartments 
with 5,104 significantly co-regulated genes (Figure 54B). A minority (2,495) were not significantly 
co-regulated, and thus were compartment specifically regulated (most of them are only regulated 
in one compartment), 1,519 in the cytoplasm and 942 in the nucleus. The former group was further 
divided into four subsets according to their read coverage, 4,620 genes were sufficiently covered 
in the nucleus (nucleus expressed), 484 genes were not sufficiently covered in the nucleus 
(cytoplasm enriched), 4,964 genes which were sufficiently covered in the cytoplasm (cytoplasm 
expressed) and 140 genes which were not sufficiently covered in the cytoplasm (nucleus enriched; 
Figure 54C). For these six subgroups, we observed a lncRNA distribution of 15.2 % specifically in 
the nucleus, 23.2 % specifically in the cytoplasm, 29.2 % enriched in the cytoplasm and 36.5 % 
enriched in the nucleus (Figure 54D). The highest number of eRNAs according to our definition of 
an eRNA was found in the subset of genes enriched in the cytoplasm. We noticed no major 
difference in length of the lncRNAs in the different subgroups (Figure 54E). Thus, we could not 
confirm compartment specific distribution of lncRNA classes. Furthermore, we observed no 
difference between the subgroups of co-regulated genes with respect to the splice status (Figure 
54F). In the compartment specific subsets we found that the lncRNAs specifically regulated in the 
cytoplasm appear to have fewer exons than lncRNAs specifically regulated in the nucleus. 
Here we show that most of the target genes of E2 are found in both compartments, with varying 
read coverages in nucleus and cytoplasm. Furthermore, we found genes solely regulated in one of 
the compartments. The greatest number of E2 regulated lncRNAs was found in the nucleus 
enriched fraction. This is particularly important as much of the described activity of lncRNAs occurs 
in the nucleus, e.g. lincRNAs chromatin association (Khalil et al., 2009). Hence, we anticipated 
that the majority of lncRNA would reside in the nucleus. The FANTOM project reported lncRNAs to 
bear 5’ capping and polyadenylation (Carninci et al., 2005; Hon et al., 2017). 5’caps and PolyA-
signals are responsible for RNA export from the nucleus in the cytoplasm and furthermore for the 
stability of the RNAs (reviewed in Lewis & Izaurflde, 1997; Wickens, Anderson, & Jackson, 1997; 
Sachs, Sarnow, & Hentze, 1997). It may be that lncRNAs are first exported to the cytoplasm before 
they exert their function in the nucleus. Moreover, the majority of lncRNAs have been shown to 
interact with ribosomes in the cytoplasm (Carlevaro-Fita et al., 2016). Thus, it is not unexpected 
that despite a nuclear function, lncRNAs can be detected in both compartments. Similarly, despite 
a cytoplasmic function, the lncRNA are also detected in the nucleus, as the locus of origin. 
Additionally, the biochemical fractionation can also be not completely clean. Thus, a clear 
distinction is not feasible. One could further enrich for chromatin associated RNAs using special 
chromatin associated techniques like ChIRP (Chu, Qu, Zhong, Artandi, & Chang, 2011) or ChAR-
Seq (Bell et al., 2018). With ChIRP (Chromatin Isolation by RNA Purification), tiling oligonucleotides 
capture specific lncRNAs with bound protein and DNA sequences, which subsequently can be 
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sequenced. ChAR-Seq (Chromatin-associated RNA sequencing) maps all RNA-to-DNA contacts 
across the genome. 
E2 preferentially binds at enhancers (Glaser, PhD thesis, 2017; B. Zhao et al., 2011). Enhancer 
activation has been shown to involve PolII binding and eRNA synthesis (T.-K. Kim et al., 2010). As 
mentioned above, the definition of an eRNA might be inadequate. As discussed by Laurent et al., 
classification of lncRNAs remains challenging, since the transcription of a lncRNA could start at an 
enhancer element or start distal to an enhancer element and merely overlap it, yet both would be 
classified as eRNAs (St Laurent, Wahlestedt, & Kapranov, 2015). Moreover, it is possible that 
lncRNA association with an enhancer element is not sufficient for eRNA classification. Additionally, 
our eRNA definition included all lncRNA genes with a TSS (of corresponding transcripts) overlapping 
with at least 1 bp, which might be a too tolerant cutoff. Most likely, we were not able to detect 
eRNAs in general. eRNAs are extremely unstable, at the moment of their generation they begin to 
be degraded by exosomes. Hence, special methods are required for their detection such as TT-Seq 
(transient transcriptome; Schwalb et al., 2016), GRO-Seq (global run on; Core, Waterfall, & Lis, 
2008) or RNA-Seq with prior exosome depletion (Pefanis et al., 2015). All these methods enrich 
for the transient, nascent transcriptome and the chance to detect eRNAs would be increased. 
However, it may be that we detected fractional amounts of eRNAs which were somehow stabilized 
our accumulated in our cell systems. Since eRNAs are so unstable, they should be only detectable 
in the nucleus. The fact, that under our definition, we detect the majority of eRNAs in the cytoplasm 
enriched fractions indicates an erroneous assumption in our analysis. Finally, the enhancer 
chromatin state assignment is derived from the CSS for the LCL GM12878 of the ENCODE project. 
In this cell line, E2 and E3A are constitutively expressed and a chromatin signature is well 
established. The chromatin state of a “LCL” with no active E2 or E2 active for 6 h might be different 
given that E2 can rearrange the chromatin architecture as discussed above. Therefore, it may be 
that enhancer marks are already lost in GM12878, because for example E3A has repressed the 
enhancer locus.  
We anticipated, that the lncRNAs residing in the nucleus would be shorter in average length and 
mostly monoexonic, since they should include most of the eRNAs. Most eRNAs are thought to be 
bidirectionally transcribed and neither spliced nor polyadenylated (and shorter than 2kb), however 
unidirectional transcribed eRNAs can be spliced and polyadenylated (and longer than 4kb; 
reviewed by Lam, Li, Rosenfeld, & Glass, 2014). We found, that the regulated lncRNAs have fewer 
exons than mRNA as already described (Derrien et al., 2012; Iyer et al., 2015). Further, lncRNAs 
are shorter in length than mRNA. In our study, most eRNAs were found in the cytoplasm enriched 
fraction and the transcripts in this subset were neither shorter nor less spliced than transcripts of 
other subsets. We expected to find shorter, monoexonic transcripts in the nucleic subsets, however 
they do not differ from the other subsets. 
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As with the ENSEMBL annotated genes, covered intergenic transcribed genes were filtered 
according to indicated thresholds. This resulted in two subgroups (Figure 55A). For the intergenic 
genes, also the majority is similarly regulated in both compartments as we found 360 significantly 
co-regulated genes (Figure 55B). A minority (243) not significantly co-regulated genes, were genes 
which are compartment specifically regulated, 201 in the nucleus, and 34 in the cytoplasm. The 
former group was further divided into four subsets according to their read coverage, 288 genes 
were sufficiently covered in the nucleus (nucleus expressed), 72 genes which were not sufficiently 
covered in the nucleus (cyto enriched), 233 genes which were sufficiently covered in the cytoplasm 
(cytoplasm expressed) and 127 genes which were not sufficiently covered in the cytoplasm 
(nucleus enriched; Fig 48 C). When intersecting the intergenic genes (no overlap with the ENSEMBL 
annotation) with the comprehensive lncRNA database LNCat, we identified unannotated genes 
(Figure 55D). The highest number of unannotated genes were located in the nucleus and are 
enriched there. Further, the specific nuclear subset was also enriched for unannotated genes 
compared to the cytoplasmic subset. The transcripts in the cytoplasm were shorter than those in 
the nucleus (Figure 55E). For the majority of genes no CSS was assigned to the TSS flanking region 
of their corresponding transcripts by Ernst et al. (Ernst et al., 2011), for the rest of the genes, a 
chromatin state of active transcription was principally assigned (Figure 55F). For the genes only 
regulated in the nucleus, an enrichment for the enhancer state can be noticed.  
With these correlative data we identified novel intergenic transcribed genes regulated by E2. It is 
immediately obvious that regulated intergenic genes are more compartment specific than 
ENSEMBL annotated genes. Following the assumption that all protein coding genes have been 
discovered already, these genes might all be lncRNAs. Most of these lncRNAs have not been 
annotated until now. Thus, these lncRNAs might be specific for E2 regulation. As anticipated, they 
are preferentially located in the nucleus, which may indicate more chromatin related functions. 
One possible reason, why the detected genes in the cytoplasm were shorter could be the immature 
nature of the transcripts in the nucleus. Thus, they may not be readily spliced and lead to an 
increased length. The CSS assignment is less informative for the novel lncRNAs. As discussed 
above, the CSS is derived for a wt LCL with constitutively expressed E2. Most likely, it does not 
recapitulate the chromatin state immediately following E2 activation. 
LncRNAs were suggested to contribute to cell identity as their expression is more cell type specific 
or tissue specific than is the case for protein isoforms (Cabili et al. 2011). This would support the 
observation of E2 specific regulation of these transcripts. The reason why they have not been 
detected in GM12878 cells so far might be because their transcriptional abundance has 
decreased already. Moreover, particularly the nucleic RNA has not been investigated for GM12878 
so far. It could be possible that we detected a small portion of novel eRNAs which were somehow 
stabilized in our cell systems, seen as the lncRNAs only regulated in the nucleus.  
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These potential novel lncRNA transcripts should be further investigated for their coding potential. 
Moreover, one could investigate the hypothetical eRNAs for bidirectional transcription. 
Bidirectional transcription is characteristic for some eRNAs. However, transcription is always 
bidirectional in the first place and can be monitored at both, enhancers and promoters, since PolII 
function is not strand directed, only cryptic polyA sites or dense nucleosomes lead it in one direction 
(Seila et al., 2008). Thus, bidirectional transcription is not an enhancer unique feature. 
 
4.2.2.6.2 E2 regulated lncRNAs are also partly regulated in the absence of de novo protein 
synthesis 
 
E2 regulates primary/direct targets, some of which are themselves involved in gene regulation, 
such as MYC or LMP1. Genes regulated by direct targets of E2 can be considered 
secondary/indirect E2 targets. In order to dissect these secondary targets, ChX treatment was 
employed. However, this approach is only applicable to protein-coding genes. As already 
mentioned, treatment with ChX resulted in high variations between the biological replicates, most 
likely because it impacts RNA stabilization. This variation was too high in the cytoplasm for analysis 
to proceed, thus the analysis was only completed for the nucleus. Given the fact that ChX has an 
impact on RNA metabolism, we only analyzed genes regulated by E2 with and without ChX 
treatment. This analysis was applied to ENSEMBL annotated genes and novel detected intergenic 
lncRNAs.  
Filtering of covered genes resulted in 174 genes which are similarly regulated with present and 
absent de novo protein synthesis and considered significantly co-regulated (defined as “direct” 
targets). While 4,501 genes were solely significantly regulated with present de novo protein 
synthesis (defined as “secondary” targets; Figure 56A-C). 20 % of the potential direct targets are 
lncRNAs, 6 % are eRNAs by definition (Figure 56D). The CSS at the TSS flanking region of 
transcripts derived from E2 regulated genes was enriched for open chromatin of enhancers and 
promoters for all E2 targets, which decreases again modestly with absent de novo protein synthesis 
(Figure 56E). When assigning E2 peaks to the transcripts corresponding to E2 regulated targets in 
order to reveal possible connections between binding and regulation, we observed a strong 
increase of E2 binding somehow linked by proximity to -/+ ChX regulated genes (Figure 57A). 
Finally, we intersected E2 binding sites linked to transcripts corresponding to genes of different 
subsets with defined E2 peak clusters (Figure 57B). We found a strong enrichment towards cluster 
I for both subgroups, the genes regulated by E2 with present and with absent de novo protein 
synthesis. Filtering of covered genes resulted in only nine intergenic transcribed genes which are 
significantly co-regulated by E2 with present and absent de novo protein synthesis, while 372 
intergenic transcribed genes were solely significantly regulated with present de novo protein 
synthesis (Figure 58A/B). When assigning E2 peaks to the transcripts corresponding to E2 
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regulated intergenic transcribed genes in order to reveal a possible connection between binding 
and regulation, we observed mostly peaks in the common TAD with co-regulated genes (Figure 
58C). 
These data correlations indicated some target genes of E2, which are most likely direct targets of 
E2, which compromise only 4 % of all E2 targets. This would support the fact that E2 has numerous 
targets which themselves initiate transcription. Thus, E2 triggers a huge cascade of transcriptional 
initiations. Among the targets following blockade of de novo protein synthesis are a substantial 
number of lncRNAs which could support a role for E2 mediated chromatin changes in target gene 
regulation. The fact that 61.5 % of the genes regulated under blocked de novo protein synthesis 
can be linked to E2 peaks in the TSS flanking region or the genebody of their derived transcripts 
suggests a direct regulation (Figure 57A). Transcripts of the majority of regulated genes could be 
linked to peaks predominantely residing in cluster I. Cluster I is characterized by correlation with 
EBF1, CBF1 and CUX1 binding, as well as high signals for open chromatin. It is well known, that E2 
binds preferentially to open chromatin. Our data proposes a link between those binding sites and 
regulated genes including lncRNAs and eRNAs. Only nine intergenic transcribed genes could be 
detected as co-regulated and could be considered as direct target. These nine transcripts could be 
regulated by E2 peaks residing in the common TAD. 
We could provide data on “direct” E2 targets, and detected more lncRNAs which may be involved 
in gene regulation such as eRNAs detected by Liang et al. (Liang et al., 2016). To confirm this, 
knock downs/ knock outs of our detected E2 regulated lncRNA studies would be required. We 
associated peaks looping to the TSS flanking regions using data provided by Mifsud et al. (Mifsud 
et al., 2015). Zhou et al. detected E2 bound EBV super-enhancers and that these super-enhancers 
were not in genomic proximity to TSSs, but that most of these super-enhancers can be found in the 
same TAD as their corresponding genes (Zhou et al., 2015). We paired up peaks residing in the 
same TAD and regulated genes. The information on TADs, or contact domain respectively were 
provided by Rao et al. (Rao et al., 2014). These contact domains are reported to be smaller than 
TADs and not defined by specific borders, as such, they are not TADs. As already discussed, the 
CSS could not recapitulate the chromatin landscape at 6 h post E2 activation. Same can be 
transferred to the identified binding sites. The E2 peaks were obtained from ChIP-Seq data in wt 
LCLs. The binding sites may be different at 6 h post E2 activation. Indeed, there may be much more 
binding, since target gene transcription is most abundant at 6 h post infection. The cluster analysis 
was conducted for features which were all obtained in wt LCLs. The determination of novel 
intergenic and intronic transcribed genes was very conservative and one might detect more direct 
intergenic and intronic transcribed targets with loosened thresholds. E2 may be involved in 
chromatin remodeling, the whole analysis was conducted disregarding this circumstance. A well-
characterized mechanism by which lncRNAs modulate gene expression both in cis and in trans 
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requires an interaction with chromatin to facilitate histone modification (Khalil et al., 2009). Thus, 
E2 could utilize lncRNAs to achieve changes in the chromatin environment. 
In order to associate binding with regulation one would need to conduct Hi-C experiments or E2 
binding sites knock out experiments with subsequent analysis of transcriptional changes. 
 
4.2.2.6.3 E2 regulated lncRNAs are also partly counter-regulated by E3A 
 
E3A is known to antagonize the activation of E2 at various promoters. We sought to determine the 
genome-wide antagonism of E2 gene expression by E3A. E2 and E3A ENSEMBL and intergenic 
transcribed target genes were compared by examining genes significantly regulated by E2 in the 
nucleus and E3A regulation in the nucleus.  
70 % of ENSEMBL genes significantly regulated by both TFs were significantly counter-regulated 
(Figure 59A/C). 16 % of them are lncRNAs, with most of them found in both compartments. Not all 
lncRNAs are counter-regulated in both compartments, to some extent they are nucleus specifically 
regulated (Figure 59B). Defining genes with a read coverage of > 20 reads as expressed, 75 % of 
the counter-regulated genes are still expressed in wt LCLs. The co-regulated genes are almost all 
expressed in wt LCLs, except for the genes co-repressed by E2 and E3A (Figure 59B). Competition 
for gene regulation can only partly be mirrored in a binding pattern when attempting to determine 
the counter-regulation of genes between E2 and E3A (Figure 59D). Strikingly, when testing the 
counter-regulated genes for enrichment in biological processes, we found a most of the enriched 
processes to be connected to development, genesis, proliferation and differentiation (Table S2). 
A similar picture emerged for the intergenic transcribed genes. 70 % of intergenic transcribed 
genes significantly regulated by both TFs were significantly counter-regulated by E3A (Figure 60A). 
Defining genes with a read coverage of > 20 reads as expressed, half of the counter-regulated 
genes are still expressed in wt LCLs. The co-regulated intergenic transcribed genes are almost all 
expressed in wt LCLs (data not shown). For over 80 % of transcripts counter-regulated between E2 
and E3A both TFs reside in a position supporting regulation (data not shown). 
This analysis proved that antagonism of E3A of E2 regulated transcripts is present genome-wide. 
Taking the model of competition for binding at enhancer sites into account, we observed, that the 
capacity of E2 for regulation prevailed over E3A for the majority of genes. All co-regulated genes 
were expected to be expressed in wt LCLs. This was the case for the induced genes, however, E2 
and E3A also can coordinately repress genes, which appear to be not expressed in wt LCLs. The 
counter-regulated genes can be partly linked to binding of both TFs which could explain their 
regulation. GO-terms related to genesis and proliferation were found to be counter-regulated, which 
may indicate a capacity of E3A to dampen processes which could be involved in neoplastic 
activities. 
It bares repetition that the determination of novel intergenic and intronic transcribed genes was 
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very conservative and one might detect more direct intergenic and intronic transcribed targets with 
loosened thresholds.  Glaser studied binding patterns of E2 and E3A in a comprehensive manner, 
and found strong antagonistic binding genome-wide which could explain the antagonistic gene 
regulation observed in this study (Glaser, PhD thesis, 2017). Furthermore, comparing the results 
of microarray analysis of E2 and E3A regulation, shared subsets of target genes could be monitored 
(data of Harth-Hertle reviewed in Glaser, PhD thesis 2017). Until now it was not known how 
common E2 and E3A antagonistic regulation of host genes was (Allday et al., 2015). This analysis 
indicates that the majority of the shared target genes are counter-regulated in the nucleus. Similar 
results were obtained by the examination of cytoplasmic genes. 
One has to bear in mind that similar as for E2 binding sites, E3A binding sites were obtained for wt 
LCLs and the binding pattern might be different in ER/EB2-5 cells, 6 h post E2 reinduction. 
However, E3A is constitutively expressed in ER/EB2-5 and constitutively exerting its transcriptional 
activity. Alterations in E2 activity could have consequences for E3A activity, especially as E2 
induces E3A transcription as discussed below. E3A/C are thought to be onco-proteins, while E3B 
is described as a tumor-suppressor (Allday et al., 2015). E3A is involved in the repression of 
important tumor suppressive pathways (Styles, Paschos, White, & Farrell, 2018) contrasting with 
our finding where E3A counter-regulated neoplastic activities. Possibly, E3A could exert a dual 
function with oncogenic and tumor-suppressor capabilities (Shen, Shi, & Wang, 2018).  
It may be that a strong permanent repression by E3A might dampen E2’s gene activation in the 
ER/EB system. As already discussed, EBV most likely did not evolve to be a harmful oncogenic 
virus, thus, E3A may act to limit the pro-proliferative capacity of E2 which is required to establish 
latency. The counter-regulation of the lncRNA CCDC26 would support this hypothesis, as CCDC26 
is thought to be involved in leukemic cell growth (Hirano et al., 2015). 
It would be interesting to submit E2 and E3A regulated lncRNAs to a GO enrichment or KEGG 
pathway analysis. In general, functional annotation of the regulated and especially the counter-
regulated lncRNAs would be informative in assessment of their role during establishment of 
latency. There exists already several online tools such as Co-LncRNA or LncADeep which conduct 
various analysis based on protein-coding genes proximal to lncRNA signature, mostly independent 
of their transcriptional direction (Yang et al., 2018; Z. Zhao et al., 2015), which could be useful. 
Even specialized analysis tools for cancer risk associated lncRNAs exists (Y. Xu et al., 2017). 
However, all of these tools assume a genomic proximal protein coding and non-coding genes to be 
involved in the same pathways, which does not account for the long-distance regulatory functions 
of some lncRNAs. Similar pathway association studies as for annotated lncRNAs could be 
performed for novel detected genes in order to assign a potential function. 
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In conclusion, this study provides extended information on the transcriptional regulation network 
of the EBV nuclear antigens E2 and E3A. In general, E2 regulates its target genes in CRGB, broad 
blocks of genes were observed to be co-regulated. E2 regulates numerous annotated lncRNAs as 
well novel intergenic transcribed genes, which might impact on neighboring gene regulation, since 
regulation of lncRNAs and distal protein coding genes correlates positively. The identification of 
target genes is strictly dependent on chosen thresholds for read coverage, significance and fold 
change. This study applied very strict thresholds for the identification of novel genes which will 
need further fine-tuning. We did however detect up to 1000 annotated and hundreds of potential 
novel lncRNAs regulated by E2 and E3A, which we further characterized according to subcellular 
localization, E2 regulatory dependence on de novo protein synthesis, chromatin state, E2 binding 
sites and E3A counter-regulation. Thus, EBV could exploit lncRNAs to achieve transcriptional 
changes in the cellular genome. Results on the viral transcriptome need further investigation and 
data acquisition, but provide a good initial starting point. The sum of changes regarding the 
transcriptome of the host and the virus could promote tumorigenesis.  
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Figure S1: Treatment scheme for ER/EB2-5 cells. For three biological replicates, 2 x 108 cells of four different 
treatments were harvested: EBNA2 inactive (ER/EB2-5 cells cultivated without estrogen for 4 d), EBNA2 
active (ER/EB2-5 cells cultivated without estrogen for 4 d, then estrogen is added for 6 h), EBNA2 
inactive/ChX treated (ER/EB2-5 cells cultivated without estrogen for 4 d; treated with cycloheximide for 7 h) 
and EBNA2 active/ChX (ER/EB2-5 cells cultivated without estrogen for 4 d then treated with cycloheximide 
for 7 h and estrogen for the last 6 h). 
 
 
 
 
Figure S2: The expression of HA-E2 in the EBV negative DG75 cell lines can be induced by doxycycline (dox) 
Stably transfected DG75 cell lines carry a vector encoding HA-E2. Dox treatment induces the simultaneous 
expression of HA-E2 in one and the bicistronic reporter construct of a truncated nerve growth factor receptor 
gene (tNGFR) and enhanced green fluorescent protein (eGFP) gene in the other direction from a bidirectional 
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promoter. E2 expression was induced with 1 µg/ml dox for 24 h and can be verified by monitoring the eGFP 
expression by flow cytometry. DG75doxHA-E2/ CBF1 wt cells (upper panel) and DG75doxHA-E2/CBF1 ko cells 
(lower panel) without Dox (left) and after 24 h Dox treatment (right). Percentages of GFP positive and 
negative cells are shown (representative experiment). 
 
 
 
 
Figure S3: The expression of HA-E3A in a E3A defective LCL can be induced by doxycycline (dox). Stably 
transfected ∆E3A LCLs carry a vector encoding HA-E3A. Dox treatment induces the simultaneous expression 
of HA-E3A in one and the bicistronic reporter construct of a truncated nerve growth factor receptor gene 
(tNGFR) gene in the other direction from a bidirectional promoter. E3A expression was induced with 1 µg/ml 
dox for 24 h. tNGFR expression can be monitored by antibody-directed staining and subsequent flow 
cytometry. This signal is indicatory for the E3A expression. ΔE3A-LCLdoxHA-E3A without Dox (left) and after 
24 h Dox treatment (right). Percentages of NGFR positive and negative cells are shown (representative 
experiment). 
 
 
 
 
 
Figure S4: Treatment scheme for siRNA-mediated EBF1 knock down and subsequent E2 induction. For two 
biological replicates, 5x 106 cells were transfected by electroporation with 100 pmol siRNA. 8 h post 
transfection, Dox was added to induce E2 expression. 24 h post transfection (=16 h post dox induction) 107 
cells were harvested for further analysis.  
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Figure S5: RNA quality control by BioAnalyzer. Visualization of Fractionation by enrichment (cytoplasm) or 
depletion (nucleus) of 18S/28SrRNA (left) and loss of 18S/28SrRNA by rRNA depletion by RiboZero 
Magnetic Gold Kit (right). 
 
 
 
 
Figure S6: Conformation of fractionation of cell compartments. Cytoplasmic fraction was separated from 
nucleic fraction of 108 cells using a mild buffer and centrifugation. RNA was isolated from 107 cell 
equivalents for total and cytoplasmic RNA, 2 x 108 cell equivalents were used to isolate RNA from the 
nucleus. Graph Pad Prism was used for plotting. 
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Figure S7: Cluster analysis for E2 peaks identified eight distinct clusters of TF combinations which are 
associated with different histone modifications. TFs identified to cluster with E2 in the EBNA peak wide TF 
cluster analysis were used to generate a new cluster analysis in order to sort E2 peaks according to 
compositions of associated TFs. To this end, the E2 peaks were used as reference regions for an intersection 
analysis creating a matrix which depicts hits for each selected TFs at every E2 peak. The resulting matrix was 
used as template for cluster search applying Jaccard similarity correlation index (performed by Björn 
Grüning). A The E2 peaks were sorted according to the eight identified TF clusters and heatmaps for each TF 
were generated. Sorted E2 peaks were centered and genomic regions of 2 kb in each direction from peak 
center are show. The scale of each heatmap was set to the maximum signal detected at an E2 peak. Anchor 
plots depicting mean signal distributions of B E2 and the three cluster determining TFs as well as C histone 
modifications and PolII at the different E2 peak clusters. As in A a region of 2 kb in each direction of the peak 
center was analyzed. ChIP-seq signals from ENCODE were normalized to their respective input samples and 
RPKM. D E2 peaks of the eight different clusters were analyzed for their location on functional chromatin 
elements as determined by ENCODE css. Centers of E2 peaks were used to assign chromatin states (Figure 
and text adopted from Glaser, PhD thesis, 2016). 
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Figure S8: Comparison of four different mappers shows different alignment efficiencies between the mapper 
aligning reads to hg19. Bar graphs displaying the percentage of all reads aligning to the human genome built 
hg19 mapped by ContextMap2, HISAT, STAR or TopHat2 for A the E2 cell system and B the E3A cell system. 
Graph Pad Prism was used for plotting. 
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Figure S9: Comparison of four different mappers shows different alignment efficiencies to annotated 
transcripts between replicates of the cytoplasm and the nucleus. Bar graphs displaying the percentage of all 
reads aligning to ENSEMBL (GRCh37.75) transcripts mapped by ContextMap2, HISAT, STAR or TopHat2 for 
A the E2 cell system and B the E3A cell system. Graph Pad Prism was used for plotting. 
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Figure S10: Comparison of four different mappers shows different alignment efficiencies to intergenic 
regions between replicates of the cytoplasm and the nucleus. Bar graphs displaying the percentage of all 
reads aligning to intergenic regions mapped by ContextMap2, HISAT, STAR or TopHat2 for A the E2 cell 
system and B the E3A cell system. Graph Pad Prism was used for plotting. 
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Figure S11: Comparison of four different mappers shows different alignment efficiencies to intronic regions 
between replicates of the cytoplasm and the nucleus. Bar graphs displaying the percentage of all reads 
aligning to intronic regions mapped by ContextMap2, HISAT, STAR or TopHat2 for A the E2 cell system and B 
the E3A cell system. Graph Pad Prism was used for plotting. 
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Figure S12: Comparison of four different mappers shows different alignment efficiencies to known junctions 
between replicates of the cytoplasm and the nucleus. Bar graphs displaying the percentage of all reads 
aligning to known junctions mapped by ContextMap2, HISAT, STAR or TopHat2 for A the E2 cell system and 
B the E3A cell system. Graph Pad Prism was used for plotting. 
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Figure S13: Comparison of four different mappers shows different alignment efficiencies to novel intergenic 
junctions between replicates of the cytoplasm and the nucleus. Bar graphs displaying the percentage of all 
reads aligning to novel junctions mapped by ContextMap2, HISAT, STAR or TopHat2 for A the E2 cell system 
and B the E3A cell system. Graph Pad Prism was used for plotting. 
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Figure S14: Comparison of raw read counts between all three biological replicates displaying only expected 
variations in the lower (1 to 102 read counts) region. Scatterplots of raw read counts of ER/EB2-5 samples 
depleted for estrogen and reactivated for 0 h (- estr.) or 6 h (+estr.); cytoplasmic compartment. Each dot 
represents a gene (plots generated by Gergely Csaba). 
 
 
 
 
Figure S15: Comparison of raw read counts between all three biological replicates displaying only expected 
variations in the lower (1 to 102 read counts) region. Scatterplots of raw read counts of ER/EB2-5 samples 
depleted for estrogen and reactivated for 0 h (- estr.) or 6 h (+estr.); nucleic compartment. Each dot 
represents a gene (plots generated by Gergely Csaba). 
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Figure S16: Comparison of raw read counts between all three biological replicates displaying also 
variations at higher (103 to 104 read counts) region. Scatterplots of raw read counts of ER/EB2-5 samples 
depleted for estrogen and reactivated for 0 h (- estr.) or 6 h (+estr.) under additional treatment of 
cycloheximide (ChX); nucleic compartment. Each dot represents a gene (plots generated by Gergely Csaba). 
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Figure S17: Comparison of raw read counts between all three biological replicates displaying expected 
variations in the lower (1 to 102 read counts) region. Scatterplots of raw read counts of wt or ∆E3A LCL 
samples; cytoplasmic compartment. Each dot represents a gene (plots generated by Gergely Csaba). 
 
 
 
 
Figure S18: Comparison of raw read counts between all three biological replicates displaying expected 
variations in the lower (1 to 102 read counts) region. Scatterplots of raw read counts of wt or ∆E3A LCL 
samples; nucleic compartment. Each dot represents a gene (plots generated by Gergely Csaba). 
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Figure S19: Size distribution of E2 regulated blocks. Cumulative plots displaying the % of block with size of 
≤ x indicated on the x-axes. 1,319 blocks were regulated by E2 in the cytoplasm (upper left), 1,242 blocks 
were regulated by E2 in the nucleus (upper right), 716 blocks were regulated by E3A in the cytoplasm (lower 
left) and 821 blocks were regulated by E3A in the nucleus (lower right); mtDNA (mitochondrial DNA) and 
chromosomes containing < 5 regulated genes are excluded. For all comparisons of real to random, p-values 
(by Kolmogorov–Smirnov test) = 0 (plots generated by Gergely Csaba). 
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Figure S20: Confirmation of spliced transcripts by endpoint PCR and agarose gel. Spliced transcripts of 
lncRNAs LINC00977 and RP11-528G1.2 could be repeatedly confirmed by RT-PCR with several template 
cDNAs of different total RNA preparations of the condition +estr.. Representative gel image shown. Primer 
pairs for both loci resulted in heterogeneous products for different template concentrations with RT-qPCR. 
Running a temperature gradient under the same conditions as for the Lightcyler (double produced distinct 
products at correct size (no side products) at 58 °C, 59 °C and 60.9 °C for LINC00977 and at 58 °C for 
RP11-528G1.2 exon-exon junction primer; fragments loaded on 2% agarose gel, visualization with EtBr 
under UV-light, image inverted. 
 
 
 
 
Figure S21: The majority of promoter or “other” fragments used as bait for capture Hi-C experiments are 
larger than 1000bp. Cumulative plot showing length of the fragments in bp versus the % of fragments of all 
significant interactions. For the contacts of promoter with promoter, the black indicates the bait fragment, 
blue indicates the target fragment; for the promoter to other contacts, red indicates the bait fragment, green 
indicates the target fragment (plot generated by Gergely Csaba). 
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Figure S22: Inference of intron exon structure of novel intergenic regions uncertain. Cumulative plots 
showing the number of introns per transcript versus the number of intergenic genes. High sensitivity= up to 
three mismatches allowed, only two detected fragments for junction required; High specificity= zero 
mismatches allowed, eight detected fragments for junction required; inf. = inferred (plots generated by 
Gergely Csaba). 
 
 
 
 
 
 
 
 
Table S1: Cell harvest for 3.2.2.2.8, p. 94 and RNA isolation 
 
    time point 
c(RNA) 
in 
µg/ml 
c(RNA) 
in 
µg/µl 
estim. 
total v 
(Eluat) 
in µl 
total 
mass 
in µg 
Harv. 
#cells/ 
prep 
cells/µl 
µg 
per 
106 
cells 
µl 
for 1 
µg 
RNA 
µl 
for 
RNA 
of 
106 
cells 
cells per 
1µg cDNA 
prep 
pr
im
ar
y 
B 
ce
lls
 
D
on
or
 1
 
b.i.* 322 0.32 40 12.9 1.0E+07 2.50E+05 1.29 3.1 4 7.76E+05 
8 h 
p.i.** 158 0.16 40 6.3 5.0E+06 1.25E+05 1.26 6.3 8 7.91E+05 
24 h 
p.i. 80 0.08 40 3.2 5.0E+06 1.25E+05 0.64 12.5 8 1.56E+06 
48 h 
p.i. 91.8 0.09 30 2.8 5.0E+06 1.67E+05 0.55 10.9 6 1.82E+06 
3 d 
p.i. 198 0.20 30 5.9 1.0E+07 3.33E+05 0.59 5.1 3 1.68E+06 
6 d 
p.i. 488 0.49 30 14.6 1.0E+07 3.33E+05 1.46 2.0 3 6.83E+05 
12 d 
p.i. 448 0.45 50 22.4 5.0E+06 1.00E+05 4.48 2.2 10 2.23E+05 
21 d 
p.i. 1230 1.23 50 61.5 1.0E+07 2.00E+05 6.15 0.8 5 1.63E+05 
42 d 
p.i. 1290 1.29 50 64.5 1.0E+07 2.00E+05 6.45 0.8 5 1.55E+05 
D
on
or
 2
 
b.i. 156 0.16 40 6.2 5.0E+06 1.25E+05 1.25 6.4 8 8.01E+05 
8 h 
p.i. 134 0.13 40 5.4 5.0E+06 1.25E+05 1.07 7.5 8 9.33E+05 
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24 h 
p.i. 138 0.14 40 5.5 5.0E+06 1.25E+05 1.10 7.2 8 9.06E+05 
48 h 
p.i. 167 0.17 30 5.0 5.0E+06 1.67E+05 1.00 6.0 6 9.98E+05 
3 d 
p.i. 166 0.17 30 5.0 5.0E+06 1.67E+05 1.00 6.0 6 1.00E+06 
6 d 
p.i. 524 0.52 30 15.7 5.0E+06 1.67E+05 3.14 1.9 6 3.18E+05 
12 d 
p.i. 542 0.54 50 27.1 5.0E+06 1.00E+05 5.42 1.8 10 1.85E+05 
21 d 
p.i. 740 0.74 50 37.0 5.0E+06 1.00E+05 7.40 1.4 10 1.35E+05 
42 d 
p.i. 1650 1.65 50 82.5 1.0E+07 2.00E+05 8.25 0.6 5 1.21E+05 
D
on
or
 3
 
b.i. 186 0.19 40 7.4 5.0E+06 1.25E+05 1.49 5.4 8 6.72E+05 
8 h 
p.i. 134 0.13 40 5.4 5.0E+06 1.25E+05 1.07 7.5 8 9.33E+05 
24 h 
p.i. 118 0.12 40 4.7 5.0E+06 1.25E+05 0.94 8.5 8 1.06E+06 
48 h 
p.i. 96.8 0.10 30 2.9 5.0E+06 1.67E+05 0.58 10.3 6 1.72E+06 
3 d 
p.i. 402 0.40 30 12.1 1.0E+07 3.33E+05 1.21 2.5 3 8.29E+05 
6 d 
p.i. 1610 1.61 30 48.3 1.0E+07 3.33E+05 4.83 0.6 3 2.07E+05 
12 d 
p.i. 1000 1.00 50 50.0 1.0E+07 2.00E+05 5.00 1.0 5 2.00E+05 
21 d 
p.i. 1120 1.12 50 56.0 1.0E+07 2.00E+05 5.60 0.9 5 1.79E+05 
42 d 
p.i. 1760 1.76 50 88.0 1.0E+07 2.00E+05 8.80 0.6 5 1.14E+05 
 
*before infection; ** post infection 
 
 
Table S2: GO enrichment analysis of 741 E2 and E3A counter-regulated genes. 40 out of 78 (p-value 
≤ 0.05) GO terms with ≥ 10 % enriched genes are shown 
Term ID Term 
Genes 
in term 
Target 
genes in 
term 
FDR 
% 
enrich. 
genes 
GO:0045123 cellular extravasation 27 8 0.00 30% 
GO:0010464 regulation of mesenchymal cell proliferation 38 9 0.00 24% 
GO:0048640 negative regulation of developmental growth 30 7 0.01 23% 
GO:0072088 nephron epithelium morphogenesis 26 6 0.01 23% 
GO:0010463 mesenchymal cell proliferation 42 9 0.00 21% 
GO:0002053 
positive regulation of mesenchymal cell 
proliferation 
33 7 0.01 21% 
GO:0008038 neuron recognition 29 6 0.02 21% 
GO:0072009 nephron epithelium development 40 8 0.01 20% 
GO:0072028 nephron morphogenesis 30 6 0.02 20% 
GO:0000188 inactivation of MAPK activity 26 5 0.05 19% 
GO:0002702 
positive regulation of production of molecular 
mediator of immune response 
27 5 0.05 19% 
GO:0072006 nephron development 78 13 0.00 17% 
GO:0072073 kidney epithelium development 55 9 0.01 16% 
GO:0050771 negative regulation of axonogenesis 44 7 0.03 16% 
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GO:0032835 glomerulus development 46 7 0.03 15% 
GO:0030856 regulation of epithelial cell differentiation 63 9 0.02 14% 
GO:0021675 nerve development 64 9 0.02 14% 
GO:0016525 negative regulation of angiogenesis 50 7 0.04 14% 
GO:0046847 filopodium assembly 53 7 0.05 13% 
GO:0001936 regulation of endothelial cell proliferation 77 10 0.02 13% 
GO:0003014 renal system process 62 8 0.04 13% 
GO:0060560 
developmental growth involved in 
morphogenesis 
134 17 0.00 13% 
GO:0031345 
negative regulation of cell projection 
organization 
86 10 0.03 12% 
GO:0050679 positive regulation of epithelial cell proliferation 121 14 0.01 12% 
GO:0050680 
negative regulation of epithelial cell 
proliferation 
78 9 0.04 12% 
GO:0060348 bone development 113 13 0.01 12% 
GO:0001935 endothelial cell proliferation 89 10 0.03 11% 
GO:0030198 extracellular matrix organization 291 31 0.00 11% 
GO:0048588 developmental cell growth 94 10 0.04 11% 
GO:0043062 extracellular structure organization 292 31 0.00 11% 
GO:0050678 regulation of epithelial cell proliferation 200 21 0.00 11% 
GO:0030178 
negative regulation of Wnt receptor signaling 
pathway 
107 11 0.04 10% 
GO:0060326 cell chemotaxis 147 15 0.01 10% 
GO:0001822 kidney development 188 19 0.00 10% 
GO:0050770 regulation of axonogenesis 109 11 0.04 10% 
GO:1901342 regulation of vasculature development 161 16 0.01 10% 
GO:0045765 regulation of angiogenesis 145 14 0.02 10% 
GO:0016358 dendrite development 135 13 0.03 10% 
GO:0007411 axon guidance 346 33 0.00 10% 
 
red= immune response; orange= proliferation, blue= development and genesis 
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Table S3: Viral genes significantly (FDR ≤ 0.05) differentially expressed by E2 and E3A detected by RSEM 
Only genes with ≥ 20 reads counts are shown; *genes only regulated under ChX (=potential false 
positives)/genes regulated by E3A in opposite directions in different compartments; italic: E2 regulated 
genes with log2FC < 0.85 or E3A regulated genes with log2FC < 1; bold: wt versus ΔE3A mut 
  
log2FCs 
genes +estr./-estr. cyto +estr./-
estr. 
nucl 
+estr./-
estr. 
ChX_nucl 
wt/mut 
cyto 
wt/mut 
nucl 
BGLF4 9.85 0.00 0.00 0.00 0.00 
BFLF2 9.62 3.04 9.53 4.38 0.00 
BMRF2 9.50 5.48 4.35 2.18 0.00 
BKRF3 9.45 1.66 10.53 5.23 0.00 
BZLF1 9.39 3.17 8.36 3.16 0.00 
BALF2 9.35 3.49 7.63 5.90 2.90 
BDLF3.5_1 9.29 0.00 0.00 0.00 0.00 
BLLF3 9.17 0.00 0.00 4.51 0.00 
BMRF1 9.11 3.74 5.74 8.13 0.00 
BBLF2/BBLF3 8.99 2.95 7.15 4.87 1.54 
BGLF5 8.94 2.20 6.11 4.06 0.00 
BSLF2/BMLF1 8.90 2.12 6.48 5.89 0.00 
BaRF1 8.82 1.86 3.30 1.37 0.71 
BORF2 8.73 3.50 4.29 2.20 1.03 
BRLF1 8.72 2.39 6.66 5.35 0.00 
BRRF1 8.72 1.61 2.57 0.00 1.00 
LMP-1 8.66 3.33 6.31 -0.44 0.00 
BLLF2 8.61 0.00 8.55* 0.00 0.00 
BFRF1 8.54 0.00 0.00 0.00 -6.10 
BFRF1A 8.41 1.77 3.10 1.08 0.00 
BORF1 8.35 2.48 5.27 2.52 0.67 
BSLF1 8.20 1.88 5.72 5.54 0.00 
BXLF1 8.14 0.82 4.82* 3.64 1.11 
BARF1 7.95 0.00 0.00 0.00 2.52 
BGLF3.5 7.93 1.93 6.98 5.36 0.00 
BDLF2 7.77 -0.35 2.62* 0.00 0.00 
BNLF2a 7.74 2.21 5.63 1.29 0.00 
BBLF4 7.52 1.20 4.64 0.00 1.63 
BGLF2 7.48 0.92 4.42* 5.35 0.00 
BILF1 7.38 0.41 3.35* 0.00 0.00 
BGLF3 7.22 0.76 3.76* 4.57 0.00 
BFLF1 7.11 1.40 4.30 4.44 0.00 
BBRF2 7.07 0.62 1.31* 0.00 0.00 
BLRF2 7.02 0.00 3.87* 4.64 1.61 
LF2 6.99 0.45 3.43* 0.00 0.00 
BVRF1 6.98 1.19 1.59 0.00 0.00 
BALF5 6.81 0.00 0.00 0.00 0.00 
BALF3 6.79 0.00 0.00 0.00 0.00 
BALF1 6.49 0.00 6.1* 0.00 0.00 
BTRF1 6.48 1.39 2.48 0.93 0.84 
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BRRF2 6.41 1.74 1.76 1.68 0.80 
Cp-EBNA3A 6.41 1.94 2.33 10.82 11.44 
BALF4 6.37 0.00 0.00 4.30 3.33 
LMP-2A 6.27 4.49 3.90 0.64 1.79 
BLRF1 6.24 1.42 2.35 0.00 0.73 
BXLF2 6.02 0.00 0.00 0.00 0.00 
BVRF2 5.88 1.74 2.64 0.00 1.18 
BdRF1 5.80 0.00 4.96* 0.00 0.00 
BDLF3 5.77 0.33 2.02* 0.00 0.00 
BBRF3 5.73 1.44 1.62 1.90 0.98 
BGRF1/BDRF1 5.70 1.68 2.14 0.00 1.01 
BcRF1 5.70 2.11 2.14 0.00 0.72 
BVLF1 5.64 0.45 2.65* 0.00 0.00 
BBRF1 5.60 1.57 1.69 0.00 0.91 
BSRF1 5.46 1.39 1.76 0.00 0.72 
BKRF2 5.42 1.53 2.07 1.66 0.86 
BNRF1 5.19 4.55 4.68 2.55 1.75 
BcLF1 5.12 0.00 0.00 3.60 0.00 
Qp-EBNA1 4.97 0.36 1.86* 0.00 0.79 
BCRF1/IL10 4.92 0.00 0.00 0.00 0.00 
BXRF1 4.85 1.72 2.65 0.00 1.18 
BHRF1_latent_splice_variant 4.76 1.64 2.34 0.00 0.00 
BOLF1 4.73 1.51 4.88 0.00 0.00 
LF3 4.69 0.90 3.29* 0.00 0.00 
BLLF1-splice_variant 4.68 0.00 0.00 5.50 0.00 
BLLF1 4.44 0.51 2.16* 0.00 0.00 
BDLF1 4.02 0.18 3.22* 4.96 0.00 
BHLF1 3.53 1.69 5.50 5.96 4.60 
Cp-EBNA3C 3.02 0.00 0.00 1.56 1.57 
Cp-EBNA3B 2.86 0.00 0.00 2.22 0.88 
BZLF2 2.79 0.82 3.88* 2.40 1.25 
LMP-2B 1.91 0.00 0.00 0.00 4.44 
BHRF1 1.46 1.13 1.02 0.00 0.00 
A73 0.00 0.65 -0.38* 0.00 1.76 
BALF5 0.00 0.88 3.74* 0.00 1.70 
BDLF3.5 0.00 1.69 5.49 4.80 0.00 
BFRF2 0.00 1.73 2.84 2.84* -9.45* 
BFRF3 0.00 2.09 2.64 3.47 0.00 
BKRF4 0.00 1.55 3.18 1.81 0.89 
BNLF2b 0.00 2.35 6.23 0.00 0.00 
BWRF1 0.00 1.47 0.76 0.00 0.47 
Cp-EBNA1 0.00 2.81 7.78 5.29 2.89 
EBER1 0.00 0.00 0.00 -1.81 0.00 
EBNA-LP 0.00 0.00 0.00 0.00 -5.69 
RPMS1 0.00 0.00 0.00 1.31 1.44 
EBER2 -0.79 0.00 0.00 0.00 0.00 
LF1 -4.33 0.00 0.00 0.00 0.00 
BDLF4_1 -5.35 0.00 0.00 0.00 0.00 
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